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The brain:  the blood-brain barrier and cerebral autoregulation.
The brain is one of the most highly perfused organs of the human body because 
of its high metabolic needs that are critical for normal functioning 1. Therefore, 
its blood supply requires strict regulated transport of nutrients with exclusion of 
potentially harmful plasma constituents 1, 2. To accomplish this strictly regulated 
transport, the cerebral vasculature has several unique features compared to the 
peripheral vascular system. First, the cerebral vessels contain an unique endothelial 
lining that forms the blood-brain barrier (BBB). For all other tissues in the human 
body, water and several ions and solutes such can move easily between the 
vascular endothelial cells and the surrounding tissues 2-4. However, the BBB acts as 
a ‘physical barrier’ between the brain and other tissues and prevents extravasation 
of virtually all molecules except those that are small and liphophilic 3.  The BBB 
lacks fenestrations, has only few endocytotic vesicles and contains complex 
high electrical resistance tight junctions between adjacent endothelial cells all 
of which results in restricted transcellular and paracellular flux 2-4. Consequently, 
under physiological conditions, these unique properties prevent proteins and 
ions to cross the BBB and thereby minimizing the effect of hydrostatic pressure 
on capillary filtration of water due the remaining osmotic pressure gradient in the 
vessels 2-4. Therefore, the BBB is a strict regulator of transport of nutrients and a 
strong protective mechanism against formation of vasogenic brain edema, that is 
involved in numerous pathologic neurologic conditions. 
Another important aspect of the cerebral vasculature is that it has the intrinsic 
ability to maintain a relatively constant cerebral blood flow (CBF) in the face of 
changing perfusion pressures 1, 5. Where peripheral vasculature can vary their blood 
flow due to changes in perfusion pressure, the brain needs a constant supply of 
oxygen. Constant blood supply towards the cerebral tissues is therefore critical 
for its homeostasis 1. This “cerebral autoregulation” of blood flow ensures that the 
blood flow through the brain is maintained at a relatively constant level despite 
changes in perfusion pressure or arterial blood pressure. Cerebral autoregulation is 
maintained between the arterial pressures of 50-60 mm Hg to 150-160 mm Hg and 
forms an autoregulatory plateau to provide the brain an relatively constant oxygen 
supply 5-7. Blood flow is related to the fourth power of the vessel radius and thus 
even small changes in lumen diameter in cerebral vessels can significantly change 
cerebrovascular resistance (CVR) and thereby CBF 5. Therefore, the occurence 
of the autoregulatory plateau is regulated through different intrinsic myogenic 
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mechanisms, and endothelial derived or metabolic factors that modulate CVR and 
thereby maintain a constant CBF to maintain optimal function of the brain 8, 9. 
The effect of circulating factors on the brain during pregnancy
During normal pregnancy, the endometrium, decidua and placenta initiate a 
profound rise in cytokines and circulating permeability-increasing factors such as 
vascular endothelial growth factor (VEGF) and placental growth factor (PLGF)10. 
These circulating factors released in the systemic circulation seem to be critical 
for the normal development and growth of the maternal-fetal unit and also 
direct the cardiovascular adaptation to pregnancy by initiating a high flow and 
low resistance circulation10. One growth factor that is important for a successful 
pregnancy is VEGF 11. VEGF is produced in significantly higher levels during 
pregnancy by several cell types, including endothelial cells and is increased both 
locally in the maternal fetal unit and systemically in the maternal circulation 12, 
13. VEGF was initially discovered as a permeability factor, but it is known now to 
also have important roles in angiogenesis, vascular growth, endothelial cell 
survival and vasorelaxation, including in the brain and cerebral circulation 14-16. 
Several studies have shown that VEGF can increase BBB permeability and thereby 
inducing vasogenic edema in neurologic conditions such as stroke 17, 18. However, 
in normal pregnant women, increased VEGF increases vascular permeability locally 
in the uterine circulation without apparently affecting BBB permeability because 
in pregnant women vasogenic edema does not normally occur. Currently, there 
is still limited understanding of how the BBB is affected in pregnancy, especially 
regarding to the increased circulating permeability factors and the delicate balance 
between supply and drainage and with it the formation of vasogenic brain edema. 
VEGF affects BBB permeability through a complex interaction between VEGF 
and its two VEGF receptors, known in rats as FMS-like tyrosine kinase1 (Flt1) and 
fetal liver kinase1 (Flk1), but also known as VEGFR1 and VEGFR2, respectively 19. 
These two receptors can, after phosphorylation of the cytoplasmic tyrosine kinase 
domains of either Flt1 or Flk1, transphosphorylate adjacent domains (“cross-talk”) 
and even form Flt1/Flk1 receptor-dimers 19-22. VEGFR-mediated signaling to induce 
vascular permeability has been studied intensively in peripheral tissues. However, 
it still remains unclear whether Flt1, a receptor with low tyrosine kinase activity 
compared to Flk1, is involved in VEGF-induced permeability or if it functions as a 
non-signaling reservoir for VEGF 19-24.  Little is known about the VEGFR-mediated 
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signaling pathway in the cerebral endothelium to induce BBB permeability. In 
addition to VEGF, PLGF, another member of VEGF-family, is produced in high levels 
in the placenta and is highly present in the maternal blood circulation. PLGF is 
known only to bind to Flt1 and is also involved in the angiogenesis and endothelial 
viability through its own pathway and by amplifying VEGF-driven actions 19. 
Although PLGF has shown to increase vascular permeability in peripheral tissues, 
it is unknown if PLGF affects the BBB during pregnancy 25, 26. Nevertheless, it is 
important to understand the possible pathways that affect the BBB during normal 
pregnancy in the face of neurologic complications that occur due to BBB disruption 
in pregnancy and preeclampsia.  
Preeclampsia and its neurologic complications
Preeclampsia is a complex heterogeneous disorder unique to the second half 
of pregnancy, that affects 3-8% of all pregnancies worldwide 27, 28. Preeclampsia 
is defined by high blood pressure (blood pressure systolic equal or higher than 
140  mm Hg and or diastolic equal or higher than 90 mm Hg) and proteinuria 
(higher than 300 mg/24 hours) in previously normotensive women 29. Although 
the incidence of preeclampsia is rising and extensive research has been performed 
over the past years 30, the exact pathogenesis of preeclampsia remains to be 
elucidated. To date, the only current curative treatment is removal of the placenta 
and thus termination of pregnancy, often resulting into iatrogenic perinatal 
morbidity and mortality 31. It is generally accepted that endothelial dysfunction 
plays a key role in the pathogenesis of preeclampsia, however, contributory causes 
remain to be determined 32-34. Epidemiologic data show that women who suffered 
from preeclampsia, have increased risk of developing cardiovascular disease in 
later life, suggesting common factors to be involved 34, 35. 
Preeclampsia is a systemic disorder that can affect multiple maternal organs 
including the liver, kidney and the brain. Neurologic complications are the most 
serious and life-threatening complications and are responsible for approximately 
75% of those maternal deaths and is thereby and is responsible for the largest 
maternal death rate worldwide. Eclampsia is the best known neurologic 
complication and is defined by the new onset of seizures  in a women with 
preeclampsia 36. In the Netherlands, the incidence of eclampsia is 6.2 per 10.000 
deliveries with a fatality rate of 1.4% 37. Importantly, epidemiologic studies suggest 
that neurologic complications such as eclampsia, cerebral hemorrhage, cerebral 
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infarction or coma occur most often in severe early-onset preeclampsia (EPE; 
preeclampsia diagnosed before 34 weeks of gestation), suggesting EPE and late-
onset preeclampsia (LPE; preeclampsia diagnosed after 34 weeks of gestation) 
have different etiologies 38-40.  Nevertheless, over the last century, the incidence of 
eclampsia has shifted from antepartum to the postpartum period. Recent studies 
suggest an incidence of 33-50% of all eclamptic cases in the postpartum period 
39, 41, 42. This is likely due to the fact that pregnant women receive more aggressive 
treatment when diagnosed with preeclampsia during pregnancy. This observation 
proposes new question about the care of women during the postpartum period. 
Only recently, late post-partum eclampsia was recognized as a defined entity 
41. Late-postpartum eclampsia is defined as eclampsia occurring later that 48 
hour postpartum. Late postpartum eclampsia is serious problem due to lack of 
recognition of prodromes and symptoms that could result into eclampsia, when 
women have exceeded the 48 hour postpartum period.   
The pathogenesis of neurologic complications in preeclampsia
Previous studies have shown that vasogenic brain edema may be the hallmark 
event in the development of  neurologic complications in preeclamptic women 
5, 43, 44. In a recent retrospective study comparing 47 women with eclampsia, 46 of 
these women show evident vasogenic edema in the parietal-occipital lobes on 
MRI-imaging 45. Vasogenic brain edema is the result of BBB disruption, suggesting 
that the BBB plays a central role in the development of neurologic complications 
in preeclampsia. However, the unique factors contributing to the development of 
BBB disruption in preeclampsia are currently not known. 
One theory is that eclampsia represents as a form of PRES (posterior reversible 
encephalopathy syndrome), a syndrome that is a variant of hypertensive 
encephalopathy 46. PRES is diagnosed by the clinical findings and imaging, 
most preferably on MRI that shows edema in the parietal-occipital lobe. PRES 
can have several causes including immunosuppressive therapy, systemic lupus 
erythematosus, kidney disease and pregnancy 47. Both hypertensive encephalopathy 
and PRES can arise from an acute elevation in blood pressure. This acute rise in 
blood pressure can overcome myogenic constriction of the cerebral arteries and 
arterioles resulting in a loss of autoregulatory capacity. When autoregulation is lost, 
decreased CVR results into hyperperfusion that may lead to BBB disruption and 
vasogenic brain edema. However, it is important to realize why eclampsia represents 
31956 Schreurs, Malou.indd   13 08-01-15   14:10
Chapter 1
14
a form of PRES instead of a form of hypertensive encephalopathy. Previous reports 
showed that more than half of eclamptic women do not show blood pressures 
that reach the upper limit of the autoregulatory curve and even 17 % of the 
eclamptic women were normotensive 39, 45. These numbers suggest that cerebral 
autoregulation is impaired during pregnancy or that autoregulatory breakthrough 
is not necessarily involved. Or it may be that the deltas of the rise of blood pressure 
is more important than the actual blood pressure and that women with low index 
blood pressure are more at risk for developing eclampsia at relatively low blood 
pressure. Previous studies in vitro have found that forced dilation occurred at lower 
pressure in cerebral arteries from late-pregnant animals compared to nonpregnant 
animals 48, however, in vivo the upper limit of the autoregulatory curve was not 
decreased in pregnancy 49. Nevertheless, when autoregulatory breakthrough did 
occur in pregnant animals, cerebral edema formation was increased in pregnancy 
compared to the nonpregnant state 49. These findings suggest that autoregulation 
breakthrough is not the only explanation in the occurrence of vasogenic brain 
edema. BBB disruption due to circulating factors that increase BBB permeability 
in pregnancy may be involved in the occurrence of vasogenic brain edema and 
neurologic complications in pregnancy and preeclampsia.  
One of the many factors that is increased in pregnancy and  preeclampsia is low-
density lipoprotein (LDL). In normal pregnancy, levels of lipids such as LDL are 
increased and hormonally controlled to encourage lipogenesis and fat storage in 
preparation of rapid fetal growth in the late pregnancy but does not normally lead 
to endothelial dysfunction 50. However, in preeclampsia the rise in lipids is often 
more dramatic and preeclamptic women show increased levels of circulating 
oxidized low-density lipoprotein (oxLDL) 51-53. Increased oxidative stress in the 
placenta causes oxidative conversion of LDL to oxLDL 54, 55. oxLDL has found 
to induce a wide variety of responses, such as the induction and expression of 
adhesion molecules, pro-inflammatory cytokines and reactive oxygen species, 
causing endothelial dysfunction in several cardiovascular diseases such as 
hypertension, diabetes, atherosclerosis and cerebral ischemic conditions 56. In 
preeclampsia, decidual vessels of the placenta show fibrinoid necrosis of the 
vascular wall and focal accumulation of lipid-laden macrophages, similar as in 
atherosclerosis 57. oxLDL binds to its receptor LOX-1 that is predominantly expressed 
on endothelial cells 58, 59. Previous studies have shown that oxLDL is able to increase 
BBB permeability and peripheral vascular permeability 60, 61. In addition, previous 
reports have associated increased LOX-1 expression in placental tissue and human 
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umbilical vein endothelial cultures cells with preeclampsia 62-64. Further, women 
that suffered from preeclampsia, have a greater risk of developing atherosclerosis 
and other cardiovascular disease in later life, suggesting similar etiologies. Thus, 
it is tempting to speculate that oxLDL and LOX-1 activation are involved in BBB 
disruption, vasogenic brain edema and neurologic complications in preeclampsia. 
In addition, it is interesting to see if women that develop eclampsia, already have 
underlying metabolic disorder that is unmasked by the pregnancy itself. 
Therapeutic options for protecting the maternal brain in preeclampsia.
Magnesium sulfate (MgSO4)  has been used throughout the 20
th century in the 
prevention and treatment of eclampsia and other neurologic complications 
in preeclampsia 65. Currently, MgSO
4
 is still the primary and superior protective 
treatment for the prevention of neurologic complications in preeclampsia when 
termination of the pregnancy is not desired. MgSO
4
 has been shown to be protective 
of the BBB and prevent cerebral edema during numerous conditions including 
traumatic brain injury, septic encephalopathy, hypoglycemia, and preeclampsia, 
however, its mechanism is poorly understood 66-68. MgSO
4 
is an unique calcium 
antagonist  that can act on most type of calcium channels in vascular smooth 
muscle and decreases intracellular calcium, resulting in vasorelaxation in large 
systemic arteries 69. However, other studies have shown that the unique cerebral 
arteries are less sensitive to the vasodilatory effects of MgSO
4
66, 67. Apparently, 
MgSO
4
 elicits more protective effects than merely vasodilation.  
Pressurized arteriograph system
For all animal studies performed in this thesis we will use a pressurized 
arteriograph system, specifically developed at the University of Vermont to 
measure hydraulic conductivity and vascular reactivity in both cerebral arteries 
and veins. A pressure-servo controller and a peristaltic pump maintain the 
intravascular pressure in isolated vessels and pressure can be adjusted manually. 
For the permeability measurements, the pressure-servo controller and peristaltic 
pump are disconnected from the transducer, and the intravascular pressure is 
allowed to decrease over time due to the volume flux across the vessel wall. The 
drop in intravascular pressure is recorded continuously. A leak in the pressurized 
system should influence the results because there will be a greater decrease in 
intravascular pressure not due to filtration. Therefore, the system is tested for 
leaks during set up for each experiment. If a leak is detected, all connections are 
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tightened until no leak is observed. For the reactivity experiments, the pressure-
servo controller maintains pressure during the entire experiment and increases 
or decreases autormatically due to the servo mechanism when needed. Lumen 
diameter in response to changes in pressure or the addition of pharmacological 
agents are recorded continuously via video microscopy. Thus, this in vitro system 
is able to measure hydraulic conductivity of cerebral vessels providing important 
information about BBB permeability and to visualize myogenic responses that 
could influence cerebral vascular function and cerebral autoregulation. 
Aims of this thesis.
This thesis will contain 5 separate studies, each of which were designed to 
determine the following aims:
1. To investigate the impact of increased angiogenic and anti-angiogenic 
factors on BBB permeability in pregnancy and the adaptation of the BBB to 
these factors. (Chapter 2)
2. To investigate if and how high levels of lipids impact the cerebral vasculature 
in pregnancy compared the nonpregnant state. (Chapter 3)
3. To investigate the effects and underlying mechanism of oxLDL on BBB 
permeability in preeclampsia. (Chapter 4)
4. To investigate the mechanism of oxLDL-induced BBB permeability and the 
effects of oxLDL on cerebral vascular reactivity. (Chapter 4 and 5)
5. To investigate the effect of MgSO4 on oxLDL-induced cerebral dysfunction. 
(Chapter 5)
6. To investigate blood pressure and metabolic factors in a cohort of women 
that suffered from eclampsia compared to women that were diagnosed 
with preeclampsia only. (Chapter 6 )
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Abstract
Vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) 
are increased in the maternal circulation during pregnancy. These factors may 
increase blood-brain barrier (BBB) permeability, yet brain edema does not normally 
occur during pregnancy. We therefore hypothesized that in pregnancy, the BBB 
adapts to high levels of these permeability factors. We investigated the influence 
of pregnancy-related circulating factors on VEGF-induced BBB permeability by 
perfusing cerebral veins with plasma from non-pregnant (NP) or late-pregnant 
(LP) rats (n=6/group) and measuring permeability in response to VEGF. The effect 
of VEGF, PLGF and VEGF-receptor (VEGFR) activation on BBB permeability was also 
determined. Results showed that VEGF significantly increased permeability (x107 
µm3/min) from 9.7±3.5 to 21.0±1.5 (p<0.05) in NP veins exposed to NP plasma, that 
was prevented when LP veins were exposed to LP plasma; (9.7±3.8;p>0.05). Both 
LP plasma and soluble FMS-like tyrosine-kinase1 (sFlt1) in NP plasma abolished 
VEGF-induced BBB permeability in NP veins (9.5±2.9 and 12±2.6;p>0.05). PLGF 
significantly increased BBB permeability in NP plasma (18±1.4;p<0.05), and 
required only VEGFR1 activation whereas VEGF-induced BBB permeability required 
both VEGFR1 and VEGFR2. Our findings suggest that VEGF and PLGF enhance BBB 
permeability through different VEGFR-pathways and that circulating sFlt1 prevents 
VEGF- and PLGF-induced BBB permeability during pregnancy. 
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Introduction
The blood-brain barrier (BBB) comprises a unique endothelium compared with 
endothelium of peripheral organs in that it lacks fenestrations, contains high 
electrical resistance tight junctions, and has restricted paracellular flux of ions 
and proteins 1-3. Under physiological conditions, these unique properties prevent 
entry of ions and large proteins into the brain from blood and minimize the 
effect of hydrostatic pressure on capillary filtration of water, all of which result in 
a strong protective mechanism against vasogenic brain edema 1-4. During normal 
pregnancy, the endometrium, decidua and placenta initiate a large increase in 
release of cytokines and angiogenic growth factors into the circulation 5-8. Many of 
these growth factors are essential for the increasing demand of the fetal-placental 
unit and normal intrauterine development of the fetus 6, 8, 9. Several of these factors 
are vasoactive, can induce vascular permeability 6, 8, and may have the ability to 
affect BBB permeability. However, despite high levels of these permeability factors 
produced during pregnancy, vasogenic brain edema does not normally occur 10, 11. 
Thus, the BBB appears to adapt during normal pregnancy to maintain its protective 
state in the face of these circulating permeability factors.   
One growth factor important for a successful pregnancy is vascular endothelial 
growth factor (VEGF) 12.  It is produced in significantly higher levels during 
pregnancy by a variety of cells including endothelial cells and is increased both 
locally in the maternal-fetal unit and in the maternal circulation 13, 14. VEGF was 
initially discovered as a vascular permeability factor, but it is now known to also 
have important roles in angiogenesis, vascular growth, endothelial cell survival 
and vasorelaxation, including in the brain and the cerebral circulation 15-19. VEGF 
affects BBB permeability through a complex interaction between VEGF and its two 
VEGF receptors (VEGFRs) known in rats as FMS-like tyrosine kinase1 (Flt1) and fetal 
liver kinase1 (Flk1), but also known as VEGFR1 and VEGFR2, respectively. These two 
receptors can, after phosphorylation of the cytoplasmic tyrosine kinase domains 
of either Flt1 or Flk1, transphosphorylate adjacent domains (“cross-talk”) and 
even form Flt1/Flk1 receptor-dimers 15, 19-21. VEGFR-mediated signaling to induce 
vascular permeability has been studied intensely in peripheral tissues. However, 
it still remains unclear whether Flt1, a receptor with low tyrosine kinase activity 
compared to Flk1, is involved in VEGF-induced permeability or if it functions as a 
non-signaling reservoir for VEGF 15, 19-23. To our knowledge, little is known about the 
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VEGFR-mediated signaling pathway in the cerebral endothelium to induce BBB 
permeability. Further, how the brain and BBB might adapt to high levels of the 
permeability factor VEGF during pregnancy is also not known.   
In addition to VEGF, circulating levels of placental growth factor (PLGF), another 
member of the VEGF family, that is highly produced in the placenta during 
pregnancy, are also significantly elevated in the blood during normal pregnancy 
24. PLGF binds only to Flt1 and is involved in angiogenesis and endothelial cell 
viability, both by inducing its own signaling pathway and by amplifying VEGF-
driven actions 20. Although PLGF has been shown to increase vascular permeability 
in peripheral tissue, whether PLGF also affects the cerebral endothelium to 
enhance BBB permeability, or through which signaling pathway, are not known 21, 
24, 25. Thus, the first goal of this study was to determine if VEGF or PLGF could induce 
BBB permeability and by which VEGFR-mediated pathways. Because pregnancy is 
accompanied by increased levels of VEGF and PLGF in the circulation, our second 
goal was to investigate the adaptation during pregnancy that might diminish the 
influence of these permeability factors on BBB permeability.
The bioavailability of VEGF and PLGF is essential for successful pregnancy and is 
thought to be regulated by anti-angiogenic factors, such as soluble Flt1 (sFlt1) 12, 
26, a soluble variant of Flt1 which lacks the cytoplasmic domains of Flt1 27, 28. A third 
trimester rise of sFlt1 reflects a physiologic anti-angiogenic shift of the placental 
milieu corresponding to the completion of placental growth 5, 6, 29.  Because sFlt1 
is an important regulator of VEGF-mediated activity in the maternal-fetal unit, we 
hypothesized that an underlying mechanism by which the BBB is protected from 
the permeability effects of VEGF during normal pregnancy is through elevated 
levels of this soluble receptor. Therefore, we determined the influence of sFlt1 on 
VEGF-induced BBB permeability using levels found in normal pregnancy as well as 
in preeclampsia, a pregnancy-related hypertensive disorder with increased levels 
of sFlt1, beyond that of normal pregnancy that causes endothelial dysfunction in 
peripheral tissues. The influence of sFlt1 on VEGF signaling at the BBB is not known, 
but likely important because vasogenic brain edema is involved in neurological 
complications of preeclampsia 5, 30-33. 
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Materials and Methods
Animals. Female Sprague Dawley rats were used for all experiments. Female virgin 
nonpregnant (NP; 260-310g), or late-pregnant (LP; day 20; 300-340g) rats were 
purchased from Charles River, Canada. All of the procedures were approved by the 
University of Vermont Institutional Animal care and Use Committee and complied 
with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. Animals were housed in the Animal Care facility, which is an Association 
for Assessment and Accreditation of Laboratory Animal Care-accredited facility. 
Animals had access to food and water ad libitum and maintained a 12-hour light/
dark cycle. 
Plasma samples. Plasma samples were obtained from trunk blood from female 
Sprague Dawley Rats, either virgin NP or LP (described as above). The plasma 
was collected in plasma separation tubes, pooled from approximately 20 rats to 
minimize biological diversity, and stored at -80°C until experimentation. For all 
experiments, plasma was diluted to 20% in HEPES buffer. 
BBB permeability measurements. The effect of NP and LP rat plasma on BBB 
permeability and the role of VEGF, PLGF and sFlt1 were measured as previously 
described with slight modification 1. Briefly, cerebral veins were carefully dissected 
out of the brain of either NP or LP rats and the proximal end mounted on one 
glass cannula in an arteriograph chamber. Veins were perfused intraluminally with 
NP (n=6) or LP (n=6) rat plasma in a HEPES buffer and equilibrated for 3 hours at 
10±0.3 mmHg. After equilibration, intravascular pressure was increased to 25±0.1 
mmHg and drop due to filtration was measured for 40 minutes. The decrease of 
intravascular pressure per minute (mmHg/min) was converted to volume flux 
through the vessel wall (µm3) using a conversion curve, as previously described 1.  
The first set of experiments tested the influence of VEGF and its receptor activation 
on BBB permeability by perfusing cerebral veins with NP plasma with or without 
the addition of 50 ng/ml VEGF (n=6/group). Receptor activation was determined 
by the addition of the selective antibodies against VEGFR1 (33 µg/ml for 75% 
neutralization rate; n=6) or VEGFR2 (4 µg/ml for 90% neutralization rate; n=6). A 
separate group of vessels was perfused with plasma plus a non-immune IgG (33 
µg/ml; n=6)  permeability measured as a control for the presence of the antibodies 
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in the lumen. A second set of experiments was performed to investigate the effect 
of PLGF on BBB permeability by the addition of 50 ng/ml PLGF to NP rat plasma 
perfused in a NP vein (n=6). Similarly, VEGFR activation in response to PLGF was 
determined by measuring permeability after the addition of selective VEGFR1 (33 
µg/ml for 75% neutralization rate; n=6) or VEGFR2 (4 µg/ml for 90% neutralization 
rate; n=6) antibodies.
A third set of experiments was performed to examine the influence of pregnancy 
on VEGF-induced BBB permeability by measuring permeability after the addition 
of 50 ng/ml VEGF into NP veins perfused with NP plasma and a LP vein perfused 
with LP plasma (n=6). To isolate the effect of LP plasma on VEGF-induced BBB 
permeability, a separate group of NP veins was perfused with LP plasma and the 
permeability to VEGF measured (n=6). The last set of experiments was performed 
to determine the influence of sFlt1 on VEGF-induced BBB permeability during 
pregnancy by perfusing NP veins with 50 ng/ml (n=6) or 500 ng/ml (n=6) sFlt1 to 
NP plasma and measuring BBB permeability in response to 50ng/ml VEGF. 
Determination of VEGF and VEGFR mRNA expression using real-time quantitative 
PCR.  Total RNA was extracted from individual cerebral veins taken from NP 
(n=3-5) and LP rats (n=3-7) using the STAT-60 total RNA/mRNA isolation reagent 
(Tel-Test), as previously described 34, 35. cDNA was synthesized from 1µg of total 
RNA per sample using SuperScript II reverse transcriptase and random hexamer 
primers with the SuperScript II Preamplification System (Invitrogen) in a 20-
µl final reaction volume. All samples were reverse transcribed simultaneously 
to obviate reaction variability.  The quantitative PCR standards for all transcripts 
were prepared with amplified rat VEGF, VEGFR1, VEGFR2, neuropilin-1, and 
18S cDNA products ligated directly into pCR2.1 TOPO vector using the TOPO 
TA cloning kit (Invitrogen); the fidelity of the cDNA inserts were verified by 
direct sequencing. The quantitative PCR primers for the rat transcripts were 
as follows: VEGF, (S) 5’-ATCATGCGGATCAAACCT-3’, (AS) 5’-ATTCACATCTGCTATGCT-3’; 
VEGFR1, (S) 5’-AAGACTCGGGCACCTATG-3’, (AS) 5’-TCGGCACCTATAGACACC-3’; VEGFR2, 
5’-ACGGGGCAAGAGAAATGAAT-3’, (AS) 5’-GCAAAACAC-CAAAAGACCAC-3’; neuropilin-1, 
(S) 5’-CGCCTGGTGAGCCCTGTGGTCTATT-3’, (AS) 5’- TGTTCTTGTCGCCTTTCCCTTCTTC-3’. To 
estimate the relative expression of the receptor transcripts, 10-fold serial dilutions of 
stock plasmids were prepared as quantitative standards. For real-time quantitative 
PCR the reverse transcribed cDNA samples were diluted fivefold to minimize the 
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inhibitory effects of the RT reaction components and assayed using SYBR Green 
I JumpStart Taq ReadyMix (Sigma-Aldrich, St. Louis, MO) containing 5 mM MgCl
2
; 
dATP, dGTP, dCTP, and dTTP (200 mM each); 0.64 U of Taq DNA polymerase; and 
primer (300 nM each) in a final 25-µl reaction volume. The real-time quantitative 
PCR was performed on an Applied Biosystems 7500 Fast Real-time PCR system 
(Applied Biosystems, Foster City, CA, USA) 34, 35 as follows: 1) 94°C for 2 min and 2) 
amplification over 40 cycles at 94°C for 15 s and at 58–62°C (depending on the 
primer set) for 30 s. SYBR Green I melting analysis of the amplified product from 
these amplification parameters was carried out by ramping the temperature of 
the reaction samples from 60°C to 95°C to verify unique product amplification 
in the quantitative PCR assays. Data analyses were performed with Sequence 
Detection Software version 1.4 (Applied Biosystems, Foster City, CA, USA) using 
default baseline settings. The standard curves were constructed by amplification 
of serially diluted plasmids containing the target sequence. The increase in SYBR 
Green I fluorescence intensity (ΔRn) was plotted as a function of cycle number and 
the threshold cycle (C
T
) was determined by the software as the amplification cycle 
at which the ΔR
n
 first intersects the established baseline. The transcript levels in 
each sample were calculated from the C
T
 by interpolation from the standard curve 
to yield the relative changes in expression. All data were normalized to 18S in the 
same samples; transcript levels in control NP samples were established as 100%.
Drugs and Solutions. HEPES physiological salt solution was made fresh daily and 
consisted of (mmol/L): 142.0 NaCl, 4.7 KCl, 1.71 MgSO
4
, 0.50 EDTA, 2.8 CaCl
2
, 10.0 
HEPES, 1.2 KH
2
PO
4
, and 5.0 Dextrose. VEGF
165
 and PLGF were purchased from 
Calbiochem, Gibbstown, NJ, USA (PF074 and 526610, respectively).  VEGFR1 
antibody, VEGFR2 antibody, sFlt1 and the goat-IgG antibody control were 
purchased at R&D systems, Minneapolis, MN, USA (321-FL, AF471, AF644 and AB-
108-C, respectively). All drugs were diluted in sterile HEPES without glucose to 
prevent growth of bacteria and kept frozen at -80°C until use. 
Statistical analysis. Data were presented as means ± standard error of the mean. 
Analyses were performed by one-way ANOVA with a post-hoc Student Newman 
Keuls test for multiple comparisons. Differences were considered statistical 
significant at P < 0.05.  
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Results 
The effect of circulating VEGF and PLGF on BBB permeability and VEGFR activation. 
VEGF-induced BBB permeability involves complex signaling by its two receptors 
15, however, little is known about VEGFR activation that induces BBB permeability. 
Thus, we determined BBB permeability in the cerebral vein of Galen from a NP rat 
perfused with plasma from a NP rat in which 50 ng/ml VEGF was added. The vein 
of Galen was used for all experiments because this vein has BBB properties and 
has been shown to be a major site of BBB disruption in pathological states, such as 
acute hypertension 36. Permeability was also compared between veins that were 
perfused with selective Flt1 or Flk1 neutralizing antibodies to determine which 
receptors were involved in permeability. Figure 1 shows that VEGF significantly 
increased BBB permeability in NP veins. Neutralizing either Flt1 or Flk1 abolished 
VEGF-induced permeability, suggesting both receptors are necessary to induce 
BBB permeability in response to VEGF, with possible crosstalk between the two 
receptors. The IgG-antibody control group confirmed that the physical presence 
of the antibody itself in the plasma did not affect VEGF-induced BBB permeability. 
In addition to VEGF, PLGF has been shown to increase peripheral vascular 
permeability 24, 25, but little is known about the effect of PLGF on BBB permeability. 
Interestingly, after exposing a vein from a NP rat to NP plasma with 50 ng/ml PLGF, 
it also significantly increased BBB permeability similar to VEGF (Figure 2). To our 
knowledge, these results are the first showing the ability of PLGF to enhance BBB 
permeability. PLGF is known to interact only with Flt1, with higher affinity than 
VEGF 21. As expected, selectively neutralizing Flt1, but not Flk1, inhibited PLGF-
induced BBB permeability (Figure 2). 
mRNA expression of VEGF and the VEGFRs in cerebral veins during pregnancy. During 
pregnancy, VEGF is highly expressed in peripheral tissue beyond that of the non-
pregnant state 37. However, whether VEGF expression is altered in cerebral vascular 
tissue during pregnancy that might affect BBB permeability is not known. Thus, 
we determined the expression of VEGF and its receptors in cerebral veins by qPCR 
from NP and LP rats. Figure 3A shows that VEGF mRNA expression was significantly 
increased in veins from LP versus NP rats. However, VEGFR1 and VEGFR2 mRNA 
expression was similar in veins from LP and NP rats (Figure 3B). Also, the expression 
of the neuropilin receptor, a receptor  that enhances VEGFR activity 22, did not 
change. Thus, pregnancy caused increased VEGF expression in the cerebral 
circulation without an increase in VEGFR expression.
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Figure 1: Effect of vascular endothelial growth factor (VEGF) on blood-brain barrier (BBB) permeability. 
Flux as a measure of BBB permeability of cerebral veins from nonpregnant (NP) rats perfused with plasma 
from NP rats in the absence or presence of 50 ng/ml VEGF. Selective neutralizing antibodies to VEGFR1 or 
VEGFR2 were also added to determine the role of each receptor in VEGF-induced BBB permeability. VEGF 
significantly increased BBB permeability. Neutralizing with specific antibodies (Ab) for either Flt1 or Flk1 
prevented VEGF-induced BBB permeability. The IgG control group showed that the presence of antibody 
alone did not induce BBB permeability. (**p<0.01 vs. all)
Figure2: Effect of placental growth factor (PLGF) on blood-brain barrier (BBB) permeability. Flux as a 
measure of BBB permeability of cerebral veins from nonpregnant (NP) rats perfused with plasma from NP 
rats in the absence or presence of 50 ng/ml PLGF. Selective neutralizing antibodies to VEGFR1 or VEGFR2 
were also added to determine the role of each receptor in PLGF-induced BBB permeability. PLGF also 
significantly increased BBB permeability to a similar extent as VEGF. Neutralizing Flt-1, but not Flk1, abolished 
the PLGF-induced BBB permeability. (*p<0.05 vs. all).
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Figure 3: Effect of pregnancy on vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) 
expression in cerebral veins using qPCR. (A) mRNA expression of VEGF in cerebral veins from nonpregnant 
and late-pregnant rats. Expression of VEGF was significantly increased during pregnancy in cerebral veins. 
(B) mRNA expression of VEGFRs: VEGFR1 (Flt1), VEGFR2 (Flk1) and neuropilin in cerebral veins from 
nonpregnant and late-pregnant rats. There was no change in VEGFR expression with pregnancy.   (*p<0.05 
vs. nonpregnant)
The effect of plasma and sFlt1 on VEGF-induced BBB permeability in pregnancy. 
Circulating angiogenic factors during pregnancy may have an important role 
in protecting the BBB from permeability effects caused by factors such as VEGF 
and PLGF. Thus, we examined the role of circulating factors during pregnancy 
in mediating VEGF-induced BBB permeability. We choose VEGF as a well-known 
and widely accepted representative of all permeability factors in the VEGF family 
and thereby focused further experiments on examining the effect of VEGF. 
We compared permeability in veins from NP rats perfused with NP plasma and 
compared this to veins from LP rats perfused with LP plasma and measured BBB 
permeability in response to VEGF. Similar to the above result, Figure 4 shows that 
VEGF significantly increased BBB permeability in veins from NP animals perfused 
with NP plasma. However, VEGF had no effect on BBB permeability in veins from 
LP animals perfused with LP plasma. To determine if the lack of response to VEGF 
in veins from LP rats perfused with LP plasma was due to circulating factors in the 
LP plasma or to the vasculature being from LP animals, we perfused a cerebral vein 
from a NP animal with plasma from a LP animal and measured BBB permeability 
in response to VEGF. Importantly, LP plasma prevented the increase in BBB 
permeability in response to VEGF in NP veins, suggesting circulating factors in the 
LP plasma were responsible for the prevention of VEGF-induced BBB permeability 
during pregnancy. 
31956 Schreurs, Malou.indd   32 08-01-15   14:11
BBB permeability in pregnancy
33
2
Figure 4: Effect of pregnant plasma on vascular endothelial growth factor (VEGF)-induced blood-brain 
barrier (BBB) permeability. Flux as a measure of BBB permeability in response to 50 ng/ml VEGF in cerebral 
veins from non-pregnant rats (NP
v
) perfused with NP plasma (NP
pl
) and veins from late-pregnant  rats (LP
v
) 
perfused with LP plasma (LP
pl
). VEGF-induced permeability was prevented in LP vessels perfused with LP 
plasma.  The lack of response to VEGF during pregnancy was due to circulating factors present in LP plasma 
since perfusing LP plasma in a cerebral vein from a NP rat also prevented VEGF-induced BBB permeability. 
(*p<0.05 vs. all).
Because elevated sFlt1 could be responsible for preventing VEGF-induced BBB 
permeability in LP plasma, we determined the specific effect of sFlt1 on VEGF-
induced BBB permeability by perfusing NP plasma with 50 ng/ml sFlt1 into a vein 
from a NP rat and measuring BBB permeability in response to VEGF. We found 
that VEGF-induced BBB permeability was abolished by the presence of sFlt1, 
confirming the importance of sFlt1 in controlling VEGF actions at the BBB (Figure 
5). Because excess levels of sFlt1 that lead to an angiogenic imbalance are thought 
to be important in the pathogenesis of preeclampsia, we created this angiogenic 
imbalance by increasing the sFlt1:VEGF ratio from 1 to 10, similar to preeclampsia 
31, 38. In this angiogenic imbalance, sFlt1 is thought to not only control VEGF-
induced angiogenesis, but to also inhibit other VEGF-mediated actions which 
can result in vasoconstriction and endothelial cell damage 12, 32. Interestingly, 
VEGF-induced BBB permeability was abolished similarly compared to the lower 
and more physiological concentration of sFlt1 (Figure5). Thus, sFlt1 also regulates 
VEGF-induced permeability at a high sFlt1:VEGF ratio, and does not appear to 
cause endothelial dysfunction in these cerebral veins. 
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Figure 5: Effect of soluble FMS-like tyrosine kinase-1 (sFlt1) on vascular endothelial growth factor 
(VEGF)-induced blood-brain barrier (BBB) permeability. VEGF-induced permeability in cerebral veins from 
NP rats exposed to NP plasma was prevented by sFlt1 at both 50 ng/ml and 500 ng/ml, suggesting sFlt1 is 
an important circulating factor released during pregnancy that controls VEGF-induced permeability. 
(**p<0.01 vs. all).
Discussion
The major finding of this study was that circulating factors in LP plasma prevented 
VEGF-induced BBB permeability and preserved barrier function during pregnancy in 
the face of high circulating angiogenic factors. BBB permeability without exogenous 
VEGF was similar in both the NP and LP states, despite the finding that veins from 
LP rats showed increased VEGF mRNA expression. Exogenous VEGF initiated a 
significant increase in BBB permeability in the NP state, while it did not affect BBB 
permeability in LP. Interestingly, after exposing a vein from a NP rat to LP plasma with 
VEGF, increased BBB permeability was prevented, suggesting circulating factors in 
the LP plasma were responsible for this adaptation that limited the permeability 
effects of VEGF. Furthermore, sFlt1 regulated VEGF-induced permeability similar to 
LP plasma in that it abolished permeability in response to VEGF. Lastly, our results 
showed that PLGF had similar potential as VEGF to enhance BBB permeability. 
However, VEGF and PLGF appear to induce BBB permeability through distinct 
VEGFR activation, eg. PLGF-induced BBB permeability acted through Flt1, whereas 
VEGF-induced BBB permeability required activation from both receptors.  
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The BBB contains unique endothelium that provides a strong protective 
mechanism against edema in the brain 2, 3. From our results here measuring 
transvascular water flux, VEGF can clearly increase BBB permeability. This finding 
is similar to what was found in previous studies measuring solute permeability 
of cerebral venules in vivo 16, 36.  In pregnancy, significant higher expression and 
levels of VEGF have been measured in the periphery and circulation, which is 
necessary for the development and maintenance of the maternal-fetal unit and 
uteroplacental circulation 5, 6, 12, 13. Increased VEGF during pregnancy might also 
increase BBB permeability and promote edema formation. It is known that VEGF is 
expressed in the cerebral tissue regulating microvascular permeability 39, but the 
expression of VEGF in the brain during pregnancy, or the effect of VEGF on the 
BBB permeability in normal pregnancy have not been examined previously. Our 
results showed that similar to other tissues, there is increased expression of VEGF in 
cerebral veins during pregnancy, suggesting that the cerebral circulation may also 
be affected by higher levels of VEGF during pregnancy. Few studies examined the 
effects of VEGF on the BBB, and have shown increased expression of VEGF in the 
brain and in the cerebral circulation during brain injury that also caused vasogenic 
edema 16, 39, 40. However, our results showed no increase in BBB permeability in 
pregnancy (Figure 4), despite increased expression of VEGF in the cerebral veins. 
There are 2 possible explanations for these findings. First, the BBB itself might 
adapt to the increased levels of VEGF during pregnancy through altered VEGFR 
expression in cerebral veins. Osol et al. examined VEGFR expression in uterine 
vessels and found increased VEGFR1 expression during pregnancy, accompanied 
by increased uterine venous permeability 41. In contrast, our results showed no 
increased expression of VEGFRs in the cerebral veins and also no increase in BBB 
permeability. This could reflect a possible protective mechanism in the brain 
compared to the uterine circulation that requires increased vascular permeability 
for controlled extravasation of intravenous molecules in the maternal-fetal unit 42, 
while the BBB must maintain its protective state to prevent brain edema. 
A second explanation for the apparent discrepancy between increased VEGF 
expression in the cerebral circulation and the lack of VEGF-induced BBB permeability 
during pregnancy is that there are circulating factors present in the LP plasma 
protecting the BBB from VEGF-induced BBB permeability. Our results showed 
that permeability in response to VEGF was prevented by LP plasma, supporting 
this concept. One important candidate is sFlt1 that is elevated during pregnancy 
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along with VEGF. It selectively binds VEGF and is an important regulator of the 
bioavailability of VEGF in both the nonpregnant and pregnant state. Our results 
here confirmed the importance of increased sFlt1 in normal pregnancy controlling 
the permeability actions of VEGF in the cerebral circulation as addition of sFlt1 in NP 
plasma abolished VEGF-induced BBB permeability. This finding is consistent with 
previous studies showing that sFlt1 controlled the actions VEGF during pregnancy 
in the maternal peripheral circulation 6, 12.  However, this is the first study that we 
are aware of showing sFlt1 critically regulates VEGF action at the BBB. 
Although sFlt1 appeared to have an important role in limiting VEGF-induced BBB 
during normal pregnancy, it is also generally accepted that excess levels of sFlt1 are 
involved in the pathogenesis of preeclampsia and might cause endothelial damage 
12, 31-33. In this study, we measured VEGF-induced BBB permeability with a 10-fold 
higher concentration of sFlt1 than in the physiological condition of pregnancy. 
The VEGF-induced BBB permeability was abolished by higher concentrations of 
sFlt1 similarly as the physiological concentration. Thus, after acute exposure of 
increased sFlt1:VEGF ratio in cerebral veins, it did not appear to cause endothelial 
damage or have a greater effect on BBB permeability. However, this interpretation 
is limited because of the rather short exposure of the BBB to sFlt1 (3 hours). In 
addition, other cytokines present during pregnancy and preeclampsia were not 
examined in this study. However, previous studies also raised questions about 
the connection between sFlt1 with the etiology of neurological complications of 
preeclampsia. For example, Maynard et al. infused rats with high sFlt1 and found 
that these rats showed symptoms of preeclampsia, but none had complications of 
HELLP syndrome or eclampsia 27. Karumanchi et al. also did not find BBB disruption 
in rats exposed to high sFlt1, but did find some BBB disruption in rat models 
exposed to both sFlt1 and soluble endoglin (sEng), suggesting an interaction 
of cytokines may be necessary for inducing vasogenic edema in preeclampsia 
10. It is worth noting that these previous studies lacked appropriate controls for 
both pregnancy and hypertension, ie., high sFlt1 likely causes similar effects in NP 
animals or the effects noted may be due to hypertension and not sFlt1. A recent 
study showed that sFlt1 did not cause endothelial damage itself, but sensitized 
VEGFRs to pro-inflammatory cytokines like TNF-α resulting in endothelial damage 
43. This finding could explain why in the present study exposure to excess sFlt1 did 
not increase BBB permeability and also why in previous studies rats treated with 
excess sFlt1 alone did not induce brain edema and neurological complications of 
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preeclampsia. Further, the association between sFlt1 and other pro-inflammatory 
cytokines present in preeclampsia such as TNF-α could explain why in normal 
pregnancy, a state with high levels of sFlt1, no apparent endothelial damage 
occurs.
In addition to VEGF, PLGF is also increased during pregnancy. This factor also has 
been shown to have permeability effects in the periphery 44, but to our knowledge 
no previous study has examined the effect of PLGF on BBB permeability. Previous 
studies showed that, similar to VEGF, PLGF is a strong vasodilator 41, however the 
role of PLGF in permeability during pregnancy was not investigated. Our results 
show, for the first time, that PLGF significantly increased BBB permeability and 
is a permeability factor in the cerebral endothelium. Little is known about the 
signaling pathway of PLGF that increases BBB permeability. In the present study we 
examined the receptor activation of both VEGF and PLGF and showed that PLGF-
induced permeability was, as expected, abolished after neutralizing Flt1, but not 
after neutralizing Flk1. However, we also found that in contrast to PLGF, neutralizing 
either Flt1 or Flk1 abolished VEGF-induced BBB permeability, suggesting these 
two related factors need different receptor activation and possibly act through 
different signaling pathways to affect BBB permeability. Autiero et al. found using 
mass spectrometry that PLGF and VEGF interact with Flt1 with distinct patterns of 
tyrosine phosphorylation 21. This result is consistent with our findings that VEGF 
and PLGF appear to act trough different receptor activation. Other studies also 
found that both VEGFRs are able to form heterodimers, especially after binding of 
VEGF, but not after binding PLGF 21, 45. Further studies are needed to understand 
the distinct and complex signaling of VEGFRs after binding PLGF or VEGF in the 
cerebral endothelium that can affect BBB permeability.
Summary and perspectives
The present study found that VEGF and PLGF both induce BBB permeability 
through distinct VEGFR-mediated pathways. In addition, circulating sFlt1 controls 
the permeability actions of VEGF during pregnancy that may prevent vasogenic 
edema in normal gestation. To our knowledge, this is the first study showing 
effects of VEGF, PLGF and sFlt1 on the BBB during normal pregnancy. The finding 
that increased sFlt1 protects the BBB against VEGF-induced permeability raises 
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some new questions about the role of high sFlt1 in the onset of neurological 
complications in preeclampsia. As high sFlt1 appears to be protective of the BBB, 
there may be other pro-inflammatory factors released during preeclampsia, but 
not during normal pregnancy, that are responsible for increased BBB permeability 
and edema formation. Thus, these results may be important for understanding 
VEGF- and PLGF-induced BBB permeability during normal pregnancy when these 
factors are increased, but also for understanding the pathogenesis of neurological 
complications in preeclampsia.
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Abstract 
In preeclampsia, hyperlipidemia is enhanced compared to normal pregnancy that 
could adversely affect vascular function. In the cerebral vasculature, this could 
lead to dysregulation of cerebral blood flow and neurological complications. Here, 
we examined the effect of excessive hyperlipidemia, as seen in preeclampsia, on 
cerebral artery function and expression of inflammatory markers in pregnancy. 
Pregnant and nonpregnant rats received a 14-day high cholesterol diet or normal 
chow and posterior cerebral artery function was compared. High cholesterol 
significantly increased sensitivity of posterior cerebral arteries to the nitric oxide 
donor sodium nitroprusside that was accompanied by an ~12 fold increased 
mRNA expression of inducible nitric oxide synthase in late-pregnant rats only. 
Further, high cholesterol significantly increased peroxynitrite-induced dilation 
and decreased myogenic tone in cerebral arteries from late-pregnant compared 
to nonpregnant animals. These results suggest that pathologically high levels 
of cholesterol in pregnancy enhance inflammatory responses and peroxynitrite 
generation in cerebral arteries. 
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Introduction
Preeclampsia is a complex, hypertensive disorder that affects 5-8% of all pregnancies 
and is a main cause of maternal mortality in developed countries.1, 2 It is established 
that endothelial vascular dysfunction plays a central role in the pathogenesis 
of preeclampsia, however, contributory causes remain to be elucidated.2, 3 
Epidemiological data suggest that women with previous preeclampsia have an 
increased risk of atherosclerotic vascular disease in later life, suggesting common 
risk factors are involved.4-6 Pregnancy might act as a “stress-test” that unmasks a 
woman’s predisposition to metabolic syndrome that may re-emerge in later life, 
thus increasing the risk for atherosclerotic vascular disease.7 Metabolic syndrome 
includes hyperlipidemia which is known to compromise endothelial function 
and contribute to atherosclerotic vascular disease, but may also be involved in 
endothelial dysfunction that occurs in preeclampsia.8, 9 
During normal pregnancy, plasma lipid levels including cholesterol are increased 
due to elevated production of pregnancy-related hormones.10, 11 This hormonally 
controlled “physiological hyperlipidemia” encourages lipogenesis and fat storage 
in preparation for rapid fetal growth in late-pregnancy, but does not normally 
cause endothelial dysfunction in the maternal vascular system.10 However, women 
who develop preeclampsia might demonstrate poor adaptation to this stress-test 
in pregnancy because the increase in lipid levels is more dramatic compared to 
normal pregnant women.8 This excessive hyperlipidemia in preeclampsia has an 
atherogenic profile, characterized by increased low-density lipoprotein (LDL) that 
may cause acute atherosclerosis in the maternal-fetal unit, vascular dysfunction and 
inflammation.12, 13 The term “acute” reflects that the damaging effects induced by 
lipids in pregnancy develop over a shorter time compared to outside of pregnancy, 
suggesting that pregnancy is more susceptible to damaging effects of excessive high 
lipid levels.12 If these acute events caused by excessive hyperlipidemia in pregnancy 
occur in the cerebral vasculature, it could promote dysregulation of cerebral blood 
flow and contribute to neurological complications seen in preeclampsia. We 
hypothesized that pathologically high levels of lipids during pregnancy will cause 
cerebral vascular dysfunction that may contribute to neurological complications as 
seen in preeclampsia. To our knowledge, no study has investigated the effects of 
hyperlipidemia on cerebral vascular function in pregnancy. Thus, the first aim of this 
study was to determine the effect of excessive hyperlipidemia on cerebral artery 
function in pregnancy compared to the nonpregnant state. 
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Hypercholesterolemia enhances oxidative stress by increasing the production of 
superoxide through enhanced NAPDH-oxidase activity.14, 15 Superoxide rapidly 
binds nitric oxide (NO) which is elevated in pregnancy to form peroxynitrite (ONOO-
), a relatively stable reactive oxygen and nitrogen species.16-18 ONOO- is known to 
cause endothelial and vascular dysfunction due to reduced bioavailability of NO.19, 
20 Increased ONOO- generation has been shown in the maternal-fetal unit and the 
systemic vasculature of women with preeclampsia.21 In addition, NADPH-oxidase 
activity is greater in the cerebral circulation compared to the systemic vasculature, 
potentially making the production of superoxide through NADPH-oxidase 
induced by hypercholesterolemia greater in the cerebral vasculature.22 Thus, we 
hypothesized that the cerebral vasculature would be particularly adversely affected 
by substantial ONOO- generation due to increased NADPH-oxidase expression 
stimulated by excessive hyperlipidemia in pregnancy. Therefore, the second aim of 
this study was to determine the effects of ONOO- generation due to pathological 
high levels of cholesterol on cerebral artery function in pregnancy. Additionally, 
we measured mRNA expression of inducible nitric oxide synthase (iNOS) and the 
NADPH-oxidase isoform NOX2 in the cerebral vasculature under conditions of 
high cholesterol as potential sources of NO and superoxide, respectively.  
Methods
Animals. All animal procedures were approved by the University of Vermont 
Institutional Animal Care and Use Committee and complied with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Female 
Sprague Dawley rats aged 12-14 weeks were used for all experiments. Early 
pregnant rats (day 6 of gestation) and age-matched virgin nonpregnant rats 
were purchased (Charles River, Canada) and housed for 14 days at the University 
of Vermont Animal Care Facility, an Association for Assessment and Accreditation 
of Laboratory Animal Care-accredited facility. Rats were divided into 4 groups: 
nonpregnant control (NP-CTL; n=7), nonpregnant high cholesterol (NP-HC; n=8), 
late-pregnant control (LP-CTL; n=6) and late-pregnant high cholesterol (LP-HC; 
n=7). NP-CTL and LP-CTL received Prolab® 3000 for 14 days with day 14 being the 
day of experimentation. Because our goal was to achieve a significant increase in 
cholesterol levels in NP-HC and LP-HC rats, these animals received a 14 day diet 
consisting of Prolab® 3000 rodent chow, including 2% cholesterol and 0.5% cholic 
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acid (added to lower hepatic clearance of cholesterol) to significantly increase 
total cholesterol and LDL-cholesterol, as shown in earlier reports.23 All groups of 
animals had access to food and water ad libitum and maintained a 12-hour light/
dark cycle. 
Plasma cholesterol measurements. Plasma samples were obtained from trunk blood 
from all rats. Blood was collected in EDTA separation tubes and centrifuged for 
10 minutes at 2500 revolutions per minute. Plasma was aliquoted and stored in 
-80ºC until needed for the lipid measurements. Lipid measurements, including 
total cholesterol and HDL cholesterol, were measured on the Roche Cobas Integra 
400 Plus instrument using an enzymatic colorimetric method per manufacturer’s 
protocol (Roche Integra®). LDL-c was calculated using the Friedewald’s equation 
according to manufacturer’s protocol. 
Experimental protocols. On the day of experiment, animals were anesthetized with 
3% isoflurane in oxygen and quickly decapitated. The brain was removed and 
placed in cold physiological salt solution (PSS). Two third-order branches of the 
posterior cerebral artery (PCA) were carefully dissected for isolated arteriograph 
experiments. Vessels were mounted on 2 glass cannulas within an arteriograph 
chamber and experimented separately. Arteries were perfused with PSS at a pH 
of 7.40 ± 0.05 and a temperature of 37.0 ± 0.5 °C. The proximal cannula of the 
arteriograph was connected to a pressure transducer and servo controller that 
maintained intravascular pressure at a set pressure or changed manually. The 
distal cannula was closed to avoid flow-mediated responses. Lumen diameter was 
continuously measured via video microscopy during the entire experiment.
The first experiment was started after an equilibration time of 1 hour at a pressure 
of 50 mmHg. Intravascular pressure was then increased in steps of 25 mmHg to 
150 mmHg, which reflects the myogenic pressure range of these cerebral arteries. 
Active lumen diameter was recorded at each pressure once stabilized. Pressure 
was then returned to 75 mmHg and vessel diameter was compared to the 
vessel diameter at 75 mmHg prior to the pressure steps to confirm that tone was 
restored. For the remainder of the experiment, the pressure was kept on 75 mmHg. 
A single high concentration (0.1mmol/L) of the NOS inhibitor L-nitro-arginine 
(L-NNA) was added to the bath and constriction in response to NOS inhibition 
was measured. After approximately 20 minutes in the presence of L-NNA, the NO 
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donor sodium nitroprusside (SNP) was cumulatively added to the bath (10-8 M-10-5 
M) and the dilation to SNP was measured at each concentration. At the end of the 
experiment, zero-Ca2+ PSS was added to the bath to obtain fully relaxed diameters. 
Passive diameters were then recorded at pressures from 5 to 175 mmHg using 
video microscopy.
The second experiment was performed to determine the influence of the 
ONOO- decomposition catalyst FeTMPyP on active myogenic responses in the 
high cholesterol-treated animals. This particular compound was chosen because 
previous studies have shown it is selective for blocking ONOO- effects without 
interfering with NO or superoxide. 24 The second third-order branch of PCA was 
mounted in the arteriograph and perfused with 50µM FeTPMyP. This concentration 
was used based on one of our earlier studies where  FeTMPyP was used in 
isolated arteries to scavenge ONOO-.25 After equilibration, intravascular pressure 
was increased in steps of 25 mmHg to 150 mmHg. Active lumen diameter was 
recorded at each pressure once stabilized. Afterwards, zero-Ca2+ PSS was added to 
the bath and passive diameters were recorded at pressures from 5 to 175 mmHg.
Messenger RNA expression of iNOS and NOX 2. Because both left and right PCAs from 
each animal were used for the isolated artery experiments, the middle cerebral 
arteries (MCAs) from the same animals were used for PCR analysis of iNOS and NOX2. 
Total RNA was extracted from middle cerebral arteries from NP-CTL (n=6), NP-HC 
(n=6), LP-CTL (n=6) and LP-HC (n=7) by using Trizol reagent (Life Technologies) 
followed by purification using an Rneasy Micro Kit (Qiagen) per manufacturer’s 
protocols. RNA concentrations and quality were determined using an Agilent 
Bioanalyzer (Agilent). Real-time PCR was performed in a two-step process. RNA 
was reverse transcribed using a mix of oligo dT primers and random primers 
using the iScript cDNA Synthesis Kit (Biorad). For each sample cDNA was used to 
amplify the target genes iNOS and NOX2 and two housekeeping genes, Hprt1 and 
Ywhaz. Primers were designed by the Obstetrics and Gynecology Departmental 
Molecular Core Facility at the University of Vermont using PrimerSelect 
(DNASTAR). The quantitative PCR primers for the rat transcripts were: iNOS (f ): 
-GAGAAGTCCAGCCGCACCAC- and (r): -GAACAATCCACAACTCGCCCAAG-; NOX2 
(f ): -TTAGCATCCATATCCGCATTGT-TG- and (r): CTATCTTAGGTAGTTTCCAGGCATCTT; 
Hprt1 (f ): -CTCATGGACTGTT-ATGGACAGGAC- and (r): -GCAGGTCAGCAAA-
GAACTTATAGCC-; Ywhaz (f ): -GATGAAGCCATTGCTGAACTTG- and (r): - 
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GTCTCCTTGGGTATCCGATGTC-.  One microliter of cDNA was used per reaction 
with 150 nM of the forward and reverse primers and 12.5 µl of Power Sybrgreen 
Master mix (Life Technologies) in a 25 µl reaction. The reactions were performed 
using an initial denaturation of 3 minutes at 95°C, 40 cycles of 15 seconds at 
95°C and 60 seconds at 60°C, followed by a melt curve analysis to ensure only 
the correct product was amplified. One set of PCR products for each gene were 
checked for correct size on a 2% Agarose gel. Each sample was run in triplicate on 
the ABI 7000 Sequence Detection System (ABI). Negative water controls were run 
for each primer set in the real-time PCR reaction to ensure no contamination in the 
reagents as well as no secondary primer structures were amplified. In each primer 
set at least one primer was designed over an exon-exon junction or the amplicon 
was designed to span an exon-exon junction to make sure that genomic DNA was 
not amplified. 
Data Calculations Percent tone was calculated as the percent decrease in diameter 
from the fully relaxed diameter in zero-Ca2+ PSS by the equation: ((Øpassive- Øactive)/ 
Ø
passive
) x 100%, where Ø
passive
 is the diameter in zero- Ca2+ PSS and Ø
active
 is the 
diameter with tone. Percent constriction to L-NNA was calculated with the 
equation: ((Ø
baseline
-Ø
drug
)/ Ø
baseline
) x 100% where Ø
baseline
 is diameter before giving 
L-NNA and Ø
drug
 is diameter with presence of L-NNA. Percent sensitivity to the 
NO donor SNP using a concentration-response curve was calculated with the 
equation: ((Ø
drug
-Ø
minimum
)/(Ø
maximum
 – Ø
minimum
)) x 100% where Ø
drug
 is diameter at 
a specific concentration of SNP, Ø
minimum
 is diameter at the lowest concentration 
of SNP and Ø
maximum
 is the diameter at the highest concentration of SNP. To 
calculate the effective concentration that produced half maximal dilation (EC
50
) 
of SNP, the concentration-response curve was log transformed and plotted for 
each experiment separately. The EC
50
 was then determined off the best-fit curve 
and averaged for each group.  For PCR measurements, relative expression was 
determined using the 2-DDCT method.26  
Drugs and solutions. A bicarbonate-base PSS buffer was used for all experiments. 
The composition was (mmol/L) NaCl 119.0, NaHCO
3
 24.0, KCl 4.7, KH
2
PO
4
 1.18, 
MgSO
4
.7H
2
O 1.17, CaCl
2
 1.6, EDTA 0.026, and glucose 5.5. PSS was aerated with 
5% CO
2
, 10% O
2
 and 85% N
2
 to maintain pH at 7.40 ± 0.05 and stored without 
glucose at 4°C. Glucose was added before each experiment. L-NNA and SNP were 
purchased from Sigma, FeTMPyP was purchased from Calbiochem. 
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Statistical analysis. Data from the isolated artery experiments are presented as 
mean ± standard error of the mean. Data from PCR measurements are presented as 
means only because values were averaged in each group due to limited samples. 
Data were analyzed using one-way ANOVA and post hoc Student-Newman 
Keuls test for multiple comparisons where appropriate or with a Student t-test. 
Differences were considered statistically significant when P<0.05.  
Results
Plasma cholesterol levels in NP and LP rats. Total cholesterol levels were similar in NP 
and LP control animals, being 77 ± 3mg/dl and 79 ± 6 mg/dl respectively. High 
cholesterol diet caused a significant increase in total cholesterol levels in both LP-
HC and NP-HC animals. In NP-HC rats, total cholesterol increased 550% to 500 ± 
52 mg/dl and in LP-HC total cholesterol increased 740% to 669 ±81 mg/dl. The 
difference between total cholesterol levels in NP-HC and LP-HC animals was not 
statistically different (P=0.12). LDL-c levels could not be calculated in the control 
animals because levels of determinants needed for calculating LDL-c were too 
low. LDL-c levels in NP-HC animals were 400 ± 40 mg/dl and in LP-HC animals 
547 ± 78 mg/dl (P= 0.13). HDL was increased only in LP-HC animals from 42 ± 4 
mg/dl in LP-CTL rats to 77 ± 6 mg/dl in LP-HC rats (P<0.05). In NP-HC rats, HDL-
cholesterol remained stable compared to NP-CTL rats and was 50 ± 5 mg/dl and 
44 ± 5mg/dl respectively (P=0.27). We also calculated the HDL/LDL ratio and found 
no difference between LP-HC and NP-HC animals being 0.14 and 0.13 respectively, 
which confirms significant hypercholesterolemia in both NP and LP animals.            
Effect of hypercholesterolemia on active myogenic responses in PCAs from NP and LP 
rats. A high cholesterol diet caused a trend towards decreased tone in PCAs from 
both goups of animals, although this decrease was not statistically different. In NP-
CTL rats, percent tone of PCAs at the physiological pressure of 75 mmHg was 14 ± 
6 % compared to 5 ± 2% in NP-HC rats (P=0.18). Percent tone in PCAs from LP-CTL 
rats was 11 ± 6 % compared to 4 ± 3 % in LP-HC rats (P=0.25).
Effect of hypercholesterolemia on constriction to NOS inhibition in PCAs from NP 
and LP animals. To assess the contribution of endothelium-derived NO to tone, 
constriction to NOS-inhibition was determined by the addition of a single high 
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concentration of L-NNA to the cerebral arteries from all 4 groups of animals. L-NNA 
caused constriction in PCAs from all animals, suggesting basal NO that inhibits 
tone was present in all vessels. However, there were no significant differences in 
the amount of constriction between the animals. In NP-CTL animals, the percent 
constriction was 20 ± 3 % compared to 18 ± 2 % in NP-HC animals (P > 0.05). In 
LP-CTL rats, the percent constriction to L-NNA was 22 ± 5 % compared to 18 ± 2% 
in LP-HC rats (P > 0.05).
Effect of hypercholesterolemia on NO-mediated vasodilation in the PCAs from NP and 
LP animals. To determine if the response of the smooth muscle to NO was different 
in PCAs from high cholesterol-treated animals, the sensitivity to the NO donor SNP 
was compared. A high cholesterol diet in NP rats did not cause significant changes 
in the response of cerebral arteries to SNP compared to NP-CTL animals (Figure 
1A). However, PCAs from LP-HC rats displayed significantly greater sensitivity to 
SNP compared to LP-CTL animals (Figure 1B). Further, the EC50 of SNP showed no 
difference between NP-CTL and NP-HC animals (Figure 1C). However, the EC
50
 was 
significantly lower in the LP-HC rats compared to LP-CTL animals (Figure 1D). These 
results suggest that the vascular smooth muscle in PCAs from LP-HC animals was 
more sensitive to NO compared to the cerebral arteries from the other groups.  
Figure 1: Effect of hypercholesterolemia on SNP vasodilation in posterior cerebral arteries from 
nonpregnant and late-pregnant rats. Graphs showing sensitivity to the NO donor SNP (A,B) and the EC
50
 of 
SNP (C,D) as percentage of the maximum dilation in the presence of NOS-inhibition in posterior cerebral 
arteries (PCAs). There was no difference in dilation to SNP in PCAs from NP-CTL or NP-HC rats. However, PCAs 
from LP-HC rats showed a significant increase in sensitivity to SNP compared to LP-CTL animals. NP-CTL: 
nonpregnant control animals; NP-HC: nonpregnant high cholesterol-treated animals; LP-CTL: late-pregnant 
control animals; LP-HC: late-pregnant high cholesterol-treated animals. *P<0.05 vs. LP-CTL.
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The effect of FeTMPyP on active myogenic responses in PCAs from high cholesterol-
treated NP and LP rats. We determined the effect of the ONOO- decomposition 
catalyst FeTMPyP on active myogenic responses in PCAs from high cholesterol-
treated NP and LP rats only by perfusing the PCAs with 50 µM FeTMPyP. 
Treatment with FeTMPyP caused PCAs from both NP-HC and LP-HC rats to display 
significantly smaller diameters (Figure 2A). Interestingly, the decrease in diameter 
after perfusion with FeTMPyP was significantly greater in the PCAs from the LP-HC 
animals compared to the NP-HC animals. Further, PCAs from NP-HC and LP-HC 
animals perfused with FeTMPyP caused a significant increase in pressure-induced 
tone between 75 mmHg and 150 mmHg (Figure 2B). In addition, tone in PCAs 
from LP-HC animals perfused with FeTMPyP was significantly greater than the 
tone in FeTMPyP-treated PCAs from the NP-HC animals. Thus, FeTMPyP decreased 
vessel diameter and increased tone in PCAs from both NP-HC and LP-HC animals, 
an effect that was more pronounced in the LP-HC animals.   
  
Figure 2: Effect of FeTMPyP on the active lumen diameter and percent tone of posterior cerebral arteries 
from nonpregnant and late-pregnant high cholesterol-treated rats. Graphs showing active lumen 
diameter (A) and percent tone (B) of posterior cerebral arteries (PCAs) as a function of intravascular pressure. 
There were no differences in active lumen diameter between NP-HC and LP-HC. However, treatment with 
the ONOO- scavenger FeTMPyP caused a significant decrease in active lumen diameter in PCAs from both 
NP-HC and LP-HC animals, that was significantly greater in LP-HC animals compared to NP-HC animals. 
Treatment with FeTMPyP caused a significant increase in tone in the PCAs from both NP-HC and LP-HC 
animals, that was significantly higher in FeTMPyP treated LP-HC animals compared to FeTMPyP treated NP-
HC animal. NP-CTL: nonpregnant control animals; NP-HC: nonpregnant high cholesterol treated-animals; 
LP-CTL: late-pregnant control animals; LP-HC: late-pregnant high cholesterol-treated animals. *P<0.05 vs. 
NP-HC and LP-HC. #P<0.05 vs. all.
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Effect of high cholesterol diet on iNOS and NOX-2 mRNA expression in middle cerebral 
arteries from NP and LP rats. We have previously shown that PCAs from normal 
pregnant animals have increased iNOS mRNA expression.27 Therefore, we wanted 
to determine the effect of high cholesterol diet on iNOS mRNA expression that 
may contribute to increased sensitivity to SNP and increased ONOO- generation 
in PCAs from LP-HC rats. We measured the relative change in mRNA levels of iNOS 
in MCAs from NP-HC, LP-CTL and LP-HC animals compared to NP-CTL animals 
(Figure 3A). Because only 2 vessels in both the NP-CTL and NP-HC groups showed 
expression of iNOS within 40 treshold cycles (C
T
), we averaged the DC
T
’s values of the 
vessels from these groups. This approach was then used for all other comparisons. 
Also, vessels were excluded if replicates were > 0.5 C
T
 apart. Treatment with high 
cholesterol in NP rats did not cause an increase in iNOS expression in cerebral 
arteries. However, expression of iNOS was increased in pregnancy compared to 
the nonpregnant state, as reported previously.27 In addition, high cholesterol diet 
in pregnancy caused a ~12 fold increase in iNOS mRNA expression compared to 
NP-CTL rats which was a higher than the ~6 fold increase in LP-CTL rats. 
NADPH-oxidase has 3 different isoforms expressed in the cerebral vasculature 
(NOX1, NOX2 and NOX4), however, NOX2 has been shown to be the major source 
for superoxide generation.28 Thus, we wanted to determine the relative change 
in mRNA expression of NOX2 in MCAs from NP-HC, LP-CTL and LP-HC animals 
compared to NP-CTL animals (Figure 3B). Treatment with high cholesterol in NP 
rats caused an ~2 fold increase in mRNA expression of NOX2 compared to NP-CTL 
rats. However, there was no increase in mRNA expression of NOX2 in the cerebral 
vasculature from LP-CTL or LP-HC animals compared to NP-CTL animals. 
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Figure 3: Effect of high cholesterol on mRNA expression of iNOS and NOX2 in middle cerebral arteries 
from nonpregnant and late-pregnant animals. Graphs showing the relative change in mRNA expression 
for iNOS (A) and NOX2 (B) in middle cerebral arteries from LP-CTL, LP-HC and NP-HC animals compared to 
NP-CTL animals. Cholesterol treatment in NP rats caused no change in iNOS mRNA expression. In contrast, 
pregnancy caused an ~6 fold increase in iNOS mRNA expression and an ~12 fold increase in iNOS mRNA 
expression when LP rats were treated with high cholesterol. High cholesterol caused an ~2 fold increase in 
NOX2 mRNA expression in NP rats. However, pregnancy did not appear to change the mRNA expression of 
NOX2 with or without treatment of high cholesterol. NP-CTL: nonpregnant control animals; NP-HC: 
nonpregnant high cholesterol-treated animals; LP-CTL: late-pregnant control animals; LP-HC: late-pregnant 
high cholesterol-treated animals.
Discussion
In the present study, we examined the effects of pathologically high levels of 
lipids, as seen in preeclampsia, in the cerebral vasculature of pregnant animals. 
Our results showed that an excessive hyperlipidemia caused PCAs to have less 
myogenic tone in both NP and LP animals. In addition, the ONOO- decomposition 
catalyst FeTMPyP caused significantly smaller vessel diameters and increased 
myogenic tone in both LP-HC and NP-HC animals, with the effect being greater in 
the LP-HC animals compared to the NP-HC animals. Further, treatment with high 
cholesterol sensitized PCAs from LP animals to the effects of the NO donor SNP and 
increased iNOS mRNA expression that was not seen in high cholesterol-treated NP 
animals. Taken together, excessive hyperlipidemia caused a greater inflammatory 
response and oxidative stress in cerebral arteries in pregnancy compared to the 
nonpregnant state. 
Preeclampsia presents with an excessive hyperlipidemia compared to normal 
pregnancy that may adversely affect overall vascular function as seen in 
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atherogenic vascular disease.13, 29, 30 In pregnancy, excessive hyperlipidemia 
causes acute atherosclerotic changes in the maternal-fetal unit over a shorter 
period of time than outside of pregnancy.12 This suggests that in some women, 
pregnancy is more sensitive to the damaging effects of high cholesterol. In the 
present study, we sought to determine the effects of excessive hyperlipidemia in 
pregnancy compared to the nonpregnant state by using a high cholesterol rat 
model. Although we attempted to match the levels seen in preeclamptic women, 
the levels of cholesterol in the HC-treated rats were higher than those measured 
during  preeclampsia and should be considered in the interpretation of the results. 
However, because the levels were pathologically high compared to control rats, 
we were able to determine the effects of high cholesterol in pregnancy on PCA 
function. Only a few studies measured active myogenic responses in the cerebral 
vasculature during hypercholesterolemia and to our knowledge no studies 
investigated the effects in pregnancy.31-34 Myogenic responses describe the extent of 
constriction of the vessels in response to an increase or decrease in pressure and are 
important to maintain cerebral blood flow.31 We found that hypercholesterolemia 
caused a trend to decrease myogenic tone in both LP-HC and NP-HC groups. 
This is in contrast with Ramirez et al, where they found an increase in myogenic 
constriction in mesenteric arteries in pregnancy due to hypercholesterolemia.32 
However, the cerebral vasculature differs from the systemic vasculature and may 
experience different effects from hypercholesterolemia. For example, McCalden 
et al. found a decrease in myogenic constriction in cerebral arteries due to 
hypercholesterolemia, however, this study was performed in rabbits instead of rats 
and pregnancy was not examined.33 It is worth noting that changes in tone due 
to treatment with high cholesterol were mild and not statistically significant. In 
addition, responses to L-NNA were similar in both high cholesterol treated groups 
compared to the CTL animals. This is in contrast to a previous study that found 
that cerebral arteries in monkeys that received long-term atherogenic diet had 
reduced response to soluble guanylate cyclase inhibition, suggesting decreased 
NO production during atherosclerosis.34 It is possible that this lack in significant 
differences could be explained by limitations of our rat model. First, rats are known 
to adapt to high cholesterol and exhibit little to no atherosclerotic changes 
because of the ability to carry most plasma cholesterol in HDL-particles and a high 
rate of hepatic clearance.35 Also, in the present study, the high cholesterol diet was 
started at day 6 of pregnancy resulting in a 14-day high cholesterol diet. Thus, the 
duration of the diet may have been too short to unmask significant differences in 
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the active myogenic responses due to hypercholesterolemia in the pregnant and 
nonpregnant animals.
The mechanism of decreased myogenic tone in hypercholesterolemia may be 
explained with increased ONOO- generation. Previous reports have shown that 
hyperlipidemia causes increased ONOO- generation in the systemic vasculature 
and other organs.20, 36 We found that by using the ONOO- decomposition catalyst 
FeTMPyP, vessel diameters significantly decreased and myogenic tone significantly 
increased in PCAs from both NP-HC and LP-HC animals. Because FeTMPyP is 
considered suitable to assess direct ONOO- contribution in functional rat studies, 
we suggest that presence of ONOO- significantly inhibited tone in these high 
cholesterol treated animals.37 Our findings are consistent with multiple previous 
reports that ONOO- reduced tone in the cerebral vasculature. 38-40 However, these 
studies were not related with hypercholesterolemia. One other study showed 
in a rabbit model that hypercholesterolemia decreased basal vascular tone 
in systemic resistance arteries due to an increased production of NO.41 These 
findings are similar to our findings since increased NO production could lead 
to increased ONOO- generation. Interestingly, in the present study, the effect of 
FeTMPyP was significantly greater in the LP-HC animals compared to the NP-
HC animals, suggesting pathological high levels of lipids in pregnancy result in 
higher generation of ONOO- compared to NP-HC animals. This increased ONOO- 
generation due to high cholesterol in pregnancy would be of particular interest 
in the pathogenesis of preeclampsia, where increased levels of ONOO- have been 
found in the placental circulation in preeclampsia.21  
Previous reports showed that hypercholesterolemia induces cerebral artery 
dysfunction through NADPH-oxidase activity, which is the major source of 
production of superoxide.14, 15, 42 Superoxide rapidly binds to NO to form ONOO-
.20 In addition, NADPH-oxidase activity is greater in the cerebral vasculature 
compared to the systemic vasculature.42 The NADPH-oxidase isoform NOX2 
appears to be more important than other isoforms in superoxide production in 
the cerebral vasculature, especially during pathological conditions including 
hypercholesterolemia.14, 28 Interestingly, while the effects of FeTMPyP were the 
highest in LP-HC animals, our results showed that only the NP-HC, but not the 
LP-HC animals, had an ~2-fold increase in mRNA NOX2 expression. Thus, in LP-HC 
animals, high ONOO- generation was not likely due to high superoxide production 
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from increased NOX2 expression. However, our measurements were limited 
to mRNA expression of NOX2 only and it could be that NOX2 activity or other 
enzymes that generate superoxide are increased in pregnancy compared to the 
nonpregnant state. 
Another explanation for the increased generation of ONOO- in pregnancy 
compared to the nonpregnant state could be the increased expression of iNOS. 
iNOS is known to produce excessive amounts of NO that is a critical factor for 
ONOO- generation.20 Our results showed that high cholesterol treatment caused 
an increase in iNOS mRNA expression in pregnancy compared to the nonpregnant 
state. Although our data are limited to mRNA expression, these results showed 
an increase in iNOS mRNA and support our earlier work that pregnancy alone 
can be considered as a state of inflammation.27 Interestingly, high cholesterol 
treatment further increased iNOS mRNA expression in the cerebral arteries from 
LP animals, which has also been found in placental tissue from preeclamptic 
women compared to normal pregnant women and in human umbilical vein 
cells after exposure to preeclamptic serum.43-45 The increase in iNOS expression 
in the LP-HC animals may also be related to the increased sensitivity to the NO 
donor SNP. Because the enhanced dilation to SNP occurred with NOS inhibition, 
an increased sensitivity of the vascular smooth muscle to the effects of NO caused 
by iNOS is most likely. For example, Gunnett et al. showed that iNOS opposes 
contraction by activating soluble guanylate cyclase in the smooth muscle that 
inhibits contractile responses and sensitizes the vascular smooth muscle to the 
effects of NO.46 In contrast, treatment with high cholesterol did not increase iNOS 
mRNA expression or sensitivity to dilation to SNP in the nonpregnant animals. This 
suggests that cerebral arteries are more sensitive to pathological high levels of 
lipids in pregnancy compared to the nonpregnant state, resulting in an excessive 
amount of NO and ONOO- generation.
In summary, this study was designed to determine if pathological levels of high 
cholesterol, similar to preeclampsia, would induce cerebral artery dysfunction 
during pregnancy. We found that oxidative stress in high cholesterol-treated LP 
animals was increased compared to high cholesterol-treated NP animals that may 
be explained by an enhanced inflammatory state, as suggested by increased iNOS 
expression. However, further studies are needed to determine what effect this may 
have in the pathogenesis of preeclampsia. 
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Abstract
Early-onset preeclampsia (EPE) is a severe form of preeclampsia that involves life-
threatening neurologic complications. However, the underlying mechanism by 
which EPE affects the maternal brain is not known. We hypothesized that plasma 
from EPE women increases blood-brain barrier (BBB) permeability vs. late-onset 
preeclamptic (LPE) or normal pregnant (NP) women and investigated its underlying 
mechanism by perfusing cerebral veins from nonpregnant rats (n=6-7/group) 
with EPE, LPE or NP human plasma and measuring permeability. We show that 
plasma from EPE women significantly increased BBB permeability vs. LPE or NP 
women (P<0.001).  BBB disruption in response to EPE plasma was due to a 260% 
increase of circulating oxidized LDL (oxLDL) binding to its receptor, LOX-1, and 
subsequent generation of peroxynitrite (P<0.001). A rat model with pathologically 
high lipid levels in pregnancy showed symptoms of preeclampsia, including 
elevated blood pressure, growth-restricted fetuses, and LOX-1-dependent BBB 
disruption, similar to EPE (P<0.05). Thus, we have identified LOX-1 activation by 
oxLDL and subsequent peroxynitrite generation as a novel mechanism by which 
disruption of the BBB occurs in EPE. As increased BBB permeability is a primary 
means by which seizure and other neurologic symptoms ensue, our findings 
highlight oxLDL, LOX-1 and peroxynitrite as important therapeutic targets in EPE. 
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Introduction
Neurologic symptoms are the most serious and life-threatening complication of 
preeclampsia 1. The new onset of uncontrolled vomiting, cortical blindness, seizure 
and coma during preeclampsia represent a severe form of disease that accounts 
for ~75% of all maternal deaths worldwide 2, 3. Epidemiologic studies have shown 
that neurologic complications occur more often in early-onset preeclampsia 
(EPE) where hypertension and proteinuria occur before 34 weeks of gestation, 
compared to late-onset preeclampsia (LPE) in which hypertension and proteinuria 
develop after 34 weeks of gestation 4-6. This importantly suggests that EPE is a more 
severe form of preeclampsia that adversely affects the maternal brain, promoting 
neurologic complications. However, the unique factors contributing to neurologic 
involvement during EPE are largely unknown.
Vasogenic brain edema has been shown in preeclampsia and is the result of disruption 
of the blood-brain barrier (BBB) and increased cerebrovascular permeability 7-9. In 
addition to brain edema, increased BBB permeability promotes the passage of 
damaging proteins and plasma constituents into the brain parenchyma that can 
activate microglia and promote seizure activity 8, 10, 11. Thus, the BBB has a central 
role in promoting neurologic symptoms during preeclampsia. We previously 
showed that plasma from preeclamptic women but not from women with normal 
pregnancy (NP) increased BBB permeability of cerebral veins, demonstrating that 
circulating factors are an important means by which BBB disruption can occur in 
preeclampsia 12. In that study, plasma was pooled from preeclamptic women with 
severe disease, however, EPE and LPE were not distinguished. The first aim of this 
study was to investigate the differential effect of circulating factors in plasma from 
EPE and LPE plasma on BBB permeability. We hypothesized that circulating factors 
in plasma from EPE women would have a greater impact on BBB disruption that 
underlies neurologic symptoms in that group.
One circulating factor that is increased in preeclampsia compared to normal 
pregnancy is oxidized low-density lipoprotein (oxLDL) 13-15. Increased oxidative 
stress in the placental circulation during preeclampsia causes oxidative conversion 
of LDL to oxLDL 16, 17. OxLDL has a greater negative charge compared to native 
LDL and therefore selectively binds lectin-like oxidized LDL receptor 1 (LOX-1), 
expressed predominantly on endothelial cells, to cause vascular dysfunction in 
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several disease states including hypertension, diabetes and atherosclerosis 18, 19. 
Thus, our second aim of this study was to investigate oxLDL and LOX-1 activation 
as an underlying mechanism by which EPE plasma possibly selectively affects 
the BBB to be more permeable. To our knowledge, no study has shown that 
circulating oxLDL and LOX-1 activation is an underlying cause of BBB disruption in 
preeclampsia. However, understanding of this mechanism would be particularly 
important in the pathogenesis of preeclampsia considering recent reports of 
increased LOX-1 expression in the systemic vasculature from preeclamptic women 
and in a rat model of preeclampsia 20-22. 
LOX-1 activation rapidly stimulates the production of superoxide in endothelial 
cells, mainly through activation of NADPH oxidase 23, 24. Superoxide decreases the 
concentration of nitric oxide (NO) by binding NO to form peroxynitrite, a relatively 
stable reactive oxygen and nitrogen species that has deleterious effects on cell 
viability and endothelial function 25. Peroxynitrite generation has been reported 
in the maternal systemic vasculature and is thought to contribute to endothelial 
dysfunction during preeclampsia. However, if peroxynitrite generation, secondary 
to LOX-1 activation, is also involved in disrupting the BBB during preeclampsia is 
not known. Thus, our last aim of the study was to determine if increased levels 
of circulating oxLDL in plasma from women diagnosed with EPE would activate 
LOX-1, resulting in subsequent peroxynitrite generation leading to BBB disruption 
in EPE women. In this study, we used an established method of measuring BBB 
permeability of cerebral veins perfused with plasma (12, 26, 27). Cerebral veins are 
used because they have BBB properties and are a major site of disruption during 
acute hypertension (26-28).
Material and Methods
Patients. Maternal plasma samples were obtained from an ongoing investigation 
of preeclampsia (Prenatal Exposures and Preeclampsia Prevention; PEPP) at 
the Magee-Womens Research Institute and Hospital, University of Pittsburgh, 
Pennsylvania. PEPP was approved by the University of Pittsburgh institutional 
review board and informed consent was obtained from all participants. The PEPP 
committee approved the use of these previously frozen samples by our institution 
and de-identified clinical data. Blood samples from all women were collected into 
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EDTA tubes. Plasma was centrifuged at 1600 revolutions per minute and aliquoted. 
Plasma was then pooled from 4 groups: NonP women who had never been 
pregnant (n=9), NP women (n=12), LPE women (n=10) and EPE women (n=5) and 
stored at -80ºC until experimentation. The women enrolled in the preeclamptic 
groups met the criteria according to the American College of Obstetricians and 
Gynecologists of blood pressure greater than or equal to 140 mmHg systolic and/
or 90 mmHg diastolic plus an increase of greater than 30 mmHg systolic and/or 15 
mmHg diastolic plus proteinuria greater than 300 mg/24hrs or at least equal to 2+ 
protein using a urine dipstick test. EPE women were diagnosed with preeclampsia 
and delivered before 34 weeks of gestation and LPE women were diagnosed 
and delivered after 34 weeks of gestation (see Table 1). Only non-smokers and 
nulliparous women were included. 
Measurement of oxLDL in human plasma samples. The levels of oxLDL in the 
plasma from the NonP, NP, LPE and EPE women were determined using a 
sandwich Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit (Immunodiagnostik, 
Bensheim, Germany) according to the manufacturers’ instructions. Measurements 
were performed in duplicate and averaged.
Animals. Female Sprague Dawley virgin nonpregnant rats (12-14 weeks; 250-300 
grams) or female Sprague Dawley pregnant rats (day 5; 12-14 weeks, 250-300 
grams) were purchased from Charles River (Saint-Constant, QB, Canada). Animals 
were housed in the Animal Care facility, an Association for Assessment and 
Accreditation of Laboratory Animal Care-accredited facility. Animals had access to 
food and water ad libitum and were maintained on a 12-hour light/dark cycle. 
The animal studies were approved by the IACUC of the University of Vermont and 
the Institutional Animal care and Use Committee and complied with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. 
High-cholesterol rat model. On day 6 of pregnancy, rats were divided into a late-
pregnant control group (LP-CTL; n=8) and a late-pregnant high-cholesterol treated 
group (LP-HC; n=8). The LP-CTL rats received Prolab® 3000 rodent chow for 14 days. 
The LP-HC animals received a 14 day diet consisting of Prolab® 3000 rodent chow, 
including 2% cholesterol and 0.5% cholic acid (added to lower hepatic clearance 
of cholesterol) to increase total and LDL-cholesterol. Experimentation was done 
on day 14 of the diet that equaled day 20 of pregnancy in all animals. Pups and 
placenta’s were weight averaged per animal. 
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Blood pressure measurements. All LP-CTL and LP-HC animals had blood pressure 
measurements taken on day 2 and day 13 of their diet. Animals were trained for 2 
days prior to the first day of blood pressure measurements to make the rats familiar 
with handling and restraint associated with the procedure and thereby avoid 
measuring artificially high blood pressures. Blood pressures were taken using a 
noninvasive tail cuff method (CODAS 8, Kent Scientific, Torrington, Connecticut). 
Briefly, animals were placed in individual holders on a heating plate and both an 
occlusion cuff and a volume pressure-recording cuff were placed on the tail close 
to the base. Animals were warmed to 30 °C for optimal volume pressure recording. 
Systolic, diastolic and mean blood pressure, heart pulse rate, tail blood volume, 
and tail blood flow were measured simultaneously. 
Rat plasma samples. Plasma samples were obtained from trunk blood from LP-
CTL and LP-HC rats. Plasma was collected in EDTA plasma separation tubes and 
centrifuged for 10 minutes at 2500 revolutions per minute. Plasma was then 
aliquoted and directly used for permeability experiments. 
BBB permeability measurements. The first set of experiments was performed to 
determine the effects of circulating factors in plasma from EPE and LPE women 
on BBB permeability compared to NP women and NonP women. We measured Lp, 
the critical transport parameter that relates water flux to hydrostatic pressure, in 
isolated cerebral veins from nonpregnant female rats after perfusing with plasma 
from one of the 4 groups of women, as described previously 26. This method of 
measuring BBB permeability was specifically developed to have a direct measure 
of water permeability and has been successfully used in several previous studies 12, 
26, 27. The vein of Galen was used for all permeability experiments as representation 
of the BBB because this vein has BBB properties and is where BBB disruption occurs 
first during acute hypertension 28. Further, only veins from nonpregnant rats were 
used to isolate the possible effects of circulating factors in the plasma and our 
previous studies have shown no difference in BBB permeability comparing vessels 
from nonpregnant and pregnant rats 27. Briefly, cerebral veins were carefully 
dissected out of the brain of nonpregnant rats and the proximal end mounted on 
one glass cannula in an arteriograph chamber. Veins were perfused intraluminally 
with 20% v/v plasma from either NonP (n=7), NP (n=7), LPE (n=6) and EPE (n=6) 
in a HEPES buffer for 3 hours at 10±0.3 mmHg and 37 ºC. The distal end of the 
vessel was tied off with a nylon suture. After this incubation period with plasma, 
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intravascular pressure was increased to 25±0.1 mmHg and the drop in pressure 
due to transvascular filtration of water out of the vessel in response to hydrostatic 
pressure was measured for 40 minutes. The decrease of intravascular pressure per 
minute (mmHg/min) was converted to volume flux across the vessel wall (μm3) 
using a conversion curve as previously described 26. After flux was determined, 
transvascular filtration per surface area (J
v
/S) and L
p
 were calculated by normalizing 
flux to the surface area and oncotic pressure of the plasma perfusate that was 
determined by a commercially available oncometer. 
In a separate set of experiments, we determined the involvement of LOX-1 
activation on BBB permeability by adding a neutralizing antibody to LOX-1 (5µg/
ml; n=6) to the plasma from EPE women before perfusing the plasma into the 
vein of Galen and the permeability experiment was repeated. Because we 
already showed that the presence of control goat IgG (also used as a control for 
this antibody) perfused with plasma in the cannula did not interfere with the 
permeability measurements 27, we did not repeat these control IgG experiments 
in the current study. 
Another set of experiments was performed to determine the involvement of 
peroxynitrite generation in plasma from EPE women by adding the peroxynitrite 
decomposition catalyst FeTMPyP (50 µM; n=6) to the plasma from EPE women 
before perfusing the plasma in the cerebral veins. FeTMPyP is a ferric-porphyrin-
complex that catalytically isomerizes peroxynitrite to nitrate in vitro and has 
been shown to be selective for blocking peroxynitrite effects without interfering 
with NO or superoxide 29. Therefore, FeTMPyP serves as a selective peroxynitrite 
decomposition catalyst. In addition, the concentration of 50 µM was based on 
one of our earlier studies where FeTMPyP was used in isolated arteries to scavenge 
peroxynitrite 30. 
A separate set of experiments was performed to determine the effects of exogenous 
oxLDL on BBB permeability by the addition of exogenous human oxLDL (3.5 µg/
ml; n=7) to plasma from NonP women before perfusing the plasma in the cerebral 
veins. For these experiments, plasma from NonP women was chosen rather than 
plasma from NP women to eliminate other possible circulating factors present 
in pregnancy that could interact with oxLDL. To determine if there was a causal 
link between oxLDL increasing BBB permeability and peroxynitrite generation, we 
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repeated these experiments with the addition of FeTMPyP (50 µM; n=6) to the 
oxLDL-plasma mixture before perfusion in the vein of Galen and measured L
p
.
The last set of experiments was performed to determine the involvement of high 
levels of cholesterol in pregnancy on pregnancy outcome and BBB disruption. 
The cerebral vein of Galen of LP rats that received either a control diet or a high-
cholesterol diet was used for the permeability experiments as described above. For 
these experiments, 20% v/v plasma in HEPES buffer was taken and perfused in veins 
from the same animals. To determine the contribution of oxLDL in increasing BBB 
permeability in the high-cholesterol treated pregnant rats, the same neutralizing 
LOX-1 antibody (5µg/ml; n=8) was added to the plasma from the LP-HC animals 
before perfusion in the cerebral veins.  
Measurement of mRNA expression of LOX-1 using real-time quantitative PCR. The 
middle cerebral artery (MCA) was used as a representative cerebral vessel to measure 
mRNA expression of LOX-1 in the LP-CTL (n=6) and LP-HC (n=7) animals, as the 
Vein of Galen was used for permeability experiments in these animals. Real-time 
quantitive PCR was performed as described earlier 31. The quantitative PCR primer 
for the rat transcripts for LOX-1was: LOX-1 (f ): -GATGATCTGAACTTCGTCTTACAAGC- 
and (r): - TCAGCAAACACAACTCCTCCTT. 
Drugs and solutions. HEPES physiological salt solution was made fresh daily and 
consisted of (mmol/L): 142.00 NaCl, 4.70 KCl, 1.71 MgSO
4
, 0.50 EDTA, 2.80 CaCl
2
, 
10.00 HEPES, 1.20 KH
2
PO
4
, and 5.00 dextrose. FeTMPyP was purchased from 
Calbiochem, (Gibbstown, NJ, USA; 341501). LOX-1 antibody was purchased from 
R&D systems (Minneapolis, MN, USA; AF1564). Highly oxLDL was purchased from 
Kalen Biomedical LLC (Montgomerey Village, Mn, USA; 770252-7). 
Statistical analysis.  Data are presented as mean ± standard error of the mean.
Analyses were performed by one-way ANOVA with a post-hoc Newman Keuls test 
for multiple comparisons where appropriate or with a Student’s t-test. Differences 
were considered statistical significant at P < 0.05. mRNA expression of LOX-1 was 
determined by quantitative PCR and calculated using the 2-DDCT method.
31956 Schreurs, Malou.indd   68 08-01-15   14:11
oxLDL in early-onset preeclampsia
69
4
Results
Patients with EPE have worse pregnancy outcome compared to LPE and normal 
pregnancy. Although the pathogenesis of preeclampsia is not clear, it is accepted 
that the pathologic release of soluble factors from the ischemic placenta into 
the maternal circulation causes endothelial dysfunction, oxidative stress and the 
symptoms of hypertension and proteinuria 16. Thus, it is reasonable to examine 
maternal blood as a source of circulating factors that might also be affecting the 
cerebral endothelium to cause BBB disruption and promote neurologic symptoms. 
Table 1. Demographics
NonP
(n=9)
NP
(n=12)
 LPE 
(n=10)
EPE
(n=5)
Age (years) 25.4 (± 4.6) 26 (± 4.5) 31 (± 3.6) 25 (± 5)
BMI 24.0 (± 3.2) 26.4 (± 3.7) 26.5 (± 7.4) 24.3 (± 3.0)
GA sample (weeks) - 34.9 (± 1.8) 35.8 (± 1.6) 32.3 (± 1.6)
GA delivery (weeks) - 40.1 (± 0.93) 36.0 (± 1.4) 32.5 (± 1.4)
SBP <20 wks gestation (mmHg) 107 (± 6.8) 110.1 (± 7.2) 119.5 (± 12.4) 122.0 (± 5.6)
DBP <20 weeks gestation (mmHg) 65.5 (± 5.5) 66.8 (± 3.9) 73.0 (± 7.3 ) 73 (± 4)
SBP at time delivery (mmHg) - 119.4 (± 7.3) 152.40 (± 8.59) 160.0 (± 9.5)
DBP at time delivery (mmHg) - 68.8 (± 11.7) 91.70 (± 6.43) 100.6 (± 11.0)
Birthweight (grams) - 3601 (± 380) 2271.3 (± 143.2) 1462 (± 223)
Birthweight centile (%) - 56.1 (± 7.1) 18.9 (± 4.9) 7.6 (± 1.8)
Abbreviations: NonP = nonpregnant; NP = normal pregnant; LPE = late-onset preeclampsia;
EPE = early-onset preeclampsia; GA = gestational age; SBP = systolic blood pressure; DBP = diastolic blood 
pressure; BMI= body mass index.
Table 1 shows the patient characteristics from which plasma samples were taken. 
There were no significant differences between the 4 groups of women with 
respect to age or BMI. Blood pressure measured in early gestation before 20 weeks 
of pregnancy was similar in all pregnant groups and was comparable to the blood 
pressure measured in the group of women who had never been pregnant. These 
results are consistent with the symptoms of preeclampsia developing after 20 
weeks of gestation, including hypertension.
At time of delivery, both systolic and diastolic blood pressure measured in NP 
women were similar to the blood pressure measured before 20 weeks of gestation. 
However, blood pressure of both preeclamptic groups was significantly increased 
and met the diagnostic criteria of preeclampsia. Although blood pressure at 
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time of delivery was higher in EPE women compared to LPE women, this was 
not significantly different. Further, all NP women delivered after 37 weeks of 
gestation. LPE women delivered after 34 weeks but before 37 weeks of gestation 
and EPE women were diagnosed and delivered before 34 weeks of gestation, in 
accordance with to the definition of EPE. Lastly, the infants born to EPE women had 
the lowest infant birth weight compared to the other groups of pregnant women. 
Importantly, only EPE women delivered babies with intrauterine growth restriction 
(< 10th percentile) compared to the LPE and NP women (> 10th percentile). Thus, 
EPE women that were diagnosed and delivered before 34 weeks of gestation from 
which plasma was taken had a more severe form of preeclampsia compared to 
LPE women.
Plasma from EPE women significantly increases BBB permeability compared to plasma 
from LPE and NP women. Epidemiologic studies suggest that women with EPE 
develop neurologic complications more often compared to women with LPE 4, 5. 
Because the BBB has a central role in the development of neurologic symptoms 
such as seizure 8, 10, 32, we measured BBB permeability in cerebral veins perfused with 
20% v/v plasma from NP, LPE or EPE women. Permeability in response to plasma 
from NonP women was used as a control. Several permeability parameters were 
measured in vitro in response to a 3 hour exposure to plasma, including filtration 
pressure drop, volume flux, transvascular filtration (J
v
/S) and hydraulic conductivity 
(L
p
). As shown in Figure 1, exposure to plasma from NP women caused an increase 
in intravascular pressure drop and J
v
/S, but not in volume flux or L
p
. However, in 
both preeclamptic groups, all permeability parameters were significantly increased 
compared to NonP. Importantly, the increase in permeability in response to LPE 
plasma was similar to NP plasma whereas EPE plasma caused a significant increase 
in permeability compared to all other groups, including LPE plasma. These results 
demonstrate that circulating factors present in plasma from EPE women disrupt 
the BBB and may relate to the propensity for neurologic complications to occur in 
that group of preeclamptic patients. 
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Figure 1. Plasma from EPE women increases BBB permeability compared to plasma from LPE or NP 
women. (A-D) The permeability parameters intravascular pressure drop, volume flux, J
v
/S and hydraulic 
conductivity (L
p
) were used to determine BBB permeability in cerebral veins from nonpregnant rats in 
response to plasma from EPE, LPE, NP and NonP women. (A) The decrease in intravascular pressure in 
response to plasma from EPE, LPE and NP women was significantly greater compared to NonP women. 
Importantly, the decrease in intravascular pressure was significantly greater in EPE women compared to all 
other groups, including LPE women. (B) Plasma from both preeclamptic groups showed a significant 
increase in flux compared to plasma from NonP women. Plasma from EPE women caused a significantly 
greater flux compared to all other groups. (C) Plasma from EPE, LPE and NP women caused a significant 
increase in J
v
/S compared to plasma from NonP women and only plasma from EPE women significantly 
increased J
v
/S compared to all other groups. (D) Plasma from both preeclamptic groups significantly 
increased L
p
 compared to NonP women and only plasma from EPE women significantly increased L
p
 
compared to all other groups. (†P < 0.01 vs. NonP; **P < 0.01 vs. all. Abbreviations: NonP, nonpregnant; NP, 
normal pregnant; LPE, late-onset preeclampsia; EPE, early-onset preeclampsia.)
Inhibition of LOX-1 activation prevents increased BBB permeability induced by EPE 
plasma. Circulating oxLDL binds its receptor LOX-1 to cause oxidative stress and 
endothelial dysfunction in many pathological states such as atherosclerosis, 
diabetes and hypertension 18, 33. To determine if LOX-1 activation is involved in 
increasing BBB permeability in response to acute exposure of plasma from EPE 
women, we neutralized LOX-1 with an antibody to inhibit its activation prior to 
perfusion with EPE plasma and measurement of permeability. Inhibition of LOX-1 
abolished the increased BBB permeability induced by circulating factors in this 
plasma (Figure 2A). Thus, LOX-1 activation is involved in increasing BBB permeability 
in plasma from EPE women. 
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Figure 2. Increased levels of oxLDL in plasma from EPE women are responsible for the significant 
increased BBB permeability. (A) BBB permeability in response to plasma from LPE women, EPE women and 
from EPE women with the addition of 5µg/ml of a neutralizing LOX-1 antibody. The LOX-1 antibody inhibited 
the increased BBB permeability induced by plasma from EPE women. (B) OxLDL levels in plasma from 
women with EPE compared to LPE, NP and NonP women. Plasma from EPE women had a 260% increase in 
oxLDL compared to plasma from LPE women. (C) L
p
 as a measure of BBB permeability in cerebral veins from 
NonP rats in response to plasma from NonP and EPE women and plasma from NonP women with addition 
of 3.5µg/ml exogenous oxLDL. Exogenous oxLDL significantly increased BBB permeability to the same levels 
as plasma from EPE women. (**P < 0.01 vs. all; Abbreviations: NonP , nonpregnant; NP , normal pregnant; LPE 
, late-onset preeclampsia; EPE , early-onset preeclampsia.)
To determine if oxLDL was increased in plasma from EPE women that was 
responsible for the LOX-1-induced increase in BBB permeability, we measured 
oxLDL levels in the plasma from all 4 groups of women by ELISA. Plasma from 
EPE women had a 260% increase in oxLDL levels compared to plasma from LPE 
women (Figure 2B). The levels of oxLDL in plasma from NonP, NP and LPE women 
were comparable. We next confirmed that oxLDL was capable of increasing BBB 
permeability without the presence of other circulating factors present in the 
plasma from EPE women by adding 3.5 µg/ml of purified human oxLDL in plasma 
from NonP women and measuring permeability. This concentration of oxLDL 
was used based on the values in the EPE plasma measured by ELISA.  Addition 
of exogenous oxLDL to plasma from NonP women caused a significant increase 
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in BBB permeability that was comparable to what was seen with plasma from 
women with EPE (Figure 2C). To our knowledge, this is the first report that suggest 
that high levels of oxLDL present in plasma from EPE women is the circulating 
factor responsible for the increase in BBB permeability in response to that plasma 
by activation of LOX-1. 
Peroxynitrite decomposition with FeTMPyP prevents increased BBB permeability 
induced by EPE plasma and oxLDL. Activation of LOX-1 leads to increased production 
of superoxide through NADPH oxidase that rapidly binds NO to form peroxynitrite 
23. To determine if peroxynitrite generation in response to LOX-1 activation by 
oxLDL is responsible for increased BBB permeability, we perfused cerebral veins 
with plasma from EPE women plus 50 µM FeTMPyP, a selective peroxynitrite 
decomposition catalyst, prior to measuring permeability. FeTMPyP significantly 
inhibited the increase in BBB permeability caused by plasma from EPE women 
(Figure 3A). This result demonstrates that peroxynitrite generation is involved in 
BBB disruption with exposure to plasma from EPE women. We next confirmed 
that the increase in BBB permeability caused by exogenous oxLDL was due to 
increased generation of peroxynitrite by adding 50 µM FeTMPyP to plasma from 
NonP women with exogenous oxLDL. Peroxynitrite decomposition with FeTMPyP 
inhibited the increase in BBB permeability induced by oxLDL (Figure 3B). Together, 
these results demonstrate that peroxynitrite generation is induced by oxLDL and 
is the underlying mechanism by which BBB permeability is increased. 
Pathologically high lipid levels during pregnancy in rats cause preeclamptic-like 
symptoms and LOX-1-dependent BBB disruption. Preeclampsia has been associated 
with high levels of LDL 13, 34.  In addition, preeclampsia is a state of increased 
oxidative stress in the placental circulation which causes oxidative conversion of 
LDL to oxLDL, resulting in increased circulating levels of oxLDL in preeclampsia 16, 
17.  Because we found high levels of oxLDL in plasma from EPE women that caused 
disruption of the BBB, we wanted to determine its effects in vivo by creating a 
rat model with pathologically high levels of LDL during pregnancy. Rats treated 
with a high-cholesterol diet during pregnancy (LP-HC) had a 350% increase 
in cholesterol compared to pregnant rats who received a normal diet (LP-CTL), 
including a significant increase in LDL cholesterol (data not shown). Table 2 shows 
that LP-HC rats had a worse pregnancy outcome compared to LP-CTL rats with 
similar characteristics as seen in EPE women. LP-HC rats had significantly higher 
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systolic and diastolic blood pressures compared to LP-CTL rats and also had worse 
pregnancy outcome, including a significantly smaller number of pups, and a 
higher rate of reabsorptions.  Further, LP-HC rats had growth restricted fetuses, 
with pup weights that were significantly lower compared to LP-CTL. 
Figure 3. oxLDL-induced increased BBB permeability in EPE women was prevented by the peroxynitrite 
scavenger FeTMPyP. (A) Graph showing hydraulic conductivity (L
P
) at 36 minutes as a measure of BBB 
permeability in cerebral veins of NonP rats in response to plasma from LPE and plasma from EPE women 
with and without the addition of 50µM FeTMPyP. FeTMPyP inhibited the BBB permeability induced by 
plasma from EPE women. (B) L
p
 as a measure of BBB permeability in response to untreated of plasma from 
NonP and EPE women, and in response to plasma from NonP women plus 3.5µg/ml oxLDL and 50µM 
FeTMPyP. FeTMPyP inhibited the BBB permeability induced by 3.5µg/ml exogenous oxLDL in plasma from 
NonP women. (**P< 0.01 vs. all; Abbreviations: LPE, late-onset preeclampsia; EPE, early-onset preeclampsia.)
Table 2. Pregnancy outcome of LP-HC compared to LP-CTL rats
LP-CTL
(n=8)
LP-HC
(n=8)
Weight (grams) 408 (± 6) 403 (± 10) 
SBP (day 13 of diet; mmHg) 118 (±2) 126 (±2) *
DBP (day 13 of diet; mmHg) 87 (±2) 94 (±2) *
Pups (#) 16 (0.5) 12  (±0.6) *
Resorptions (#) 0.7 (± 0.2) 1.4 (± 0.4) 
Avg pup weight (grams) 2.42 (± 0.06) 2.12 (±0.04) * 
Avg placenta weight (grams) 0.44 (± 0.01) 0.48 (± 0.01) *
*P <0.05 vs LP-CTL 
Abbreviations: LP-CTL = late-pregnant control rats ; LP-HC = late-pregnant high cholesterol-treated rats; SBP 
= systolic blood pressure; DSP = diastolic blood pressure; Avg= average.
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Next, we investigated if pathologically high levels of LDL in pregnant rats led to 
increased BBB permeability that was dependent on LOX-1 activation, as we have 
also shown in EPE women.  Figure 4A shows that cerebral veins from LP-HC rats 
perfused with plasma from the same animals had increased BBB permeability 
compared to control animals that was abolished by addition of the LOX-1 antibody. 
These results suggest that oxLDL is responsible for increasing BBB permeability in 
the LP-HC animals, similar to EPE. Because oxLDL and not native LDL binds to LOX-
124, these results also confirm that pathologically high levels of LDL in pregnancy 
lead to high levels of oxLDL. 
Lastly, because the pregnant rats were exposed to high levels of cholesterol during 
their entire pregnancy, we wanted to determine if LOX-1 expression was increased 
in the cerebral circulation that could cause the increased BBB permeability. Recent 
studies showed increased LOX-1 expression HUVECs after 24 hour incubation 
with preeclamptic plasma 21 and in a rat model of preeclampsia 20. To determine 
if LOX-1 mRNA expression was increased in the cerebral vasculature from LP-HC 
animals, we isolated the middle cerebral arteries (MCA) from the same animals 
used for permeability experiments and measured mRNA expression of LOX-1. 
mRNA expression of LOX-1 was similar in the LP-HC and LP-CTL animals (Figure 
4B), suggesting that the mechanism of increased BBB permeability in the LP-HC 
animals was due to circulating oxLDL activating LOX-1 as opposed to upregulation 
of LOX-1 in the cerebral endothelium. 
Figure 4. Pathologically high levels of lipids in pregnant rats show symptoms of preeclampsia and also 
lead to LOX-1 mediated increased BBB permeability. (A) Graph showing hydraulic conductivity (L
p
) as a 
measure of BBB permeability at 36 minutes in cerebral veins from LP-CTL rats in response to LP-CTL plasma 
and from LP-HC rats in response to LP-HC plasma with and without the addition of 5µg/ml LOX-1 antibody. 
LP-HC rats showed a significant increase in BBB permeability that could be inhibited with the addition of 
LOX-1 antibody. (B) mRNA expression of LOX-1 in cerebral veins from LP-CTL and LP-HC animals. There was 
no difference in mRNA expression of LOX-1 in cerebral veins from LP-HC vs. LP-CL animals. (*P< 0.05 vs. all; 
Abbreviations: LP-CTL, late-pregnant control; LP-HC, late pregnant high-cholesterol treated.)
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Discussion 
In the present study, we provide new direct evidence for a different etiology 
between EPE and LPE and reveal a novel mechanism that is responsible for 
BBB disruption in EPE women. Circulating factors in plasma from EPE women 
significantly increased BBB permeability compared to LPE or NP women. The 
increased BBB permeability was prevented by inhibiting LOX-1 and was confirmed 
in vivo in pregnant rats with pathologically high levels of LDL that also showed 
LOX-1 dependent increased BBB permeability. Circulating oxLDL, a major ligand of 
LOX-1, was significantly increased in plasma from EPE women compared to LPE or 
NP women. In addition, exogenous oxLDL in plasma from NonP women increased 
BBB permeability comparable to EPE. Additionally, the selective peroxynitrite 
decomposition catalyst FeTMPyP inhibited the increased BBB permeability 
induced by plasma from EPE women or by exogenous oxLDL. Thus, our results 
show for the first time that increased circulating oxLDL present in plasma from 
EPE women significantly increase BBB permeability through LOX-1 activation and 
subsequent increased peroxynitrite generation (Figure 5). 
The cerebral endothelium that comprises the BBB has unique features compared to 
endothelium outside the CNS, including high electrical resistance tight junctions, 
and a lack of fenestrations that results in low hydraulic conductivity 35. Disruption of 
the BBB is accompanied by increased BBB permeability and subsequent vasogenic 
edema resulting into neurologic symptoms 7-9. Preeclampsia, a hypertensive 
disorder unique to pregnancy, can be complicated with life-threatening 
neurologic symptoms, including cerebral edema, hemorrhage and seizure that is 
associated with increased BBB permeability 1, 7, 8. As we have previously shown, 
increased BBB permeability in severe preeclampsia is caused by a pathologic 
release of circulating factors into the maternal circulation that can cause BBB 
breakdown 12. Here, we demonstrated for the first time that intraluminal exposure 
of cerebral veins to plasma from EPE women for 3 hours significantly increased 
BBB permeability compared to plasma from LPE or NP women. These new findings 
point to the acute impact of circulating factors in plasma from EPE women on BBB 
permeability after a short exposure time. Also, these results directly strengthen the 
evidence that EPE and LPE have different etiologies, arising from greater placental 
underperfusion and subsequent release of circulating factors in EPE compared to 
LPE 4. To our knowledge, no studies have differentiated effects of circulating factors 
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Figure 5. Schematic showing the proposed mechanism leading to BBB disruption and neurological 
complications in EPE.  EPE women have a more severe form of disease that is associated with increased 
levels of circulating oxLDL. The increased circulating levels of oxLDL in plasma from EPE women bind to their 
receptor LOX-1 on the cerebral endothelium that comprises the BBB. LOX-1 activation leads to generation of 
peroxynitrite (ONOO-), most likely through increased production of superoxide (O
2
.-), causing BBB disruption 
and increased BBB permeability that is responsible for neurological complications in preeclampsia.
in LPE compared to EPE on BBB permeability. Only one report found increased 
permeability in mesenteric arteries from frogs in response to plasma from severe 
compared to mild preeclamptic women where the severity of preeclampsia was 
strongly correlated to EPE 36. In addition, these findings are also of great clinical 
importance as they demonstrate that EPE women only show significant BBB 
disruption and are at highest risk for neurologic symptoms, thereby confirming 
epidemiologic studies 4, 5. Although we did not examine the direct link between 
increased BBB permeability and neurologic symptoms, it is well-established that 
disruption of the BBB is a primary event in inducing neurologic complications and 
the key event for seizure activity 10, 32. Thus, we show that specific circulating factors 
present in plasma from EPE women only significantly increase BBB permeability and 
thereby make EPE women most at risk for life-threatening neurologic symptoms. 
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Increased circulating levels of oxLDL in preeclampsia has been shown in several 15, 37-
40, but not all 41, studies. In cardiovascular diseases such as atherosclerosis, oxidative 
modification of LDL increases its atherogenicity and induces a wide variety of 
cellular responses such as the induction and expression of adhesion molecules, 
proinflammatory cytokines and reactive oxygen species, resulting in endothelial 
dysfunction 42. In preeclampsia, decidual vessels of the placenta show fibrinoid 
necrosis of the vascular wall and focal accumulation of lipid-laden macrophages, 
similar as in atherosclerosis, making oxLDL also a likely and important contributor 
in the pathogenesis of preeclampsia 43. Here, we found that oxLDL levels were 
increased in plasma from EPE women but not in plasma from LPE women that was 
comparable to NP women. This increase in EPE only compared to LPE and NP may 
be related to the finding that oxidative stress was found only in placentas from EPE 
women 44, suggesting greater capacity for oxidative modification of LDL in EPE. In 
addition, we show that exogenous oxLDL to the levels as measured in plasma from 
EPE women significantly increased BBB permeability in cerebral veins, comparable 
to EPE women. Thus, increased oxLDL does not appear to be just a biomarker for 
neurological symptoms in EPE, but also the underlying cause of BBB disruption 
and a possible new target for understanding mechanisms of BBB disruption in 
several pathologic states.
 LOX-1 is an endothelial receptor for circulating oxLDL that has been studied 
extensively in pathological states such as atherosclerosis, diabetes, coronary arterial 
heart disease and hypertension 18, 33, however, data regarding LOX-1 activation in 
preeclampsia are scarce. LOX-1 was associated with preeclampsia for the first time 
in 2005 in a report that showed up regulation of LOX-1 in preeclamptic hypoxic 
placentas 45. Recently, it was found that upregulation of LOX-1 in HUVECs occurred 
in response to a 24 hour exposure to plasma from preeclamptic women and in 
a rat model of preeclampsia 20, 21. Here, we show for the first time involvement 
of LOX-1 in increasing BBB permeability after acute exposure of plasma from EPE 
women for 3 hours that contained high levels of circulating oxLDL. Because of the 
3 hour exposure time of the plasma, we did not determine possible upregulation 
of LOX-1. As shown previously, upregulation in HUVECs in response to plasma 
from preeclamptic women did not occur until 24 hours of exposure, while 
shorter exposure caused increased the production of ROS 21. These findings are 
in support of increased circulating ligands such as circulating oxLDL activating 
LOX-1 to cause endothelial dysfunction. However, it remains to be determined 
in cerebral endothelial cells if longer incubation would cause upregulation of 
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LOX-1expression in response to plasma from EPE women as seen in HUVECs in 
response to preeclamptic plasma 21. Importantly, the LOX-1-mediated increase in 
BBB permeability with EPE plasma was confirmed in vivo in pregnant rats with 
pathologically high levels of LDL, that also showed symptoms such as increased 
blood pressure and growth restricted fetuses. To our knowledge, few studies 
have investigated oxLDL/LOX-1 activation and vascular permeability. One study 
using mouse cultured cerebral endothelial cells showed that high concentrations 
of oxLDL were able to increase permeability 46. In the systemic vasculature, 
Nakano et al. showed increased vascular permeability in mesenteric arteries from 
spontaneous hypertensive rats pretreated with oxLDL that was inhibited by a 
LOX-1 antibody 47. In this study, we propose a similar, but novel mechanism that 
high levels of circulating oxLDL in EPE increase BBB permeability through LOX-1 
activation.
LOX-1 activation has been shown to induce several intracellular signaling 
pathways, including increased expression of chemokines and adhesion molecules, 
triggering the CD40/CD40L pathway that activates the inflammatory cascade and 
increased production of reactive oxygen species such as superoxide in endothelial 
cells 19. Increased levels of superoxide rapidly bind NO and form peroxynitrite, a 
toxic radical known to have deleterious effects on endothelial function 17, 25. Also, 
peroxynitrite generation has been reported in the maternal systemic vasculature 
in preeclampsia 48 and in HUVECs after exposure to plasma from preeclamptic 
women 21. Here, we show that BBB permeability induced by either plasma from 
EPE women or exogenous oxLDL to the levels of EPE women was inhibited with 
the specific peroxynitrite decomposition catalyst FeTMPyP, demonstrating that 
peroxynitrite generation caused the increased BBB permeability. Our findings that 
oxLDL/LOX-1 activation induces peroxynitrite generation are supported by earlier 
reports that showed in different cell culture models that binding of oxLDL to LOX-
1 decreased the intracellular concentration of NO by inducing the production of 
superoxide through NADPH oxidase 23 and increased peroxynitrite generation 49. 
Because NADPH oxidase expression and activity is greater in the cerebral vessels 
compared to systemic vasculature 50, the brain may be especially vulnerable for 
activation of NADPH oxidase and subsequent peroxynitrite generation. Importantly, 
peroxynitrite also stimulates LOX-1 activation and a self-perpetuating mechanism 
develops that could cause extensive endothelial damage with deleterious effects 
for the maternal cerebral vasculature 17. Finally, these findings would explain the 
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results from our previous study in which increased BBB permeability in response 
to plasma from severe preeclamptic women was prevented by VEGF receptor 
inhibition without increased circulating levels of VEGF compared to plasma from 
NP women 12. Phosphorylation of VEGF receptors results in a release of NO 51, thus, 
its inhibition would decrease the level of NO available for peroxynitrite generation, 
preventing BBB disruption (Figure 5). 
In conclusion, this is the first report to identify oxLDL as a circulating factor in 
EPE that significantly increases BBB permeability compared to LPE and thereby 
provides direct evidence for EPE and LPE having 2 different etiologies. In addition, 
we reveal a new mechanism for BBB disruption in EPE by oxLDL/LOX-1 activation 
and subsequent peroxynitrite generation. These novel findings will contribute 
to improving the identification and treatment of neurological complications 
in women diagnosed with EPE and possibly other neurological diseases where 
oxidative stress-induced BBB disruption is involved. Further studies are required 
to determine how BBB disruption induced by oxLDL leads to specific neurological 
symptoms, which could lead to treatment or prevention of these complications in 
preeclampsia.
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Abstract 
Little is known about the effects of oxidized low-density lipoprotein (oxLDL) on the 
cerebral vasculature. However, understanding is important for many neurologic 
conditions involving cerebral edema such as neurologic symptoms in severe 
preeclampsia. We hypothesized that oxLDL induced blood-brain barrier (BBB) 
disruption and cerebrovascular dysfunction through NADPH oxidase-derived 
superoxide. Further, we investigated the effect of magnesium sulfate (MgSO
4
) on 
oxLDL-induced changes in the cerebral vasculature, as this is a commonly used 
treatment in preventing cerebral edema formation. Posterior cerebral arteries 
(PCA) from female rats were perfused with 5µg/mL oxLDL in rat serum with or 
without 50µM apocynin or 16mM MgSO
4
 and BBB permeability and vascular 
reactivity were compared. oxLDL increased BBB permeability and decreased 
myogenic tone that were prevented by apocynin. oxLDL increased constriction to 
the nitric oxide synthase inhibitor L-NNA that was unaffected by apocynin. oxLDL 
enhanced dilation to the NO donor sodium nitroprusside (SNP) that was prevented 
by apocynin. MgSO
4
 prevented oxLDL-induced BBB permeablity without affecting 
oxLDL-induced changes in myogenic tone. Thus, oxLDL causes BBB disruption and 
vascular tone dysregulation through NADPH oxidase-derived superoxide, that was 
partially prevented by MgSO
4
. These results highlight oxLDL and NADPH oxidase 
as important therapeutic targets in neurologic conditions that involve circulating 
oxLDL.  
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Introduction 
It has become recognized that oxidized low-density lipoprotein (oxLDL) is one of 
the key factors in the pathogenesis of many cardiovascular diseases 1. Oxidative 
modification of physiological native LDL (nLDL) into oxLDL occurs in numerous 
disease states as a result of oxidative stress and the presence of reactive oxygen 
species 2. The formation of oxLDL initiates multiple pathways in both endothelial 
and vascular smooth muscle cells, mostly through binding to its receptor lectin-
like oxLDL receptor (LOX-1) 3. oxLDL binding to LOX-1 generates complex signaling 
cascades leading to induction of the inflammatory pathway and increased 
production of superoxide that can further promote vascular dysfunction 1-3. 
Although less understood than in peripheral or cardiovascular disease, oxLDL 
also appears to contribute to cerebrovascular disease and stroke. Previous studies 
showed a significant association between increased circulating levels of oxLDL and 
cerebral ischemic lesions in stroke patients that may be related to the presence of 
oxidative stress 4, 5.  In addition, high doses of oxLDL increases BBB permeability 
in cultured cerebral endothelial cells 6 and in isolated cerebral arteries that was 
prevented by LOX-1 inhibition and scavenging peroxynitrite 7. Thus, oxLDL may be 
an important therapeutic target for cerebrovascular disease and stroke, especially 
under conditions of oxidative stress and cerebral edema formation.
Oxidative and nitrosative stress are known to have detrimental effects on 
cerebrovascular reactivity and BBB permeability, however, the role of oxLDL in these 
events is largely unknown. oxLDL activates nicotinamide adenine dinucleotide 
phosphate  (NADPH) oxidase to produce superoxide  and may have an important 
role in cerebrovascular dysregulation 8, 9. Superoxide and peroxynitrite are known 
to affect vascular tone and myogenic reactivity that are important for control of 
cerebral blood flow (CBF) and cerebrovascular resistance (CVR)10-12. In addition, 
increased BBB permeability caused by oxLDL may also promote vasogenic edema 
formation and contribute to life-threatening neurologic symptoms associated 
with conditions such as ischemic stroke, seizure, and severe preeclampsia. In fact, 
our previous study showed that increased circulating levels of oxLDL in severe 
preeclamptic women induced BBB disruption, that was prevented by scavenging 
peroxynitrite 13. However, the mechanism by which oxLDL causes peroxynitrite 
generation to induce BBB disruption, vasogenic edema and neurologic 
complication in preeclampsia is not known. In addition, data concerning the 
31956 Schreurs, Malou.indd   87 08-01-15   14:11
Chapter 5
88
effect of oxLDL on cerebrovascular reactivity and myogenic responses are very 
limited, however potentially important in neurologic symptoms in preeclampsia 
where impaired cerebral autoregulation is an important contributor to formation 
of cerebral edema and neurologic complications in preeclampsia. In the present 
study, we hypothesize that oxLDL to the level of women with severe preeclampsia 
would decrease myogenic tone and reactivity of cerebral arteries that could 
contribute to vascular dysfunction and the formation of cerebral edema. We 
further hypothesized that NADPH oxidase-derived superoxide is involved in 
oxLDL-induced changes in the cerebral vasculature. 
Magnesium sulfate (MgSO4) has been shown to be protective of the BBB and 
prevent cerebral edema during numerous conditions including traumatic brain 
injury, septic encephalopathy, hypoglycemia, and preeclampsia 14-16. In fact, 
MgSO
4 
 is one of the primary treatments for prevention of vasogenic brain edema 
in severe preeclampsia 15, 16.  However, if MgSO
4
 is also specifically protective of 
oxLDL-induced BBB permeability or vascular tone dysregulation remains unknown. 
Thus, our last aim was to investigate the effect of MgSO
4 
on oxLDL-induced BBB 
permeability and cerebral vascular dysfunction.
Methods
Animals. All animal procedures were approved by the University of Vermont 
Institutional Animal Care and Use Committee and complied with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Female 
virgin nonpregnant Sprague Dawley rats (12-14 weeks; 250-300 grams) were 
used for all experiments. The animals were purchased from Charles River (Saint-
Constant, QB, Canada) and housed until experimentation at the University of 
Vermont Animal Care Facility, an Association for Assessment and Accreditation of 
Laboratory Animal Care-accredited facility. Animals had access to food and water 
ad libitum and maintained a 12-hour light/dark cycle. 
Rat serum samples. Serum samples were obtained from trunk blood from female 
Sprague Dawley rats and collected in serum separator tubes. After a waiting period 
of 30 minutes, the tubes were centrifuged for 10 minutes at 2500 revolutions per 
minute, and the serum aliquoted and pooled from 10 animals. The pooled serum 
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was then stored at -80 ºC until experimentation.  For every experiment, one tube 
of serum from the same pool of animals was used. 
BBB permeability studies. To investigate the effect of oxLDL on BBB permeability 
and determine the mechanism by which oxLDL increases permeability, hydraulic 
conductivity (L
p
), the critical transport parameter that relates water flux to 
hydrostatic pressure, was measured in isolated PCAs from female nonpregnant rats, 
as described previously 17. This method of measuring BBB permeability has been 
successfully used in several previous studies 17-19.  Briefly, a third-order branch of the 
PCA was carefully dissected out of the brain and the proximal end mounted on a 
glass microcannula in an arteriograph chamber. PCAs were perfused intraluminally 
with 20% v/v serum from female rats with (n=8) or without (n=8) the presence 
of 5 µg/ml oxLDL or µg/ml native LDL (nLDL; n=4) in HEPES buffer for 1 hour at 
75 ± 0.3 mmHg and 37 ºC ± 0.2 ºC. The concentration of oxLDL used for these 
experiments was based on a previous study that determined the concentration 
of oxLDL in plasma of severe preeclamptic women to be approximately 5 µg/ml 
13. To determine the involvement of NADPH oxidase activity in oxLDL-induced BBB 
permeability, a separate set of PCAs were perfused with 50 µM of the NADPH oxidase 
inhibitor apocynin (n=8) in addition to the oxLDL-serum mixture. To determine 
the effect of MgSO
4 
on oxLDL-induced BBB permeability, another set of PCAs was 
perfused with 16 mM MgSO
4
 in addition to the oxLDL-serum mixture. This dose of 
MgSO
4 
was chosen because it is within the therapautic range for MgSO
4 
for seizure 
profylaxis 16, 20. After the equilibration period,  intravascular pressure was increased 
to 80 mmHg ± 0.1 mmHg and the drop in pressure due to transvascular filtration 
across the vascular wall in response to hydrostatic pressure was measured for 40 
minutes. The decrease of intravascular pressure per minute (mmHg/min) was 
converted to volume flux across the vessel wall (μm3) using a conversion curve, as 
previously described 17. L
p
 was then determined by normalizing flux to surface area 
and oncotic pressure of the serum perfusate. 
Reactivity studies. Another set of experiments was performed to determine the 
effect of oxLDL on reactivity of PCAs. A third-order branch of the PCA was carefully 
dissected from the brain of female rats and and the proximal end mounted on 
one glass cannula in an arteriograph chamber. PCAs were perfused intraluminally 
with 20% v/v serum from female rats with (n=8) or without (n=8) the presence 
of 5 µg/ml oxLDL or 5 µg/ml nLDL (n=4) in a HEPES buffer for 2 hours at 80 ± 0.3 
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mmHg and 37 ºC ± 0.2 ºC. The distal end of the vessel was tied off to avoid flow-
mediated responses. The proximal cannula of the arteriograph was connected to 
a pressure transducer and servo controller that maintained intravascular pressure 
at a set pressure or changed manually. Lumen diameter of the PCA was measured 
via video microscopy during the experiment. After the equilibration period, 
intravascular pressure was increased in steps of 20 mmHg to 140 mmHg and lumen 
diameter was recorded at each pressure once stable. Pressure was then returned 
to 80 mmHg for the remainder of the experiment. A single concentration (0.1 
mmol/L) of the nitric oxide synthase (NOS) inhibitor nitro-L-arginine (L-NNA) was 
added to the bath and constriction in response to NOS inhibition was measured 
after approximately 20 minutes. In the presence of L-NNA, the NO donor sodium 
nitroprusside (SNP) was cumulatively added to the bath (10-8 M-10-5 M) and the 
dilation to SNP was measured at each concentration. Finally, zero-Ca2+ HEPES was 
added to the bath to obtain fully relaxed diameters. Passive diameters were then 
recorded at pressures from 140 to 5 mmHg.
Data Calculations. Percent tone was calculated as the percent decrease in diameter 
from the fully relaxed diameter in zero-Ca2+ HEPES by the equation: ((Ø
passive
- Ø
active)
/ 
Ø
passive
) x 100%, where Ø
passive
 is the diameter in zero- Ca2+ HEPES and Ø
active
 is the 
diameter when the vessels had tone. Percent constriction to L-NNA was calculated 
with the equation: ((Ø
baseline
-Ø
drug
)/ Ø
baseline
) x 100% where Ø
baseline
 is diameter before 
adding the L-NNA and Ø
drug
 is diameter with presence of L-NNA. Percent sensitivity 
to the NO donor SNP using a concentration-response curve was calculated with 
the equation: ((Ø
drug
-Ø
minimum
)/( Ø
maximum
 – Ø
minimum
)) x 100% where Ø
drug
 is diameter 
at a specific concentration of SNP, Ø
minimum
 is diameter at the lowest concentration 
of SNP and Ø
maximum
 is the diameter at the highest concentration of SNP. 
Drugs and solutions. HEPES physiological salt solution was made fresh daily and 
consisted of (mmol/L): 142.0 NaCl, 4.7 KCl, 1.71 MgSO
4
, 0.50 EDTA, 2.8 CaCl
2
, 10.0 
HEPES, 1.2 KH
2
PO
4
, and 5.0 dextrose. HEPES without Ca2+ was also made daily but 
Ca2+ was left out of the solution. Apocynin, L-NNA and SNP were purchased from 
Sigma (St Louis, MO, USA). The concentrated apocynin was diluted in double 
distilled H
2
O to reach the concentration of 50 µM and was stored in -20 ºC until 
used. L-NNA and SNP were made as stock solutions and diluted. Highly oxLDL was 
purchased from Kalen Biomedical (LLC, Montgomerey Village, Mn, USA; 770252-7) 
and stored at 4 ºC until experimentation. 
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Statistical analysis.All data are expressed as mean ± standard error of the mean. 
Data were analyzed using one-way ANOVA and post hoc Student-Newman Keuls 
test for multiple comparisons. Differences were considered statistically significant 
when P < 0.05.  
Results
oxLDL increased BBB permeability that was prevented by apocynin
We recently demonstrated that increased levels of oxLDL increased BBB permeability 
13. Here, we determined if oxLDL-induced BBB permeability involved NADPH 
oxidase-derived superoxide. Figure 1 shows that oxLDL significantly increased BBB 
permeability in PCAs compared to controls without oxLDL (P< 0.05). Importantly, 
the presence of apocynin abolished the oxLDL-induced BBB permeability (P< 
0.05), suggesting that increased NADPH oxidase activity was involved in oxLDL-
induced BBB disruption. To confirm that BBB permeability was increased due to 
the oxidative state of LDL, the effect of nLDL on BBB permeability was compared 
to oxLDL-induced BBB permeability. nLDL did not increase BBB permeability 
compared to controls, demonstrating that the increased BBB permeability was a 
result of the oxidative modification of LDL. 
Figure 1. Effect of apocynin on oxLDL-induced BBB permeability. Graph showing hydraulic conductivity 
(L
p
) as a measure of BBB permeability in response to perfusion of 20% v/v rat serum only compared to rat 
serum plus 5 µg/ml oxLDL (n=8), +/-  the addition of 50 µM apocynin (n=8). oxLDL significantly increased 
BBB permeability in PCAs from female animals compared to controls. The addition of apocynin significantly 
abolished the oxLDL-induced BBB permeability. nLDL did not change BBB permeability compared to 
controls. (* P< 0.05 vs. all other groups by one-way ANOVA. Abbreviations: CTL, control without oxLDL; 
oxLDL, oxidized low-density lipoprotein; apo, apocynin; nLDL, native LDL) 
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oxLDL decreased myogenic tone of PCAs that was prevented by apocynin
Next, we determined the effects of circulating oxLDL on cerebral vascular function 
in PCAs and the possible involvement of NADPH oxidase. Figure 2A shows active 
diameter changes in response to increased intravascular pressure. All groups had 
modest constriction in response to increased pressure, demonstrating myogenic 
reactivity was present in all vessels. PCAs perfused with oxLDL had larger diameters 
at all pressures measured, but this was not statistically significant (P = 0.17). 
Figure 2. Effect of oxLDL on myogenic tone of posterior cerebral arteries (PCA). Graphs showing (A) active 
lumen diameter and (B) percent myogenic tone in response to increased intravascular pressure in PCA from 
female rats that were perfused with 20% v/v rat serum only (n=8) compared to serum plus 5 µg/ml oxLDL 
(n=8) +/-  50 µM apocynin (n=8).  oxLDL caused larger lumen diameters compared to controls at all pressures 
that was abolished by apocynin, however, this was not statistically significant. oxLDL significantly decreased 
percent myogenic tone of PCA compared to control serum without oxLDL. The effect of oxLDL was 
prevented by the presence of apocynin.  (* P< 0.05 vs. all other groups by one-way ANOVA. Abbreviations: 
CTL, control without oxLDL; oxLDL, oxidized low-density lipoprotein; apo, apocynin) 
However, Figure 2B shows that oxLDL significantly decreased myogenic tone at 
all pressures compared to the control group (P<0.05), suggesting that the larger 
diameters were due to diminished basal tone. Importantly, apocynin prevented 
the oxLDL-induced decrease in myogenic tone in PCAs (P <0.05), suggesting 
activation of NADPH oxidase was involved in oxLDL-induced decreased myogenic 
tone. Also for these experiments, measurements were repeated with the presence 
of nLDL instead of oxLDL. nLDL did not cause any changes in myogenic responses 
or myogenic tone compared to the control group without oxLDL (data not shown), 
suggesting that the effects were due to the oxidative state of LDL. 
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oxLDL increased contriction to NOS inhibition and enhanced NO-mediated 
vasodilation
To determine the effect of oxLDL on basal endothelium-derived NO, a single 
high concentration of L-NNA was added to PCA from all 3 groups and changes 
in diameter measured (Figure 3A). All vessels constricted in response to L-NNA, 
suggesting basal NO was present and inhibited tone. The presence of oxLDL 
caused a significant increase in constriction to L-NNA compared to the controls 
(P< 0.01). 
Figure 3. Effect of oxLDL on constriction to NOS inhibition and dilation to sodium nitroprusside (SNP) in 
posterior cerebral arteries (PCA). Graphs showing (A) constriction to NOS inhibition with L-NNA and (B) 
sensitivity to the NO donor sodium nitroprusside (SNP) in PCA from female rats in response to perfusion of 
20% v/v rat serum (n=8) compared to rat serum plus 5 µg/ml oxLDL (n=8), +/-  50 µM apocynin (n=8). 
Perfusion of oxLDL caused a significant increase in constriction to L-NNA in PCA compared to control arteries 
without oxLDL. Apocynin did not affect the oxLDL-induced increase in contriction to L-NNA. oxLDL 
significantly increased sensitivity to SNP in PCA that was abolished by apocynin. (** P< 0.01 vs. all other 
groups by one-way ANOVA; * P< 0.05 vs. all other groups by one-way ANOVA. Abbreviations: CTL, control 
without oxLDL; oxLDL, oxidized LDL; apo, apocynin; SNP, sodium nitroprusside; L-NNA, nitro-L- arginine.) 
However, there was no effect of apocynin on the increased constriction to NOS 
inhibition induced by oxLDL. Figure 3B shows the effect of circulating oxLDL on 
dilation to SNP in PCA. oxLDL caused PCAs to have increased sensitivity to SNP 
compared to the control group that was abolished by the presence of apocynin, 
suggesting involvement of NADPH oxidase activity in this response (P< 0.05).  
MgSO4 prevented oxLDL-induced BBB permeability
MgSO
4
 has shown to be effective in preventing edema formation in several 
neurologic conditions, however, if  MgSO
4  
can prevent oxLDL-induced BBB 
permeability is not known. 16, 21. Figure 4 shows that MgSO
4
 prevented the oxLDL-
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induced BBB disruption (P< 0.05), suggesting a direct protective effect on oxLDL-
induced BBB permeability.  
Figure 4.  Effect of MgSO4 on oxLDL-induced BBB permeability. Graph showing hydraulic conductivity (Lp) 
at 36 minutes as a measure of BBB permeability in response to perfusion of 20% v/v rat serum (n=8) 
compared to serum plus 5 µg/ml oxLDL (n=8) +/-  16 mM MgSO
4
 (n=8). oxLDL caused an increase in BBB 
permeability that was prevented by MgSO
4
. (*P< 0.05 vs. all other groups by one-way ANOVA. Abbreviations: 
CTL, control without oxLDL; oxLDL, oxidized low-density lipoprotein; MgSO
4
, magnesium sulfate) 
MgSO4 did not affect oxLDL-induced decrease in myogenic tone 
Although the data above suggest that MgSO
4
 prevents BBB disruption caused by 
oxLDL, if MgSO
4
 affects the oxLDL- induced changes in myogenic tone of PCA 
is not known. Figure 5A and B show that despite a protective effect on the BBB 
preventing oxLDL BBB permeability, MgSO
4 
did not affect the active myogenic 
response in the PCAs or prevent the oxLDL-induced decrease in myogenic tone. 
Figure 5.  Effect of MgSO4 on oxLDL-induced changes in myogenic tone of posterior cerebral arteries 
(PCA). Graphs showing (A) active myogenic responses and (B) myogenic tone in PCA in response to 
increased intravascular pressure after perfusion with 20% v/v rat serum (n=8) compared to serum plus 5 µg/
ml oxLDL (n=8) +/- 16 mM MgSO
4
 (n=8). There was no difference in active myogenic responses between 
groups nor did MgSO
4
 affect the oxLDL-induced decrease in myogenic tone. (* P< 0.05 vs. all other groups 
by one-way ANOVA. Abbreviations: CTL, control without oxLDL; oxLDL, oxidized low-density lipoprotein; 
MgSO
4
, magnesium sulfate) 
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MgSO4 decreased oxLDL-induced dilation to SNP without affecting oxLDL-
induced constriction to NOS inhibition Figure 6A and B show the constriction 
to NOS inhibition and dilation to the NO-donor SNP of PCAs due to oxLDL with or 
without the presence of MgSO
4
. MgSO
4
 treatment with oxLDL did not significantly 
affect the constriction to L-NNA, however, it did prevent the oxLDL-induced 
enhanced dilation to SNP in PCAs (P< 0.05). 
Figure 6. Effect of MgSO4 on oxLDL-induced constriction to NOS inhibition and dilation to sodium 
nitroprusside (SNP) in posterior cerebral arteries (PCA). Graphs showing (A) constriction to NOS inhibition 
with L-NNA and (B) sensitivity to the NO donor SNP in PCA in response to perfusion of 20% v/v rat serum 
(n=8) compared to 5 µg/ml oxLDL +/-  16mM MgSO
4
 (n=8).  The presence of MgSO
4
 did not significantly 
affect the oxLDL-induced increase in contriction to L-NNA. However, MgSO
4
 prevented the increase in 
dilation to SNP in response to oxLDL in PCA. (** P< 0.01 vs. all other groups by one-way ANOVA; * P< 0.05 vs. 
all other groups by one-way ANOVA. Abbreviations: CTL, control without oxLDL; oxLDL, oxidized LDL; 
MgSO
4
, magnesium sulfate; SNP, sodium nitroprusside; L-NNA, nitro-L-arginine.) 
Discussion
In the present study, we determined the effect of oxLDL on BBB permeability and 
cerebral vascular function and investigated the mechanim by which it acts to increase 
permeability and diminsh myogenic tone. In addition, we examined the possible 
beneficial effects of MgSO
4
 on oxLDL-induced changes in BBB permeability and 
cerebral reactivity, as it has been shown to be beneficial in treating several neurologic 
conditions including severe preeclampsia. Here, we demonstrate that oxLDL, but not 
native LDL, significantly increased BBB permeability that was prevented by apocynin, 
suggesting a role for NADPH oxidase activity in this response. In addition, acute 
exposure to oxLDL significantly decreased myogenic tone in PCAs that was also 
prevented by apocynin. Further, oxLDL increased constriction to NOS inhibition and 
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induced an enhanced dilation to the NO-donor SNP. Finally, treatment with MgSO
4 
protected the BBB and prevented oxLDL-induced BBB disruption without affecting 
the oxLDL-induced changes in myogenic tone. Taken together, these results suggest 
that oxLDL causes BBB disruption and cerebrovascular tone dysregulation through 
activation of NADPH oxidase whereas the effect of MgSO
4
 treatment on oxLDL-
induced vascular dysfunction appears more limited to preventing BBB disruption 
and possibly vascular smooth muscle function. 
oxLDL has become a known key factor in the pathogenesis of  many cardiovascular 
diseases, such as hypertension, atherosclerosis and coronary heart disease 
that may also have consequences for the brain 1-3. Extensive research of oxLDL 
in the systemic and coronary vasculature have revealed complex signaling 
cascades induced by oxLDL leading to increased expression of chemokines and 
adhesion molecules, trans-endothelial migration of monocytes, triggering of 
the inflammatory cascade, and increased production of reactive oxygen species 
leading to endothelial dysfunction 1-3. However, information regarding the effects 
or mechanism of oxLDL in the cerebral vasculature remain limited. The cerebral 
endothelium that comprises the BBB differs from the peripheral vasculature in that 
it lacks fenestrations, and contains high electrical resistance tight junctions that 
limit paracellular permeability and L
p
. BBB disruption induced by oxLDL could lead 
to vasogenic brain edema and contribute to neurologic complications by allowing 
damaging proteins, toxins and plasma constituents to enter the brain parenchyma 
10, 22.  Thus, understanding the underlying mechanisms by which oxLDL affects the 
cerebral circulation and treating its damaging effects could potentially benefit 
several cardiovascular and cerebrovascular diseases.
One condition that involves increased levels of oxLDL and can be complicated with 
neurologic symptoms induced by vasogenic brain edema is preeclampsia 13, 23, 24. 
In a previous study, we revealed a novel mechanism of BBB disruption in response 
to increased circulating oxLDL in severe preeclampsia through generation of 
peroxynitrite 13. Here, we demonstrate for the first time that increased levels of oxLDL 
significantly increased BBB permeability in PCAs that was prevented by apocynin, 
suggesting the effect was mediated by NADPH oxidase-derived superoxide. We 
also show that this effect was specifically due to the oxidative modification of LDL, 
as nLDL did not affect BBB permeability. It is generally accepted that increased 
levels of superoxide rapidly bind NO to generate peroxynitrite, a toxic radical, that 
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can result in endothelial dysfunction 25. Thus, we speculate that oxLDL increases 
superoxide production through NADPH oxidase that leads to subsequent 
generation of peroxynitrite resulting in BBB disruption. Although data investigating 
the mechanism of BBB disruption in preeclampsia or other neurologic conditions 
are scarce, our proposed mechanism is supported by several previous reports using 
cell-culture models that demonstrated that increased levels of oxLDL activate 
superoxide production through NADPH oxidase leading to subsequent increased 
generation of peroxynitrite 8, 26. Importantly, because NADPH oxidase activity is 
greater in the cerebral vasculature compared to the systemic vasculature 27, oxLDL-
induced increased activity of NADPH oxidase can result in excessive production 
of superoxide in the cerebral vasculature leading to extensive damage of the BBB 
and vasogenic brain edema. Thus, oxLDL and NADPH oxidase may be important 
therapeutic targets for treatment and/or prevention of neurologic symptoms in 
preeclampsia and possibly other neurologic conditions where BBB disruption and 
edema formation is involved.
Another unique aspect of the cerebral vasculature is that it has the intrinsic ability 
to maintain a relatively constant CBF despite changes in perfusion pressure partly 
due to intrinsic myogenic mechanisms that modulate CVR. Maintenance of 
cerebral hemodynamics, including autoregulation of CBF and CVR is important in 
conditions such as preeclampsia in which women often have sustained high blood 
pressure. Here, we found that acute intraluminal exposure of oxLDL caused PCAs 
to have larger diameters and significantly decreased myogenic tone, an effect that 
could lead to hyperperfusion, cerebral endothelial damage and BBB disruption. 
To our knowledge, this is the first report to show the detrimental effects of 5µg/
ml oxLDL on PCA function. A previous study investigated the effect of 10 µg/ml 
oxLDL on PCAs from rabbits and found that oxLDL increased myogenic tone, which 
is in contrast to the results of the present study 28.  However, the concentration 
used in the previous study was higher than in the present study. Previous reports 
have described different effects from oxLDL on the systemic vasculature using 
different concentrations 29 such that concentrations of oxLDL higher than 10µg/ml 
increased myogenic tone due to decreased NO production, while concentrations 
of oxLDL between 1µg/ml and 10µg/ml increased NO production 29, 30. Our 
results show a significant increase in constriction to NOS inhibition in response to 
oxLDL, suggesting increased basal NO production in the PCAs. Thus, although the 
previous studies focused on the effects of oxLDL on the systemic vasculature, it 
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may be possible that 5µg/ml oxLDL also increased endothelium-derived NO in the 
cerebral vasculature that could contribute to decreased myogenic tone. 
The present study also found that the presence of the NADPH oxidase inhibitor 
apocynin prevented the oxLDL-induced decrease in myogenic tone, suggesting 
superoxide production may be involved in this response. In a previous study, 
we demonstrated that high cholesterol-treated rats had PCAs with decreased 
myogenic tone that was due to generation of peroxynitrite 7, 11.  Together with the 
finding that oxLDL caused increased constriction to NOS inhibition, we speculate 
that oxLDL-induced superoxide production combines with increased NO to 
generate peroxynitrite. This hypothesis is supported by previous reports that found 
that peroxynitrite is a powerful vasodilator at high concentrations and decreases 
myogenic tone in the cerebral vasculature 11, 31, 32. Thus, next to the detrimental 
effects of oxLDL-induced generation of peroxynitrite in disrupting the BBB, it may 
also decrease myogenic tone in PCAs. 
In addition, we determined the effect of MgSO
4
 on oxLDL-induced BBB disruption 
and vascular tone dysregulation. MgSO
4
 is widely used and effective in the 
management of severe preeclampsia for prevention of neurologic complications 
such as seizures21. In additon, several studies examing brain injury and acute 
hypertension have shown MgSO
4
 to be protective of the BBB, however, the exact 
mechanism remains unclear 14, 15. MgSO
4 
is a calcium antagonist and a potent 
vasodilator by inhibiting vascular smooth muscle contraction, however, these 
effects are considerabely less effective in the cerebral vasculature compared to 
the systemic arteries, suggesting MgSO
4
 is not likely acting as a vasodilator in the 
cerebral vasculature 16, 20. Here, we found that MgSO
4
 abolished oxLDL-induced 
BBB permeability without affecting oxLDL-induced changes in myogenic tone. 
These results confirm earlier reports that MgSO
4
 is protective of the BBB without 
causing significant dilation in the cerebral vasculature. However, it is not clear from 
this study if MgSO
4
 directly antagonizes the mechanism of oxLDL that leads to BBB 
disruption or if MgSO
4
 had an overall protective effect from the damaging effects 
of oxLDL. It is possible that the mechanism by which MgSO
4 
acts is through its 
ability to scavenge free radicals such as superoxide and decrease lipid-peroxidation 
33. Although this may explain the protective effect of MgSO
4
 on BBB disruption, 
oxLDL-induced decrease in myogenic tone was not prevented, suggesting MgSO
4
 
may act primarily to protect the cerebral endothelium.
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Finally, we found that oxLDL increased sensitivity to SNP that was prevented 
by both apocynin and MgSO
4
. A previous study examining effects of oxLDL on 
smooth muscle function found that oxLDL did not influence the dilation to SNP 
in the abdominal aorta 34.  However, another study found that oxLDL decreased 
dilation to SNP in carotid arteries without affecting dilation to SNP in basilar arteries, 
suggesting oxLDL may affect smooth muscle function differently in different 
vascular beds 35. Another study found that oxLDL enhances smooth muscle 
contraction in cultured cells when exposed to contractile agents, suggesting 
that oxLDL sensitizes smooth muscle after interaction with factors that influence 
smooth muscle vasomotion 36.  Importantly, all these previous studies used 
concentrations that were at least 10-fold higher in concentration than that used 
in this study. Nevertheless, we also found that oxLDL influences smooth muscle 
vasomotion in that oxLDL sensitizes the smooth muscle to the NO donor SNP. 
However, our data are too limited to fully explain how oxLDL increased sensitivity 
to SNP, or how apocynin and MgSO
4
 prevented this effect. Future studies are 
necessary to examine how 5 µg/ml oxLDL enhances dilation to SNP in PCAs and 
how apocynin and MgSO
4
 are involved in this response.  
Conclusion
In summary, the present study demonstrates for the first time that oxLDL causes 
increased BBB permeability and cerebral vascular tone dysregulation that was 
prevented by apocynin, suggesting involvement of NADPH oxidase derived 
superoxide in these oxLDL-induced damaging effects. In addition, treatment 
with MgSO
4
 prevented oxLDL-induced BBB disruption without affecting active 
cerebral myogenic responses. These results demonstrate the significance of oxLDL 
in the occurence of cerebral vascular dysfunction in conditions such as severe 
preeclampsia and may be an important marker in the pathogenesis of many 
neurologic conditions. 
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Abstract
Objective: To compare nonpregnant blood pressure and circulating metabolic 
factors between formerly preeclamptic women who did and did not deteriorate 
to eclampsia. 
Design: Retrospective observational cohort study.
Setting: Tertiary referral centre.
Population: Formerly preeclamptic women with (n=88) and without superimposed 
eclampsia (n=638).
Methods: Women who experienced preeclampsia with or without superimposed 
eclampsia during their pregnancy or puerperium were tested for possible 
underlying cardiovascular risk factors at least 6 months postpartum. We measured 
blood pressure and determined cardio vascular and metabolic risk markers in 
a fasting blood sample. Groups were compared using Mann-Whitney U test, 
Spearman’s Rho test or Fisher’s Exact test (odds ratios).  
Main outcome measures: Differences in postpartum blood pressures and features of 
the metabolic syndrome between formerly preeclamptic and formerly eclamptic 
women. 
Results: Formerly preeclamptic women who developed eclampsia differed from 
their counterparts without eclampsia by a lower blood pressure (p<0.01) with blood 
pressure correlating inversely with the likelihood of having experienced eclampsia. 
In addition, formerly eclamptic women had higher circulating C-reactive protein 
levels than formerly preeclamptic women (p< 0.05). All other circulating metabolic 
factors were comparable.
Conclusions: Formerly preeclamptic women with superimposed eclampsia have 
lower nonpregnant blood pressure compared to their counterparts without 
neurological sequellae with blood pressure negatively correlated to the occurrence 
of eclampsia.  
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Introduction
Preeclampsia is a complex vascular disease unique to pregnancy defined by 
hypertension (blood pressure ≥ 140/90 mmHg) combined with proteinuria 
(>0.3g/l) 1, 2. A serious, life-threatening complication in preeclamptic women is 
eclampsia, defined as the new onset of generalized seizures 3, 4. Although relatively 
rare (3-6 per 10,000 births), eclampsia carries a major burden on maternal and 
perinatal morbidity and mortality worldwide 5. In the brain, eclampsia relates to 
edema, haemorrhage and stroke, but also impairment of cognitive function in 
later life 3, 4. 
Eclampsia is generally accepted to be a form of posterior reversible encephalopathy 
syndrome (PRES) 6. PRES is characterized by vasogenic brain edema notably in the 
white matter of the parietal and occipital lobes, as seen in nearly all eclamptic 
patients 7-10. Blood-brain barrier (BBB) disruption is the hallmark event in the 
development of vasogenic brain edema by promoting the passage of damaging 
plasma constituents into the brain parenchyma potentially evoking seizure 
activity8, 11. BBB disruption can occur when blood pressure rises above the upper 
cerebral autoregulatory limit. However, during pregnancy, a large proportion of 
eclamptic women had no precedence of hypertension 4, 12, 13. Although animal 
studies suggest the cerebral blood flow autoregulatory curve is shifted to higher 
pressures during pregnancy, it is not known whether biological variations in this 
curve exist in healthy young women outside of pregnancy 14, 15. It is possible that 
eclamptic women without significant hypertension had even lower nonpregnant 
blood pressure resulting in a lower limit of the cerebral autoregulatory curve. 
In addition to the rise in blood pressure, circulating factors capable of initiating 
BBB disruption may be involved increasing the susceptibility to eclampsia in 
preeclamptic women. Previous studies have shown that increased plasma 
levels of oxidized low density lipoprotein (oxLDL), a known key factor in vascular 
dysfunction in severe preeclamptic women, also increase BBB permeability 16, 17,18. 
Elevated levels of oxLDL may be the result of enhanced oxidation of LDL during 
preeclampsia. Alternatively, women with preeclampsia developing eclampsia may 
differ from their non-eclamptic counterparts by a preexistent abnormal metabolic 
profile, such as dyslipidemia.
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In this study, we hypothesized that formerly eclamptic women differed from 
women that suffered from preeclampsia only by a lower blood pressure outside 
of pregnancy. In addition, we explored whether the peripheral levels of metabolic 
factors related to the metabolic syndrome are more prevalent in the nonpregnant 
state in formerly eclamptic women than in formerly preeclamptic women. 
Methods
Study population. In the period between 1996 and 2010, we screened women with 
a previous hypertensive pregnancy disorder (such as preeclampsia or eclampsia) 
several months postpartum for possible underlying cardiovascular risk factors at 
two tertiary care centers. The study was approved by the Hospital Medical Ethical 
Committees (Maastricht University Medical Center and Radboud University 
Medical Center; MEC 0-4-049, 2007/252). In the present study, we analyzed the 
data of all primiparous women enrolled in the screening program with a history 
of preeclampsia complicated by eclampsia (n=92) versus preeclampsia without 
eclampsia (n=867). Preeclampsia was defined according to the criteria of the 
Report of the National High Blood Pressure Education Program Working Group 
on High Blood Pressure in Pregnancy 2. All patients discontinued breastfeeding 
or hormonal contraceptive use at least 4 weeks before screening. Also, women 
diagnosed with pre-existing hypertension (hypertension diagnosed before 20 
weeks of pregnancy or at the time of screening) were excluded (eclampsia group: 
n=4; preeclampsia group: n= 169). Hypertension was diagnosed as systolic blood 
pressure ≥140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg, or when 
women were taking antihypertensive drugs. On the evening before the day of 
screening all patients refrained from eating, drinking and smoking until screening 
completion.
Blood pressure measurements. Measurements took place at 8:00 AM in a quiet and 
temperature-controlled room. All women were positioned in a sitting position with 
the upper part of the measurement arm at heart level, while the whole arm was 
relaxed. After an acclimatization period of 30 minutes, arterial blood pressure was 
recorded at 3-minute intervals for a period of 30 minutes using a semiautomatic 
oscillometric device (Dinamap Vital Signs Monitor 1846; Critikon, Tampa, FL) with a 
cuff size of 13.5×30.7 cm if upper arm circumference ranged from 27.5 to 36.5 cm 
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or a cuff size of 17×38.6 cm if upper arm circumference ranged from 35.5 to 46 cm. 
After accumulating 9 measurements, the median systolic, diastolic, mean arterial 
pressures and median heart rate was calculated and registered. 
Measurements of metabolic factors. All blood samples were collected in the 
morning after an overnight fast. Blood samples were taken for plasma lipid 
profile, glucose, insulin and renal function. Triglycerides, total cholesterol, high-
density lipoprotein cholesterol (HDL), uric acid, C-reactive protein (CRP) and 
glucose were determined using standard automated laboratory techniques. Low-
density lipoprotein (LDL) cholesterol was calculated by the Friedewald equation 
19. Plasma insulin concentrations were measured using AutoDelfia time-resolved 
fluoroimmunoassay. Finally, all women had collected a 24 hour urine sample to 
determine the presence of proteinuria normalized for creatinine output using 
normal lab standards. 
Statistical analysis. All data are presented as means ± standard deviation. All data 
were analyzed with Mann-Whitney U test. Sub-analysis of the blood pressure data 
was performed using trend analysis and odd ratios. Inter-group differences were 
considered statistically significant when the probability (P) was below 0.05. 
Results
Table 1 lists the demographics and clinical characteristics of the women with 
pregnancy being complicated by preeclampsia, without (PE; n=698) and with 
superimposed eclampsia (E; n=88). Both subgroups were comparable with respect 
to age, height, weight, BMI, percentage smokers, and also with respect to time 
elapsed between delivery and screening. In contrast, both subgroups differed 
from one another with respect to clinical characteristics of the index pregnancy. 
Compared to the E-subgroup, we noticed that women in the PE-subgroup had 
delivered at an earlier gestational age. In addition, the birth weight and birth 
weight centile were lower in the PE-subgroup compared to the E-subgroup, 
which was not only due to more severe prematurity but also because of a higher 
incidence of fetal growth restriction.
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Table 1. Demographics of formerly preeclamptic and eclamptic women.
Indices PE 
(n=698)
E (n=88) P
Age (yrs) 31.0 ± 4.1 30.3 ± 4.5 0.19
BMI (kg/m2)
Height (cm)
Weight (kg)
Smoking (%)
Time between delivery and 
screening (months)
25.2 ± 4.9
168.3 ± 6.5
71.4 ± 14.7
12
11 ± 8
24.9 ± 4.8
167.6 ± 6.6
70.3 ± 15.1
15
11 ± 9
0.67
0.51
0.46
0.25
0.81
Index pregnancy
  SGA (<p10;%) 33 20   0.02
  Gestational days birth
  Gestational weeks birth
232 ± 38
331/7 ± 52/7 
242 ± 31
346/7 ± 43/7
  0.01
  0.01
  Birth weight (grams) 1737 ± 864 2212.9 ± 1000 <0.01
  Birth weight centile 28 ± 14 35 ± 19   0.01
BMI = body mass index; SGA = small for gestational age. PE = preeclampsia; E= eclampsia.
At the time of screening, we compared both subgroups with respect to blood 
pressures and heart rates (Table 2). Importantly, the systolic, diastolic and mean 
arterial pressure were lower outside of pregnancy in the E-subgroup compared to 
the PE-subgroup. Also, heart rate was lower in the E-subgroup compared to the 
PE-subgroup. 
Table 2. Nonpregnant blood pressure of formerly preeclamptic vs. eclamptic women.
Indices PE (n=698) E (n=88) P
BP systolic 119 ± 12 111 ± 9  < 0.01
BP diastolic
MAP
Heart rate (beats per minute)
72 ± 9
88 ± 10
71 ± 10
67 ± 8
83 ± 8
68 ± 10 
< 0.01
< 0.01
   0.03
BP = Blood Pressure; MAP = Mean Arterial Pressure; PE= preeclampsia; E= eclampsia. 
In addition, our results demonstrate that the blood pressure is negatively 
correlated with the likelihood of the development of eclampsia (Figure 1). When 
organizing both subgroups according to different blood pressure quintiles, trend 
analysis showed a significant negative correlation between blood pressure and 
the occurrence of eclampsia (p < 0.001). Also, odds ratio of the quintile subgroups 
compared to the 20% lowest blood pressure population showed that women in 
the 4th and highest quintile group had a significant lower incidence of eclampsia 
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compared to the women in the lowest quintile group. 
Figure 1. Percentages of the occurrence of eclampsia (E) versus preeclampsia (PE) arranged in quintile 
groups of the mean arterial blood pressure (MAP). Graph showing trend-analysis that demonstrates a 
significant negative correlation between MAP and the occurrence of eclampsia (E). In addition, graph 
showing odd ratio of 2nd to 5th quintile group compared to the lowest quintile group of the MAP. Odds ratio’s 
show a decreased risk of the occurrence of eclampsia when increasing MAP in the different population 
quintiles that is reaching statistical difference in the 4th and 5th quintile group (p < 0.05). Population Quintiles 
and corresponding MAP: <p20: MAP < 79 mmHg; p20-40: MAP 79-84 mmHg; p40-60: MAP 84-89 mmHg; 
p60-80: MAP 89-97 mmHg; >P80: MAP > 97 mmHg.
We also analyzed if women diagnosed with eclampsia differed to their counterparts 
with respect to contributing signs of an underlying form of metabolic syndrome 
The difference in metabolic variables between the 2 subgroups was inconsistent, 
except for a marginally but significantly higher C-reactive protein (CRP) level in the 
E-subgroup (Table 3).
Table 3. Nonpregnant metabolic factors formerly preeclamptic vs. eclamptic women.
Indices PE (n=698) E (n=88) P
Proteinuria (mg/mmol) 7.5  ± 3.3 7.3  ± 6.0 0.19
Uric acid (mmol/l)
Total cholesterol (mmol/l)
HDL (mmol/l)
LDL (mmol/l)
Triglycerides (mmol/l)
Glucose (mmol/l)
Insulin (mmol/l)
HbA1c
CRP (mmol/l) 
4.2 ± 1.1
4.7 ± 0.9
1.4 ± 0.8
3.0 ± 0.8
1.1 ± 0.7
5.0 ± 0.7
11.1  ± 5.7
5.2 ± 0.4
3.6 ± 2.1
4.3  ± 1.0
4.8  ± 0.9
1.3  ± 0.3
2.9 ± 0.9
1.2 ± 0.7
5.1 ± 1.0
10.5± 5.3
5.4 ± 0.8
4.8 ± 3.1
0.56
0.13
0.87
0.38
0.13
0.75
0.17
0.88
0.02
PE = preeclampsia; E= eclampsia; HDL= high density lipoprotein; LDL= low density lipoprotein.; CRP= 
C-reactive protein. 
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To determine whether the occurrence of developing eclampsia relative to childbirth 
related to any of variables measured at screening, we subdivided all women that 
suffered from eclampsia Both antepartum and postpartum E-subgroups were 
similar with regard to age, height, weight, BMI and percentage of smokers (Table 
4). The antepartum E-subgroup differed from the post partum E-subgroup by 
delivery at an earlier gestational age, resulting more often in an infant with a lower 
birth weight and a lower birth weight centile (Table 4). 
Finally, we investigated if there were any differences in blood pressure or metabolic 
syndrome constituents between antepartum or postpartum eclampsia. 
Table 4. Demographics of formerly antepartum vs. postpartum eclampsia. 
Indices Antepartum 
(n=53)
Postpartum 
(n=35)
P
Age (yrs) 30.2 ± 4.1 30.5 ± 4.9 0.73
BMI (kg/m2)
Height (cm)
Weight (kg)
Smoking (%)
Time between delivery and screening 
(months)
24.8 ± 4.5
168 ± 7
70.0 ± 13.7
19
11 ± 8
25.0 ± 5.2
168 ± 7
70.6 ± 13.4
14
12 ± 9
0.95
0.94
0.81
0.26
0.50
Index pregnancy
  SGA (<p10) 20 17      0.88
  Gestational days birth
  Gestational weeks birth
222 ± 22
315/7 ± 52/7 
273 ± 9
390/7 ± 43/7
  < 0.01
  < 0.01
  Birth weight (grams) 1588 ± 847 3123 ± 416   < 0.01
  Birth weight centile 30 ± 28 47 ± 25      0.02
BMI = body mass index; SGA = small for gestational age. 
Table 5A and 5B show that blood pressure, heart rate and metabolic indices were 
similar in both groups. Women in the antepartum E-subgroup showed a trend 
towards having higher LDL and total cholesterol compared to the postpartum 
E-subgroup, but those variables did not reach statistical significance. Triglycerides 
were significantly higher in the postpartum E-subgroup.  
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Table 5A. Nonpregnant blood pressure in formerly antepartum vs. postpartum eclampsia. 
Indices Antepartum 
(n=53)
Postpartum 
(n=35)
P
BP systolic 113 ± 9 111 ± 9  0.29
BP diastolic
MAP
Pulse rate 
68 ± 8
84 ± 8
68 ± 9
66 ± 6
81 ± 8
68 ± 11 
0.25
0.63
0.87
BP = Blood Pressure; MAP = Mean Arterial Blood Pressure. 
Table 5B. Nonpregnant metabolic factors in formerly antepartum vs. postpartum eclampsia.  
Indices Antepartum 
(n=53)
Postpartum 
(n=35)
P
Proteinuria (mg/mmol) 7.3 ( ± 0.7) 7.4 ( ± 0.4) 0.19
Uric acid (mmol/l)
Total cholesterol (mmol/l)
HDL (mmol/l)
LDL (mmol/l)
Triglycerides (mmol/l)
Glucose (mmol/l)
0.24 (± 0.06)
4.7 (± 0.9)
1.3 (± 0.4)
2.9 (± 0.6)
1.09 (± 0.7)
5.2 (± 0.9)
0.20 ( ± 0.07)
4.4 ( ± 1.0)
1.3 ( ± 0.6)
2.6 (± 0.8)
1.13 (± 0.7)
4.9 (± 0.5)
0.18
0.08
0.56
0.09
0.02
0.89
Insulin (mmol/l)
HbA1c
CRP (mmol/l)
11.0  (± 5.7)
5.3 (± 0.9)
4.5 (± 2.9)
9.8 (± 4.8)
5.3 (± 0.4)
4.9 (± 3.0)
0.29
0.23
0.73
HDL= high density lipoprotein; LDL= low density lipoprotein.
Discussion
This study provides convincing evidence for formerly eclamptic women to have 
a lower blood pressure and heart rate in the nonpregnant state compared to 
women that suffered from preeclampsia only. Importantly, blood pressure is 
negatively correlated with the occurrence of eclampsia. In addition, formerly 
preeclamptic patients with or without superimposed eclampsia were comparable 
with respect to metabolic features, except for slightly higher peripheral levels of 
CRP after eclampsia.  
Eclampsia remains a significant life-threatening complication of pregnancy 
and can be considered as a form of PRES 13. A recent study found that nearly all 
eclamptic patients had MRI changes that could be interpreted radiologically as 
PRES 10. In this study, we analyzed a cohort of eclamptic women and searched 
for clinical and metabolic features predisposing to superimposed eclampsia in 
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preeclamptic women. We demonstrated that formerly eclamptic women had lower 
nonpregnant blood pressure compared to formerly preeclamptics with a negative 
correlation between blood pressure and the occurrence of eclampsia. We can only 
speculate about the clinical relevance of this finding. Preeclampsia is partly defined 
by the development of hypertension after 20 weeks of pregnancy in a previously 
normotensive woman 20. This definition does not consider the magnitude of the 
rise in blood pressure throughout the course of gestation. However, we speculate 
that the change in blood pressure in preeclamptic women throughout gestation 
is more important in the development of neurologic complications than the 
absolute number and thereby should be assessed individually.
One important contributor of the development of vasogenic brain edema and 
eclampsia is breakthrough of cerebral blood flow autoregulation 3, 13, 15. Above the 
autoregulatory pressure threshold, forced dilation of the cerebral vessels occurs, 
resulting in hyperperfusion, which may lead to significant brain tissue damage 
and vasogenic brain edema and life-threatening sequels 13, 21. Several studies 
have found a considerable percentage of eclamptic women without significant 
hypertension 10, 22. This has led to the concept that pregnancy may shift the upper 
limit of autoregulation. Although pregnancy was shown to extend the upper 
limit of the autoregulatory curve during acute hypertension in rats,14 pregnant 
rats showed brain edema formation at significantly lower blood pressures 
compared to non-pregnant rats 23. In addition, pregnancy both prevents and 
reverses medial hypertrophy of cerebral arteries resulting from chronic exposure 
to hypertension. This effect eliminates effectively the possible protective effect 
against forced dilatation of the preexistent vascular remodeling 24, 25. Here, we 
speculate that women with a relatively low pre-pregnant blood pressure who 
develop preeclampsia during pregnancy have a higher risk for eclampsia by 
autoregulatory breakthrough at a lower blood pressure than their counterparts 
with a higher nonpregnant blood pressure. However, this hypothesis assumes 
that blood pressures measured remote from pregnancy reflect antepartum blood 
pressures and needs to be addressed in future studies. 
Additionally, the incidence of postpartum eclampsia has increased at the cost of 
antepartum eclampsia, probably as a result of intensified surveillance and more 
active clinical management during pregnancy 26. Here, we found about 40% of all 
cases of eclampsia to occur postpartum, which is in line with the 30-50% incidence 
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of postpartum eclampsia reported by others 26. Importantly, previous reports 
indicated postpartum eclampsia often was not preceded by earlier diagnosed 
preeclampsia or hypertension 19, 27, 28. It follows that women with mild hypertension 
during pregnancy may have blood pressures above their autoregulatory threshold 
putting them at particular risk during the puerperium, where blood pressure 
monitoring is decreased, yet with no clinical profile to differentiate them from low-
risk women. This changing pattern of eclampsia confronts health professionals 
with the challenge of recognizing women in the puerperium with neurologic 
symptoms that need prompt referral.
Impaired cerebral autoregulation may not be the only factor associated with 
an increased risk for preeclampsia/eclampsia. Circulating factors have shown 
to increase BBB permeability, neuronal hyper-excitability and seizure activity 16, 
17. For example, physiological hyperlipidemia is a normal feature of pregnancy. 
However, this characteristic is much more pronounced during preeclampsia 29, 30, 
31. Recent studies demonstrated that elevated circulated levels of oxLDL increase 
BBB permeability and may thereby be an important contributor to vasogenic 
brain edema in severe early-onset preeclampsia 16, 32. Our results suggest that 
antepartum eclampsia occurs more often in early-onset pre eclampsia, however, 
did not indicate that eclamptic women already had an underlying metabolic 
disorder. We showed a trend, but not significant, towards higher nonpregnant 
circulating lipids in antepartum eclampsia compared to postpartum eclampsia. 
Nevertheless, previous studies support that women that suffered from severe 
early-onset preeclampsia have a higher risk of metabolic syndrome in later life 33, 
34.  Further research is needed to investigate hyperlipidemia in severe early-onset 
preeclamptic patients, combined with elevated growth factors such as vascular 
endothelial growth factor (VEGF) and placental growth factor (PLGF) that could 
interact with each other and induce significant oxidative stress. In fact, previous 
animal studies found that inhibition of VEGF receptor tyrosine kinase activity 
prevented BBB disruption induced by plasma from preeclamptic women 17. The 
mechanism underlying VEGF-induced BBB permeability in preeclamptic plasma 
was shown to be due to VEGF receptor phosphorylation and release of nitric oxide 
that binds oxidative radicals generated by activated oxLDL to cause endothelial 
dysfunction through the formation of peroxynitrite 16, 35.  Thus, circulating factors 
that cause oxidative stress and endothelial dysfunction likely have a role in cerebral 
edema formation during eclampsia. 
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Additionally, our results showed that CRP was slightly but consistently higher in 
formerly eclamptics compared to formerly preeclamptic women. Previous studies 
found that CRP may have a predictive value in predicting severe preeclampsia 36, 
37. CRP binds to the same receptor as oxLDL, the so-called LOX-1 receptor, which 
subsequently induces endothelial dysfunction by releasing toxic oxidative radicals 16, 
18, 32. Also, CRP is a risk factor for cardiovascular events 38. Thus, CRP may be involved 
in the oxLDL-LOX1 pathway that induces BBB disruption in women resulting in 
eclampsia or other neurologic sequels. Further research is necessary to examine the 
involvement and clinical significance of CRP in the pathogenesis of (pre)eclampsia.
Limitations
In this study, we were unable to access data from these women specifying their 
pre-pregnancy health status and medical check-ups during pregnancy before 
the onset of preeclampsia/eclampsia. Also, although we do not show any 
underlying metabolic disorder in these women, it may be possible that pregnancy 
itself unmasks metabolic syndrome that will re-emerge in later life, beyond the 
time frame for which this study was conducted. Another limitation is that we 
did not measure angiogenic factors, which made it impossible to assess the 
possible involvement of other growth factors such as VEGF, sFlt-1 and PLGF in 
the development of superimposed eclampsia. Finally, the fact that women with 
preeclampsia are increasingly managed more aggressively in the course of the last 
2 decades may have led to a bias in the eclamptic group. 
Conclusion
Formerly eclamptic women have significant lower non-pregnant blood pressure 
compared to formerly preeclamptic women with a negative correlation between 
blood pressure and the occurrence of eclampsia. This observation supports the 
concept that the rate and/or magnitude of the rise of blood pressure rather than 
the maximum blood pressure at the onset of eclamptic fits may be more important 
in triggering eclampsia. As about 40% of all eclamptic cases occur postpartum, 
surveillance of pre eclamptic women during childbirth should include routine 
blood pressure monitoring post partum. 
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Introduction
Healthy human and rodent pregnancy is characterized by a maternal circulatory 
transition towards a high volume- low resistance state, a condition thought to be 
necessary for a normal development of the maternal-fetal unit, and is paralleled by 
changed vessel wall integrity, hemodynamics and coagulation 1-3. Concomitantly, 
the maternal brain is challenged to maintain its constant blood supply and strict 
water homeostasis to prevent cerebral edema, and with it, seizures or other 
neurologic complications 4. Currently, there is only limited understanding of the 
adaptation of the cerebral vasculature in pregnancy in humans with more data on 
rodents. Understanding how pregnancy and pregnancy-related conditions such 
as preeclampsia affect the cerebral vasculature is of great importance, considering 
neurologic complications to be a major cause of maternal death worldwide 5, 6. 
In this manuscript, we investigated how the rat cerebral vasculature is affected 
by pregnancy and examined mechanisms of cerebral vascular dysfunction in 
pregnancy related to potentially life-threatening neurologic complications. In 
addition, we searched for potential cardiovascular differences in a cohort of 
women that were diagnosed with preeclampsia only or preeclampsia that was 
complicated by eclampsia.
Normal pregnancy: the adaptation of the blood-brain barrier.  
The cerebral vasculature has several unique features compared to the other 
peripheral vascular beds 7. First, the cerebral vasculature is the site of the 
blood-brain barrier (BBB). The BBB comprises an unique endothelial layer that 
lacks fenestrations, contains high electrical resistance tight junctions and has 
restricted transcellular and paracellular flux of ions and proteins, resulting in a 
strong protective mechanism against vasogenic brain edema 8-10. During normal 
pregnancy, the placenta releases large amounts of permeability promoting factors 
that may affect the BBB permeability, however, vasogenic brain edema does 
not normally occur 11. Apparently, the cerebral vasculature or its hemodynamics 
appears to adapt during normal pregnancy to maintain its protective state against 
vasogenic edema formation. 
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In women diagnosed with preeclampsia, development of neurologic complications 
due to BBB disruption and vasogenic brain edema may occur. As these women may 
develop epileptic seizures in absence of high blood pressure, these observations 
suggest pregnancy itself may affect the BBB. In chapter 2, we confirmed previous 
studies in that the permeability factor vascular endothelial growth factor (VEGF) 
is significantly increased in pregnancy. VEGF has been shown to be necessary for 
the development and maintenance of the maternal-fetal unit and uteroplacental 
circulation, however, other studies have shown that increased levels of VEGF can 
cause vasogenic brain edema during brain injury 12, 13. We found that VEGF could 
induce increased BBB permeability in the nonpregnant state, but that VEGF was 
unable to increase BBB permeability during pregnancy. We also examined possible 
adaptive mechanisms that prevent the BBB during pregnancy. First, the BBB itself 
could adapt to increased VEGF by alteration of VEGF-receptor (VEGFR) expression. 
A previous study observed increased permeability in uterine vessels in pregnancy 
accompanied by increased mRNA-expression of VEGF-receptors 13. In our study, no 
increased mRNA expression of VEGF-receptors was observed. This could reflect a 
possible adaptative mechanism where the uterine veins require increased vascular 
permeability for controlled extravasation of intravenous molecules into the 
maternal-fetal unit 14, while the BBB must maintain its protective state. A second 
explanation may be the presence of circulating factors in plasma during pregnancy 
preventing VEGF-induced BBB permeability. We found that sFlt1, a known regulator 
of the bioavailability of VEGF that is also increased in pregnancy 12, critically 
regulates VEGF action at the BBB by preventing VEGF-induced BBB permeability, 
even in excessive levels. This finding is interesting because it has been thought 
that excess levels of sFlt1 are involved in the pathogenesis of preeclampsia 15. 
Although these data are limited to an acute exposure time, other studies also did 
not find BBB disruption in response to sFlt1 alone, but only in interaction with pro-
inflammatory cytokines such as TNFα it appeared to cause damage 16, 17. This could 
suggest that increased sFlt1 in pregnancy does not increase BBB permeability, but 
may be a protective mechanism for the threatened BBB in that release of sFlt1 is 
triggered by high levels of permeability factors such as VEGF. 
Dyslipidemia in pregnancy, good or bad?
It has been thought that pregnancy might act as a ‘stress test’ that may unmask 
women’s  cardiovascular risk mediated through metabolic syndrome or other 
circulatory conditions related to high blood pressure 18, 19. Metabolic syndrome 
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that includes dyslipidemia, jeopardizes endothelial cell function and may even 
be involved in endothelial dysfunction in preeclampsia 20, 21. On one hand, during 
pregnancy, there is a physiological hyperlipidemia that is thought to encourage 
lipogenesis and fat storage in preparation for rapid fetal growth without affecting 
endothelial cell function 22. On the other hand, in preeclampsia, previous studies 
have showed an excessive hyperlipidemia compared to normal pregnancy that 
may promote cerebral vascular dysfunction 21, 23. Several reports investigating 
stroke have reported that dyslipidemia can cause cerebral vascular dysfunction 24, 25. 
In chapter 3, we show that excessive hyperlipidemia caused greater inflammatory 
responses en oxidative stress in cerebral arteries during pregnancy compared 
to the nonpregnant state. The fact that dyslipidemia enhanced oxidative stress 
is confirmed in studies investigating other cardiovascular diseases and thereby 
suggesting that preeclampsia show similar etiologies compared to these 
conditions.  In addition, we found in chapter 4 that women diagnosed with early-
onset preeclampsia showed excessive dyslipidemia in that levels of oxidized low 
density lipoprotein (oxLDL) were approximately 260% higher compared to women 
diagnosed with late-onset preeclampsia or women that experienced a normal 
pregnancy, suggesting that lipids are of great importance in the pathogenesis of 
pregnancy related disorders such as preeclampsia. 
The pathogenesis of the development of neurologic complications in 
preeclampsia.
Although extensive research has been performed on the pathogenesis of 
preeclampsia, understanding of the development of the life-threatening 
complications of preeclampsia such as eclampsia has received less attention. 
In this manuscript we did not only focus on the adaptation of the cerebral 
vasculature in normal pregnancy, but also on the consequences of preeclampsia 
on the cerebral vasculature. Preeclampsia is a  complex heterogenous disorder 
and its pathogenesis still remains to be elucidated 5, 26. It has been thought that 
preeclampsia can progress to a severe state and eventually into eclampsia, thus 
affecting the brain. Nowadays is has become generally accepted that eclampsia 
can be considered as a form of posterior reversible encephalopathy syndrome 
(PRES) 27. The hallmark event in the occurrence of neurologic complications may 
be the development of vasogenic brain edema, as is shown as PRES on MRI 
imaging in eclamptic patients 4, 28, 29. However, the underlying mechanisms are 
still largely unknown. Before the onset of eclamptic seizures, one theory is that 
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elevated blood pressures causes cerebral autoregulation breakthrough resulting 
in increased cerebral blood flow leading to endothelial dysfunction and vasogenic 
edema 4, 30. However, a large number of number of women that suffered from 
eclamptic seizures or other neurologic complications, such as uncontrolled 
vomiting, severe headache, cortical blindness, or cerebral hemorrhage, did not 
show elevated blood pressures 31, 32. This may suggest other limits in the cerebral 
autoregulation curve or other factors that may be involved. Chapter 6 describes 
that women that suffered from eclampsia had lower nonpregnant blood pressure 
compared to women that suffered from preeclampsia only. This observation 
suggest that those eclamptic women with lower baseline blood pressure have 
autoregulatory curve disruption at lower pressures. This was confirmed by a 
previous animal study investigating autoregulation in late pregnant rats showed 
brain edema at significantly lower blood pressures compared to nonpregnant 
rats 33. In addition, previous studies demonstrated that pregnancy prevents and 
reverses medial hyperthrophy of cerebral arteries that occurs during chronic 
hypertension, effectively eliminating any protective effect of vascular remodeling 
on forced dilatation 34, 35. Importantly, chapter 6 also shows that the blood pressure 
is negatively correlated with the occurence of eclampsia. Because more agressive 
screening and clinical management have shifted the prevalence of eclampsia from 
antepartum to postpartum, health professionals are challenged with recognising 
women in the puerperium without hypertension but already have neurologic 
symptoms that need prompt referral.  
Nevertheless, previous studies have shown that the BBB plays a central role in the 
etiology of vasogenic brain edema and neurologic complications. BBB disruption 
promotes the passage of damaging proteins and plasma constituents into the 
brain parenchyma that may activate microglia that promote seizure activity 36, 
37. In fact, a previous study has showed that circulating factors present in plasma 
from severe preeclamptic women increased BBB permeability, demonstrating the 
central role of the BBB in promoting neurologic complications in preeclampsia 38. 
We found in chapter 4 that oxLDL is substantially increased in plasma from women 
with severe, early-onset preeclampsia. We also found that exogenous oxLDL to the 
levels of preeclamptic plasma, but not native LDL (nLDL), causes BBB disruption, 
demonstrating the involvement of oxLDL in the onset of vasogenic brain edema 
and neurologic symptoms. The fact that oxLDL was mainly increased in early-onset 
preeclampsia was confirmed in that BBB permeability was significantly increased in 
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response to plasma from early-onset preeclamptic women compared to late-onset 
preeclamptic women, suggesting different etiologies. These results are supported 
by epidemiologic studies that demonstrated that neurologic complications in 
preeclampsia occurred most often in preeclampsia diagnosed before 34 weeks 
compared to preeclampsia that developed after 34 weeks 32, 39-41. Also, previous 
studies have found that this difference may arise from a greater placental 
underperfusion and subsequent increased release of circulating vasoactive factors 
40. Thus, in this manuscript, we demonstrate oxLDL as an underlying mechanism 
of BBB disruption in early-onset preeclampsia and a possible new important 
therapeutic target. Chapter 6 showed that women that suffer from severe early 
preeclampsia and eclampsia did not show underlying features of metabolic 
syndrome outside of pregnancy. Thus, women that develop severe preeclampsia 
and/or eclampsia may develop a more pronounced hyperlipidemia during 
pregnancy instead of suffering from dyslipidemia outside of pregnancy. 
oxLDL is a known key factor in the pathogenesis of many cardiovascular diseases 
42, 43. Oxidative modification of physiological nLDL into oxLDL occurs in numerous 
disease states as a result of oxidative stress and the presence of reactive oxygen 
species. The formation of oxLDL initiates multiple pathways in both endothelial 
and vascular smooth muscle cells, mostly through binding to its receptor lectin-
like oxLDL receptor (LOX-1).  oxLDL binding to LOX-1 generates complex signaling 
cascades leading to induction of the inflammatory pathway and increased 
production of superoxide that can further promote vascular dysfunction 42, 43. 
Previous studies already showed that LOX-1 could be involved in preeclampsia in 
that plasma from preeclamptic women caused upregulation of LOX-1, however, 
we support that also its ligand oxLDL increases and causing BBB disruption 
without upregulation of LOX-1 due to its short exposure time 44-46. In chapter 4 
we show that oxLDL-induced BBB permeability could be prevented with a LOX-
1 antibody, confirming the involvement of LOX-1 activation in BBB disruption. 
LOX-1 activation is known to increase production of superoxide and other 
reactive oxygen species. Several reports have shown in cell-culture that oxLDL-
LOX-1 activation decreased NO by activation of NADPH oxidase, an important 
source of superoxide production 47, 48. In fact, in chapter 4 and 5, we describe 
that oxLDL increases BBB permeability through NADPH oxidase activation and 
subsequent generation of peroxynitrite. In line with our findings, several other 
studies have showed in different cell-culture models that oxLDL is able to increase 
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NADPH oxidase activity and increase peroxynitrite 47, 48. Because NADPH oxidase 
expression and activity are greater in the cerebral vasculature compared to the 
peripheral circulation 49, the brain may be especially vulnerable for activation of 
NADPH oxidase and subsequent peroxynitrite generation. Thus, we present a 
novel mechanism for the development of neurologic complications in early-onset 
preeclampisa in that increased oxLDL binds to LOX-1, to increase NADPH oxidase 
activity, that can produce excessive superoxide. Superoxide can bind rapidly nitric 
oxide (NO) to form the toxic radical peroxynitrite, resulting in BBB disruption and 
vasogenic brain edema. 
In addition to the direct effects of oxLDL on the BBB, we also studied how oxLDL may 
impact the cerebral vascular reactivity that could contribute to the development 
of neurologic symptoms in pregnancy. In chapter 5, we found that oxLDL, but not 
native LDL, significantly decreased myogenic tone in posterior cerebral arteries, an 
effect that could lead to diminished cerebral vascular resistance, hyperperfusion, 
and BBB disruption due to high hydrostatic pressure. Together with the finding 
that oxLDL caused increased constriction to NOS inhibition, it may be possible that 
oxLDL-induced superoxide production combines with increased NO to generate 
peroxynitrite that is the vasoactive component. This hypothesis is supported by 
previous reports that found that peroxynitrite is a powerful vasodilator at high 
concentrations and decreases myogenic tone in the cerebral vasculature 50-52. 
Thus, in addition to the direct detrimental effects of oxLDL-induced generation 
of peroxynitrite disrupting the BBB, it may also decrease myogenic tone in PCAs 
affecting cerebral circulatory autoregulation. Importantly, in chapter 3, we also 
found that in pregnancy, excessive hyperlipidemia also decreased myogenic 
tone due to presence of increased peroxynitrite. Because excessive levels of lipids 
also increased BBB permeability in pregnancy that could be inhibited by a LOX-1 
antibody, it is tempting to speculate that excessive hyperlipidemia in pregnancy is 
accompanied by conversion of nLDL to the detrimental oxLDL leading to oxidative 
stress and peroxynitrite generation causing cerebrovascular dysfunction. Thus, 
in addition to direct impact on the endothelial layer of the BBB, oxLDL may also 
predispose the cerebral vascular reactivity to cerebral vascular dysfunction. 
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Magnesiumsulfate (MgSO4) therapy as prevention of neurologic complications 
in preeclampsia
 MgSO
4
 is widely used and effective in the management of severe preeclampsia 
for prevention of neurologic complications such as seizures 53, 54. Several studies 
examining brain injury and acute hypertension have shown MgSO
4
 to be 
protective of the BBB, however, the exact mechanism remains unclear 53, 54. MgSO
4 
is a calcium antagonist and a potent vasodilator by inhibiting vascular smooth 
muscle contraction, however, these effects are considerably less effective in the 
cerebral vasculature compared to the systemic arteries, suggesting MgSO
4
 is not 
likely acting as a vasodilator in the cerebral vasculature 55, 56. In chapter 5, we found 
that MgSO
4
 abolished oxLDL-induced BBB permeability without affecting oxLDL-
induced changes in myogenic tone. These results confirm the earlier reports that 
MgSO
4
 is protective of the BBB without causing significant dilation in the cerebral 
vasculature . However, it is not clear from this study if MgSO
4
 directly antagonizes 
the mechanism of oxLDL that leads to BBB disruption or if MgSO
4
 had an overall 
protective effect on the BBB. It may be possible that the mechanism by which MgSO
4 
acts is through its ability to scavenge free radicals such as superoxide and decrease 
lipid-peroxidation. Although this may explain the protective effect of MgSO
4
 on 
BBB disruption, oxLDL-induced decrease in myogenic tone was not prevented, 
suggesting MgSO
4
 may act primarily to protect the cerebral endothelium.
Conclusions
1. Pregnancy causes a unique challenge to the maternal brain. While other 
organs undergo substantial changes to increase the maternal blood flow, 
the adaptation of the cerebral circulation appears to maintain a relative 
constant blood flow and maintain the protective state of the blood-brain 
barrier (BBB). 
2. The BBB adapts in normal pregnancy and this may be the most important 
adaptation of the maternal brain in pregnancy to prevent increased 
BBB permeability, BBB disruption, vasogenic edema and neurologic 
complications. Although several permeability factors are released into the 
maternal circulation such as VEGF, BBB permeability remains unchanged 
compared to the nonpregnant state, where VEGF does cause significantly 
increased BBB permeability. It appears that the anti-angiogenic factor sFlt1 
31956 Schreurs, Malou.indd   128 08-01-15   14:11
General Discussion
129
7
is critical in regulating and preventing VEGF-induced BBB permeability in 
pregnancy. 
3. BBB disruption in pregnancy can lead to life-threatening neurologic 
symptoms such as seizure, edema, hemorrhage and coma. It appears to be 
that mainly severe early-onset preeclamptic women are at risk to develop 
neurologic symptoms. It may be that the physiologic hyperlipidemia in 
pregnancy, combined with oxidative stress during poor placentation, 
converts native LDL into oxidized LDL (oxLDL) and is significantly 
increased in plasma from early-onset preeclamptic women. oxLDL has 
shown to decrease cerebrovascular resistance that may impair cerebral 
autoregulation. Importantly, oxLDL causes significant BBB disruption 
through production of superoxide and subsequent generation of 
peroxynitrite, showing that oxLDL is not only an underlying mechanism of 
neurologic complications in preeclampsia, but also a possible important 
therapeutic target.   
4. Magnesium sulfate (MgSO4) directly prevents oxLDL-induced BBB 
permeability without preventing oxLDL-induced decrease in myogenic 
tone, suggesting MgSO
4
 may act primarily to protect the cerebral 
endothelium without affecting active cerebral myogenic responses. 
5. Women that suffered from eclampsia have lower nonpregnant blood 
pressure compared to women that suffered from preeclampsia only. 
Importantly, there is a negative correlation between blood pressure and 
the occurrence of eclampsia. Because eclampsia is not often preceded 
by hypertension and the prevalence of eclampsia is increasing in the 
puerperium, postpartum care should be intensified to identify women 
with neurologic symptoms that need acute referral to prevent eclampsia. 
Future perspectives
The development of (pre)eclampsia during pregnancy remains a life-threatening 
complication, however its exact pathogenesis still remains to be elucidated. This 
manuscript has revealed new insight on the physiologic adaptations of the maternal 
brain during normal pregnancy. Importantly, this manuscript also unraveled a new 
mechanism that is involved in the pathogenesis of eclampsia. However, future animal 
and human studies should be performed to gain further insight in the phyiologic 
and pathologic changes in the maternal brain during pregnancy. 
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Adaptations of the maternal brain during normal pregnancy. 
This manuscript demonstrates for the first time that the anti-angiogenic circulating 
factor sFlt1 is a critical regulator of the bioavailability of VEGF. It also demonstrates 
that PLGF is able to increase the BBB permeability. Several animal studies have 
demonstrated significant reversible structural changes in the maternal brain 
during normal pregnancy. Further animal studies are needed to gain further 
insight in the effect of circulating factors in the maternal brain during normal 
pregnancy combined with the structural cerebral changes that occur. It will be 
important to investigate the effects of longterm expression of sFlt1 on the BBB to 
translate its involvement in physiologic changes in the brain during pregnancy. 
Further, the exact role of PLGF on the BBB should be further investigated to 
increase our understanding if  and how PLGF may be involved in the pathogenesis 
of neurologic complications in preeclampsia. It will be important to distinguish 
whether the release of specific circulating factors during normal pregnancy either 
have a protective or detoriating effect on the maternal brain. Understanding the 
physiologic changes in the maternal brain during normal pregnancy will help 
identify the pathologic circulating risk factors during pregnancy. 
Cerebrovascular changes in the development of preeclampsia and eclampsia. 
This manuscript demonstrates a novel mechanism in the pathogenesis of neurologic 
complications in severe early-onset preeclampsia. It demonstrates that especially 
early-onset preeclamptic women are at risk for neurologic complications through 
an increased level of oxidized LDL and subsequent generation of peroxynitrite that 
will lead tot BBB disruption.  Further animal studies are needed to determine if this 
mechanism is initiated by a predisposition of underlying metabolic syndrome in 
women that have higher levels of LDL that become oxidized, or that the levels 
of LDL are similar with a higher level of oxidation. Also, further animal studies 
are needed to investigate the interaction of VEGF with oxLDL and the possible 
relevance of these interactions in the pathogenesis of preeclampsia. An important 
next step is to examine the levels of oxLDL in all pregnant women and compare 
these levels between women that experienced a normal pregnancy compared 
to a hypertensive pregnancy. It would be interesting to measure the levels of LDL 
before pregnancy as well. Also, women that have suffered from preeclampsia 
during pregnancy should be examined by MRI to investigate the occurence of 
PRES and compare early-onset preeclampsia to late-onset preeclampsia. Further, 
it would be interesting to measure the BBB in women during their pregnancy to 
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observe the changes in women that experience a pregnancy that is complicated 
by a hypertensive disorder.  If we are able to identify the specific changes and 
riskfactors in these women, new therapeutic targets could be developed for 
treatment or even preventing neurologic complications in preeclampsia. Further, 
since we have demonstrated the protective effect of MgSO4, women could receive 
improved and individualised treatment with antihypertensives and MgSO4 in 
preventing neurologic complications during pregnancy. 
Long term consequenses of (pre)eclampsia: follow up.
It has been known for over 4 decades that women that suffered from preeclampsia 
or eclampsia have an increased risk of cardiovacular disease in later life. More 
recently it has been described that only women that suffered from early-onset 
disease are at increased risk for cardiovascular disease in later life. Future large 
cohort studies could identify the exact risk factors in early-onset preeclampsia 
versus late-onset preeclampsia versus eclampsia. It would be important to identify 
possible differences in the risk profile of formerly preeclamptic versus formerly 
eclamptic patients. Since this manuscript already found differences in blood 
pressures between these two subgroups, it is very likely they have a different 
risk profile for developing cardiovascular disease in later life. Further, it would be 
interesting to know if changes in the maternal brain during eclampsia have left 
irreversible structural changes in the cerebral microcirculation that will lead to 
an increased risk for developing cerebral vascular disease in later life. A follow-
up study of formerly preeclamptic and eclamptic women would be necessary to 
identify these possible differences. If these differences are identified, treatment or 
preventive lifestyle intervention programs could be developed to minimize the 
risk for cerebrocardiovascular disease in later life.   
.
31956 Schreurs, Malou.indd   131 08-01-15   14:11
Chapter 7
132
References
1. Duvekot JJ, Peeters LL. Maternal cardiovascular hemodynamic adaptation to pregnancy. Obstet Gynecol 
Surv. 1994;49:S1-14
2. Gilson GJ, Mosher MD, Conrad KP. Systemic hemodynamics and oxygen transport during pregnancy in 
chronically instrumented, conscious rats. Am J Physiol. 1992;263:H1911-1918
3. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output 
during human pregnancy. Am J Physiol. 1989;256:H1060-1065
4. Cipolla MJ. Cerebrovascular function in pregnancy and eclampsia. Hypertension. 2007;50:14-24
5. Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in perinatology. 2009;33:130-137
6. Zeeman GG. Neurologic complications of pre-eclampsia. Seminars in perinatology. 2009;33:166-172
7. Cipolla MJ. Cerebral circulation. 2009
8. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22:11-28
9. Roberts TJ, Chapman AC, Cipolla MJ. Ppar-gamma agonist rosiglitazone reverses increased cerebral 
venous hydraulic conductivity during hypertension. Am J Physiol Heart Circ Physiol. 2009;297:H1347-
1353
10. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat 
Rev Neurosci. 2006;7:41-53
11. Zygmunt M, Herr F, Munstedt K, Lang U, Liang OD. Angiogenesis and vasculogenesis in pregnancy. 
European journal of obstetrics, gynecology, and reproductive biology. 2003;110 Suppl 1:S10-18
12. Espinoza J, Uckele JE, Starr RA, Seubert DE, Espinoza AF, Berry SM. Angiogenic imbalances: The obstetric 
perspective. American journal of obstetrics and gynecology. 2010;203:17 e11-18
13. Fischer S, Clauss M, Wiesnet M, Renz D, Schaper W, Karliczek GF. Hypoxia induces permeability in brain 
microvessel endothelial cells via vegf and no. Am J Physiol. 1999;276:C812-820
14. Celia G, Osol G. Mechanism of vegf-induced uterine venous hyperpermeability. J Vasc Res. 2005;42:47-
54
15. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble fms-like tyrosine kinase 1 and 
endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res. 2005;57:1R-7R
16. Karumanchi SA, Lindheimer MD. Advances in the understanding of eclampsia. Curr Hypertens Rep. 
2008;10:305-312
17. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS. Soluble flt1 sensitizes endothelial 
cells to inflammatory cytokines by antagonizing vegf receptor-mediated signalling. Cardiovasc Res. 
2011;89:671-679
18. Williams D. Pregnancy: A stress test for life. Curr Opin Obstet Gynecol. 2003;15:465-471
19. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and 
cancer in later life: Systematic review and meta-analysis. BMJ (Clinical research ed.). 2007;335:974
20. Enquobahrie DA, Williams MA, Butler CL, Frederick IO, Miller RS, Luthy DA. Maternal plasma lipid 
concentrations in early pregnancy and risk of preeclampsia. Am J Hypertens. 2004;17:574-581
21. Belo L, Caslake M, Gaffney D, Santos-Silva A, Pereira-Leite L, Quintanilha A, Rebelo I. Changes in ldl size 
and hdl concentration in normal and preeclamptic pregnancies. Atherosclerosis. 2002;162:425-432
22. Basaran A. Pregnancy-induced hyperlipoproteinemia: Review of the literature. Reproductive sciences 
(Thousand Oaks, Calif.). 2009;16:431-437
23. Var A, Kuscu NK, Koyuncu F, Uyanik BS, Onur E, Yildirim Y, Oruc S. Atherogenic profile in preeclampsia. 
Arch Gynecol Obstet. 2003;268:45-47
24. Miller AA, De Silva TM, Judkins CP, Diep H, Drummond GR, Sobey CG. Augmented superoxide production 
by nox2-containing nadph oxidase causes cerebral artery dysfunction during hypercholesterolemia. 
Stroke; a journal of cerebral circulation. 2010;41:784-789
25. Kitayama J, Faraci FM, Lentz SR, Heistad DD. Cerebral vascular dysfunction during hypercholesterolemia. 
Stroke; a journal of cerebral circulation. 2007;38:2136-2141
26. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799
31956 Schreurs, Malou.indd   132 08-01-15   14:11
General Discussion
133
7
27. Servillo G, Striano P, Striano S, Tortora F, Boccella P, De Robertis E, Rossano F, Briganti F, Tufano R. Pos-
terior reversible encephalopathy syndrome (pres) in critically ill obstetric patients. Intensive Care Med. 
2003;29:2323-2326
28. Loureiro R, Leite CC, Kahhale S, Freire S, Sousa B, Cardoso EF, Alves EA, Borba P, Cerri GG, Zugaib M. 
Diffusion imaging may predict reversible brain lesions in eclampsia and severe preeclampsia: Initial 
experience. American journal of obstetrics and gynecology. 2003;189:1350-1355
29. Engelter ST, Provenzale JM, Petrella JR. Assessment of vasogenic edema in eclampsia using diffusion 
imaging. Neuroradiology. 2000;42:818-820
30. Zunker P, Happe S, Georgiadis AL, Louwen F, Georgiadis D, Ringelstein EB, Holzgreve W. Maternal 
cerebral hemodynamics in pregnancy-related hypertension. A prospective transcranial doppler study. 
Ultrasound Obstet Gynecol. 2000;16:179-187
31. Katz VL, Farmer R, Kuller JA. Preeclampsia into eclampsia: Toward a new paradigm. American journal of 
obstetrics and gynecology. 2000;182:1389-1396
32. Douglas KA, Redman CW. Eclampsia in the united kingdom. BMJ (Clinical research ed.). 1994;309:1395-
1400
33. Euser AG, Cipolla MJ. Cerebral blood flow autoregulation and edema formation during pregnancy in 
anesthetized rats. Hypertension. 2007;49:334-340
34. van der Wijk AE, Schreurs MP, Cipolla MJ. Pregnancy causes diminished myogenic tone and outward 
hypotrophic remodeling of the cerebral vein of galen. J Cereb Blood Flow Metab. 2013;33:542-549
35. Cipolla MJ, Sweet JG, Chan SL. Cerebral vascular adaptation to pregnancy and its role in the neurological 
complications of eclampsia. J Appl Physiol (1985). 2011;110:329-339
36. Friedman A, Kaufer D, Heinemann U. Blood-brain barrier breakdown-inducing astrocytic transformation: 
Novel targets for the prevention of epilepsy. Epilepsy research. 2009;85:142-149
37. Foyouzi N, Norwitz ER, Tsen LC, Buhimschi CS, Buhimschi IA. Placental growth factor in the cerebrospinal 
fluid of women with preeclampsia. International journal of gynaecology and obstetrics: the official organ 
of the International Federation of Gynaecology and Obstetrics. 2006;92:32-37
38. Amburgey OA, Chapman AC, May V, Bernstein IM, Cipolla MJ. Plasma from preeclamptic women 
increases blood-brain barrier permeability: Role of vascular endothelial growth factor signaling. 
Hypertension. 2010;56:1003-1008
39. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 
2003;22:143-148
40. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS. Placental 
lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset 
preeclampsia. J Perinat Med. 2011;39:641-652
41. Douglas KA, Redman CW. Eclampsia in the united kingdom. The ‘best’ way forward. British journal of 
obstetrics and gynaecology. 1992;99:355-356
42. Mitra S, Goyal T, Mehta JL. Oxidized ldl, lox-1 and atherosclerosis. Cardiovasc Drugs Ther. 2011;25:419-
429
43. Li D, Mehta JL. Oxidized ldl, a critical factor in atherogenesis. Cardiovasc Res. 2005;68:353-354
44. Sankaralingam S, Xu Y, Sawamura T, Davidge ST. Increased lectin-like oxidized low-density lipoprotein 
receptor-1 expression in the maternal vasculature of women with preeclampsia: Role for peroxynitrite. 
Hypertension. 2009;53:270-277
45. Morton JS, Abdalvand A, Jiang Y, Sawamura T, Uwiera RR, Davidge ST. Lectin-like oxidized low-density 
lipoprotein 1 receptor in a reduced uteroplacental perfusion pressure rat model of preeclampsia. 
Hypertension. 2012;59:1014-1020
46. Lee H, Park H, Kim YJ, Kim HJ, Ahn YM, Park B, Park JH, Lee BE. Expression of lectin-like oxidized low-
density lipoprotein receptor-1 (lox-1) in human preeclamptic placenta: Possible implications in the 
process of trophoblast apoptosis. Placenta. 2005;26:226-233
47. Heeba G, Hassan MK, Khalifa M, Malinski T. Adverse balance of nitric oxide/peroxynitrite in the 
dysfunctional endothelium can be reversed by statins. Journal of cardiovascular pharmacology. 
2007;50:391-398
31956 Schreurs, Malou.indd   133 08-01-15   14:11
Chapter 7
134
48. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, 
Sawamura T. The binding of oxidized low density lipoprotein (ox-ldl) to ox-ldl receptor-1 reduces the 
intracellular concentration of nitric oxide in endothelial cells through an increased production of su-
peroxide. J Biol Chem. 2001;276:13750-13755
49. Miller AA, Drummond GR, De Silva TM, Mast AE, Hickey H, Williams JP, Broughton BR, Sobey CG. Nadph 
oxidase activity is higher in cerebral versus systemic arteries of four animal species: Role of nox2. Am J 
Physiol Heart Circ Physiol. 2009;296:H220-225
50. Miller AA, Drummond GR, Sobey CG. Reactive oxygen species in the cerebral circulation: Are they all 
bad? Antioxid Redox Signal. 2006;8:1113-1120
51. Maneen MJ, Hannah R, Vitullo L, DeLance N, Cipolla MJ. Peroxynitrite diminishes myogenic activity and 
is associated with decreased vascular smooth muscle f-actin in rat posterior cerebral arteries. Stroke; a 
journal of cerebral circulation. 2006;37:894-899
52. Maneen MJ, Cipolla MJ. Peroxynitrite diminishes myogenic tone in cerebral arteries: Role of nitrotyrosine 
and f-actin. Am J Physiol Heart Circ Physiol. 2007;292:H1042-1050
53. Euser AG, Bullinger L, Cipolla MJ. Magnesium sulphate treatment decreases blood-brain barrier 
permeability during acute hypertension in pregnant rats. Exp Physiol. 2008;93:254-261
54. Esen F, Erdem T, Aktan D, Kalayci R, Cakar N, Kaya M, Telci L. Effects of magnesium administration on 
brain edema and blood-brain barrier breakdown after experimental traumatic brain injury in rats. J 
Neurosurg Anesthesiol. 2003;15:119-125
55. Euser AG, Cipolla MJ. Magnesium sulfate for the treatment of eclampsia: A brief review. Stroke; a journal 
of cerebral circulation. 2009;40:1169-1175
56. Euser AG, Cipolla MJ. Resistance artery vasodilation to magnesium sulfate during pregnancy and the 
postpartum state. Am J Physiol Heart Circ Physiol. 2005;288:H1521-1525
31956 Schreurs, Malou.indd   134 08-01-15   14:11
31956 Schreurs, Malou.indd   135 08-01-15   14:11
31956 Schreurs, Malou.indd   136 08-01-15   14:11
Chapter 8: 
Summary
31956 Schreurs, Malou.indd   137 08-01-15   14:11
Chapter 8
138
The brain is one of the most highly perfused organs of the human body due to 
its high metabolic needs critical for normal functioning and its pivotal role in 
maintaining homeostasis throughout the whole body. Thus, its supply requires 
strict regulated transport of nutrients with exclusion of potentially harmful 
constituents. To accomplish this, the cerebral vasculature has unique features 
compared to the peripheral vascular beds. First, the cerebral vessels comprise an 
unique endothelial lining that forms the blood-brain barrier (BBB). The BBB is a tight 
regulator of transport of nutrients and forms a strong protective system against 
formation of vasogenic brain edema, a state involved in numerous pathologic 
neurologic conditions and thought to precede epileptic seizures. Second, the 
cerebral vasculature has the intrinsic ability to maintain a relatively constant 
cerebral blood flow (CBF) despite substantial changes in perfusion pressure.
Early pregnancy is accompanied by a sudden drop in total peripheral vascular 
resistance leading to decreased blood pressure and secondary increase in plasma 
volume and cardiac output. Also, there is an increased production of vasoactive 
permeability-increasing factors. However, increased BBB permeability does not 
normally occur during normal pregnancy and normal pregnant women do not 
suffer from neurologic complications. If and how the BBB and cerebral vasculature 
adapts to pregnancy-related changes is not clear. 
Preeclamptic pregnancy is thought to be superimposed upon cardiovascular 
risk factors both jeopardizing placenta and endothelial function. These risk 
factors, often consistent with the metabolic syndrome, are commonly present 
during preeclamptic pregnancy, and put substantial oxidative burden upon the 
vessel wall. This oxidative stress has potential deleterious effects on the cerebral 
vasculature in that it may cause BBB disruption, vasogenic brain edema and life-
threatening neurologic complications .To reduce the possibility of secondary 
neurologic complications in preeclampsia, MgSo4 is often used as primary choice 
of treatment. However, its exact working mechanism remains to be elucidated. 
The current thesis concentrates on the adaptation the BBB in pregnancy and the 
mechanism of BBB disruption and cerebrovascular dysfunction in preeclampsia. 
Chapter 1 presents a general introduction describing the cerebral vasculature 
and the impact of changes in the cerebral vasculature in normal pregnancy and 
preeclampsia. Chapter 1 concludes with describing the following aims for this 
thesis: 
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1. To investigate the impact of increased angiogenic and anti-angiogenic 
factors on BBB permeability in pregnancy. 
2. To investigate if and how high levels of lipids impact the cerebral vasculature 
in pregnancy compared the nonpregnant state. 
3. To investigate the effects and underlying mechanisms of oxLDL on BBB 
permeability in preeclampsia. 
4. To investigate the mechanism of oxLDL-induced BBB permeability and the 
effects of oxLDL on cerebral vascular reactivity. 
5. To investigate the effect of MgSO
4
 on oxLDL-induced cerebral dysfunction. 
6. To investigate blood pressure and metabolic factors in a cohort of women 
that suffered from eclampsia compared to women that were diagnosed 
with preeclampsia only. 
In Chapter 2 we focused on the first aim of this thesis and investigated how the 
maternal brain and specifically the BBB may adapt during pregnancy to high 
levels of the permeability factor vascular endothelial growth factor (VEGF). Also, 
we determined the influence of soluble-Flt1 (sFlt1) on VEGF signaling at the BBB, 
because BBB disruption and vasogenic brain edema are important factors in the 
involvement of neurologic symptoms in preeclampsia. Lastly, we investigated 
the permeability-inducing potential of placental growth factor (PLGF). We found 
that both VEGF and PLGF are able to significantly increase BBB permeability, 
however through activation of different VEGF receptors in that PLGF increased 
BBB permeability through VEGF-receptor1 (Flt) and VEGF required both VEGF-
receptor 1(Flt) and 2 (Flk). We found that circulating factors present in plasma from 
pregnant rats prevented VEGF-induced BBB permeability and preserved barrier 
function during pregnancy in the face of high circulating angiogenic factors such 
as VEGF. BBB permeability was similar in both the nonpregnant and late pregnant 
rats without the addition of exogenous VEGF, despite the finding that veins from 
late pregnant rats showed increased VEGF mRNA expression. Exogenous addition 
of VEGF initiated a significant increase in BBB permeability when exposed to a 
nonpregnant model, while it did not affect BBB permeability in a pregnant model. 
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Importantly, BBB permeability was also not affected to exogenous VEGF when 
mixed in plasma from pregnant rats but exposed to cerebral veins of nonpregnant 
animals, suggesting that VEGF-induced BBB permeability was specifically 
prevented due to the circulating factors present in the plasma from pregnant 
rats. Further, sFlt1 regulated VEGF-induced permeability similar to the plasma 
from pregnant rats in that it abolished permeability in response to VEGF. The 
finding that increased sFlt1 protects the BBB against VEGF-induced permeability 
raises some new questions about the role of high sFlt1 in the onset of neurologic 
complications in preeclampsia. As high sFlt1 appears to be protective of the BBB, 
there may be other pro-inflammatory factors released during preeclampsia, but 
not during normal pregnancy, that are responsible for increased BBB permeability 
and edema formation. 
As we have found that sFlt1 was protective of the maternal BBB rather than 
causing BBB disruption we changed our focus from angiogenic imbalance to the 
effect of dyslipidemia on the maternal brain in preeclampsia. In preeclampsia, 
hyperlipidemia is enhanced compared to normal pregnancy that could adversely 
affect vascular function. In the cerebral vasculature, this could lead to dysregulation 
of cerebral blood flow resulting into neurological complications in preeclamptic 
women. In Chapter 3, we examined the second aim of this thesis and determined 
the effect of excessive hyperlipidemia on cerebral artery function in pregnant rats 
compared to the nonpregnant state by creating an in vivo high cholesterol model 
in pregnant and nonpregnant rats. As it is known that peroxynitrite is generated due 
to high levels of lipids, we also examined the effect of peroxynitrite generation on 
cerebral function during hyperlipidemia. Peroxynitrite is generated by superoxide 
and nitric oxide and has been known to have deliterious effects on endothelial 
function. We showed that an excessive hyperlipidemia caused cerebral arteries to 
have less myogenic tone in both pregnancy and nonpregnancy, that was more 
pronounced in the pregnant state due to a significant amount of peroxynitrite 
generation. These findings are confirmed by previous studies that showed that 
peroxynitrite can act as a powerfull vasodilator in the cerebral vasculature. We also 
found that excessive hyperlipidemia caused a greater inflammatory response in 
cerebral arteries in pregnancy compared to the nonpregnant state in that iNOS 
expression was increased a 12-fold. 
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One of many circulating factors that is increased in preeclampsia and is associated 
with hyperlipidemia is oxLDL. oxLDL is known to cause endothelial dysfunction 
in numerous cardiovascular disease such as hypertension, diabetes and cerebral 
vascular disease, however, its involvement in preeclampsia is not known. In Chapter 
4, we investigated oxLDL and LOX-1 activation as an underlying mechanism to 
induced BBB disruption in preeclampsia. Also, we determined possible differences 
in BBB disruption between early-onset preeclampsia (preeclampsia diagnosed 
before 34 weeks of gestation) and late-onset preeclampsia (preeclampsia 
diagnosed later than 34 weeks of gestation). We provided new direct evidence for a 
different etiology between early-onset preeclampsia and late-onset preeclampsia 
and revealed a novel mechanism that is responsible for BBB disruption in women 
diagnosed with early-onset preeclampsia. Circulating factors in plasma from early-
onset preeclamptic women significantly increased BBB permeability compared to 
late-onset preeclamptic women. The increased BBB permeability was prevented 
by inhibiting LOX-1 and was confirmed in vivo in pregnant rats with pathologically 
high levels of LDL that also showed LOX-1 dependent increased BBB permeability. 
Circulating oxLDL, a major ligand of LOX-1, was 260% increased in early-onset 
preeclampsia compared to late-onset preeclampsia. The fact that this increased 
level of oxLDL was able to cause BBB disruption was confirmed by experiments 
that showed that similar levels of isolated exogenous oxLDL increased BBB 
permeability comparable to plasma from early-onset preeclamptic women. 
Also, the selective peroxynitrite decomposition catalyst FeTMPyP inhibited the 
increased BBB permeability induced by plasma from EPE women or by exogenous 
oxLDL, confirming the involvement of peroxynitrite formation in oxLDL-induced 
BBB disruption. Thus, our results here showed for the first time that increased 
circulating oxLDL present in plasma from EPE women significantly increase BBB 
permeability through LOX-1 activation and subsequent increased peroxynitrite 
generation. 
Because we wanted to further examine the mechanism of oxLDL-induced BBB 
permeability and the impact of oxLDL to cerebral vascular function, we examined 
the effect and mechanism of isolated oxLDL on posterior cerebral artery (PCA) 
permeability and vascular reactivity in Chapter 5. In Chapter 4, we found that oxLDL 
increased generation of peroxynitite, however, how this peroxynitrite generation 
occured was not investigated. In addition, in Chapter 5 we also examined the 
possible beneficial effects of MgSO4 on oxLDL-induced changes in BBB permeability 
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and cerebral reactivity, as it has been shown to primary treatment for preventing 
neurologic complications in severe preeclampsia. We showed that oxLDL, but not 
native LDL, significantly increased BBB permeability and decreased myogenic tone 
in posterior cerebral arteries that was prevented by apocynin, suggesting a role for 
NADPH oxidase activity and superoxide in these responses. Treatment with MgSO
4 
protected the BBB and prevented oxLDL-induced BBB disruption without affecting 
the oxLDL-induced changes in myogenic tone. Thus, these results suggest that 
oxLDL causes BBB disruption and cerebrovascular tone dysregulation through 
activation of NADPH oxidase. We suggest that oxLDL increases NADPH oxidase 
to produce superoxide that will form peroxynitrite when combined to nitric oxide 
that will result in endothelial damage and cerebral vascular dysfunction. Also, 
MgSO
4
 shows to be protective of the BBB whereas the effect of MgSO
4
 treatment 
on oxLDL-induced vascular dysfunction appears more limited.
In Chapter 6 we compared a large cohort of women that suffered either from 
preeclampsia only of preeclampsia complicated by eclampsia. We measured 
blood pressure in the nonpregnant state and we compared circulating factors 
that are features of the metabolic syndrome. This large cohort demonstrated that 
women that suffered from eclampsia had significant lower blood pressure outside 
of pregnancy compared to women that were diagnosed with preeclampsia only. 
Also, analysis showed a negative correlation between blood pressure and the 
occurence of eclampsia. We also found that the prevalence of eclampsia was 60% 
in the antepartum group and 40% in the postpartum group. These findings are of 
clinical significance because it is known that a significant percentage of eclampsia 
is not preceded by the definition of  hypertension. Thus, it may be that women with 
lower base line pressure have a more pronounced risk to develop eclampsia. The 
40% prevalence postpartum indicates that postpartum care should we intensified 
and changed to detect women with neurologic symptoms that could be warning 
signs for eclampsia, while blood pressure is still relatively low.  Further, metabolic 
factors were compared to determine if women that have developed eclampsia 
already suffered from underlying metabolic syndrome. Our data did not show a 
significant difference between the formerly preeclamptic and eclamptic women, 
suggesting women do not already have underlying metabolic syndrome. 
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Chapter  7 describes a general discussion of the most important findings listed in 
this thesis and the following conclusions are presented:
1. Pregnancy causes a unique challenge to the maternal brain. While other 
organs undergo substantial changes to increased the blood flow, the 
adaptation of the cerebral circulation  appears to maintain a relative 
constant blood flow and maintain the protective state of the BBB. 
2. The BBB adapts in normal pregnancy and this may be the most important 
adaptation of the maternal brain in pregnancy to prevent increased 
BBB permeability, BBB disruption, vasogenic edema and neurologic 
complications. Although several permeability factors are released into 
the maternal circulation such as the permeability VEGF, BBB permeability 
remains unchanged compared to the nonpregnant state, where VEGF 
does cause significantly increased BBB permeability.  It appears that the 
anti-angiogenic factor sFlt1 is critical in regulating VEGF-induced BBB 
permeability in pregnancy. 
3. BBB disruption in pregnancy can lead to life-threatening neurologic 
symptoms such as seizure, oedema, hemorrhage and coma. It appears to be 
that mainly severe early-onset preeclamptic women are at risk to develop 
neurologic symptoms. It may be that the physiologic hyperlipidemia in 
pregnancy, combined with oxidative stress during poor placentation, 
converts native LDL into oxLDL and is significantly increased in plasma 
from early-onset preeclamptic women. oxLDL has shown to decrease 
cerebrovascular resistance that may impair cerebral autoregulation. More 
importantly, oxLDL causes significant BBB disruption through production 
of superoxide and subsequent generation of peroxynitrite, showing that 
oxLDL is not only a underlying mechanism of neurologic complications in 
preeclampsia, but also a possible important therapeutic target in severe 
preeclamptic women.   
4. MgSO4 directly prevents oxLDL-induced BBB permeability without, 
preventing oxLDL-induced decrease in myogenic tone, suggesting MgSO
4
 
may act primarily to protect the cerebral endothelium without affecting 
active cerebral myogenic responses. 
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5. Women that suffered from preeclampsia complicated by eclampsia have 
lower nonpregnant blood pressure compared to women that suffered from 
preeclampsia only. There is a negative correlation between blood pressure 
and the occurrence of eclampsia. Since eclampsia is often not preceded 
by hypertension and the prevalence of eclampsia is increasing in the 
puerperium, postpartum care should be intensified to identify women with 
neurologic symptoms that need prompt referral to prevent eclampsia. 
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Het brein is een van de meest doorbloede organen van het menselijk lichaam. 
De hersenen hebben, om optimaal te functioneren, een hoge metabole vraag. 
De brandstofvoorziening van het brein heeft daarom een strikt gereguleerd 
transportsysteem van voedingsstoffen en zuurstof die daarnaast ook potentiele 
toxines snel af voert of buiten de hersenen houdt. Om dit regulatiesysteem goed 
te laten werken hebben de hersenen enkele unieke kenmerken in tegenstelling 
tot de perifere vasculaire vaatbedden. Ten eerste hebben de cerebrale vaten een 
unieke endotheliale cellaag die de bloed-hersen barriere (BBB) vormt. De BBB is 
een nauwkeurige regulator van het transport van voedingstoffen en vormt een 
sterke beschermend systeem om formatie van vasogeen cerebraal oedeem te 
voorkomen. Vasogeen oedeem is betrokken bij veel pathologische neurologische 
condities waaronder epileptische aanvallen. Daarnaast heeft het cerebrale vaatbed 
de intrinsieke capaciteit om een relatief constante bloedstroom te behouden 
ondanks schommelingen in de perfusiedruk.
De vroege zwangerschap gaat gepaard met een plotselinge daling in perifere 
vaatweerstand. Dit resulteert in eerste instantie in een daling van de bloeddruk 
en vervolgens een compensatoire stijging van het plasma volume en het 
hart-minuut volume. Daarnaast is er sprake van een stijging van vaso-actieve 
permeabiliteitsfactoren. Echter, tijdens een normale zwangerschap is er, ondanks 
de aanwezigheid van meer permeabiliteitsfactoren, geen sprake van een 
verhoogde BBB permeabiliteit waardoor zwangere vrouwen normaliter geen 
neurologische symptomen zullen vertonen. Of en hoe de BBB en de cerebrale 
vaten zich aanpassen aan zwangerschaps-gerelateerde veranderingen is niet 
duidelijk. 
Er wordt gedacht dat hypertensieve complicaties in de zwangerschap zoals 
preeclampsie worden veroorzaakt door cardiovasculaire risicofactoren die de 
placentaire en endotheliale celfunctie negatief beïnvloeden. Deze cardiovasculaire 
risicofactoren, waarvan velen ook tot het metabool syndroom behoren, zijn 
vaak aanwezig tijdens preeclampsie en veroorzaken substantiële oxidatieve 
stress in de vaatwanden wat kan leiden tot endotheliale celdysfunctie. In het 
cerebrale vaatstelsel kan oxidatieve stress potentiële beschadigingen veroorzaken 
zoals BBB disruptie, vasogeen oedeem en levensbedreigende neurologische 
complicaties. Om vrouwen tegen neurologische complicaties van preeclampsie 
te beschermen worden vrouwen primair of secundair preventief behandeld met 
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Magnesiumsulfaat (MgSO
4
). Het exacte werkingsmechanisme van MgSO
4
 is echter 
niet volledig bekend. Dit manuscript concentreert zich op de adaptatie van de BBB 
in de zwangerschap en mogelijke mechanismes van BBB disruptie en cerebrale 
cardiovasculaire dysfunctie in preeclampsie. 
Hoofdstuk 1 geeft een algemene introductie van het manuscript weer. Het 
beschrijft het cerebraal vaatsysteem en de impact van de veranderingen van het 
cerebraal vaatsysteem tijdens de normale zwangerschap en zwangerschappen 
gecompliceerd door preeclampsie. Daarnaast beschrijft Hoofdstuk 1 de 
doelstellingen/hypotheses van het manuscript: 
1. Vaststellen wat de impact is van gestegen angiogene en anti-angiogene 
factoren op de BBB permeabiliteit tijdens de normale zwangerschap. 
2. Onderzoeken of en hoe hogere lipiden spiegels het cerebral vaatsysteem 
kan beïnvloeden tijdens de zwangerschap in vergelijking met de situatie 
buiten de zwangerschap. 
3. Bepalen wat de mogelijke effecten zijn van geoxideerd low density 
lipoproteïne (oxLDL) op de BBB tijdens preeclampsie.
4. Onderzoeken wat het mechanisme is van oxLDL-geïnduceerde BBB 
permeabiliteit en het effect van oxLDL op de cerebrale vaatreactiviteit. 
5. Het vaststellen van mogelijke verschillen van de bloeddruk en metabole 
circulerende factoren in een groot cohort tussen vrouwen die een 
preeclapsie gecompliceerd door eclampsie of louter een preeclampsie 
hebben doorgemaakt.  
In Hoofdstuk 2 werd er dieper ingegaan op de eerste doelstelling van dit manuscript. 
We hebben onderzocht hoe het maternale brein en specifiek de BBB zich tijdens 
de zwangerschap aanpast aan hoge concentraties van de permeabiliteitsfactor 
vascular endothelial growth factor (VEGF). Daarnaast hebben we gekeken naar 
de invloed van sFlt1 op de VEGF-geïnduceerde effecten op de BBB, wetende dat 
BBB doorbraak en het daaropvolgende vasogeen cerebraal oedeem belangrijke 
factoren zijn in het ontstaan van neurologische symptomen tijdens preeclampsie. 
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Als laatste hebben we het potentiële BBB-inducerende effect van placental growth 
factor (PLGF) onderzocht. We vonden dat zowel VEGF als PLGF de mogelijkheid 
bezitten om de BBB permeabiliteit significant te laten stijgen, maar wel door 
verschillende  VEGF-receptor activatie. PLGF verhoogde de BBB permeabiliteit door 
activatie van VEGF-receptor 1 (Flt) terwijl VEGF zowel VEGF-receptor 1 (Flt) als VEGF-
receptor 2 (Flk) moest binden om effect te hebben op de BBB. Daarnaast vonden 
we dat circulerende factoren die aanwezig zijn in het bloedplasma van zwangere 
ratten VEGF-geïndcueerde BBB permeabiliteit voorkwamen en de beschermende 
functie van de BBB behielden. BBB permeabiliteit was gelijk in zowel de zwangere 
als niet-zwangere ratten, ondanks het feit dat cerebrale venen van zwangere 
ratten verhoogd VEGF mRNA expressie vertoonden. Exogeen toegevoegde VEGF 
initieerde een significante stijging van de BBB permeabiliteit in een niet-zwanger 
rattenmodel, terwijl het in een zwanger rattenmodel geen veranderingen 
veroorzaakte. Daarnaast bleef de BBB ook onaangetast als VEGF werd toegevoegd 
in plasma van zwangere ratten blootgesteld aan een cerebrale vene van een 
niet-zwangere rat, wat suggereert dat de VEGF-geïnduceerde BBB permeabiliteit 
werd voorkomen door circulerende factoren die vrijkomen in het bloed tijdens 
de zwangerschap. Verder lieten we zien dat sFlt1 de VEGF-geïnduceerde BBB 
permeabiliteit op dezelfde wijze beïnvloedde als het plasma van zwangere ratten. 
De observatie dat verhoogd sFlt1 de BBB beschermt tegen VEGF-geïnduceerde 
BBB permeabiliteit creëert nieuwe vragen over de rol van sFlt1 in het ontstaan van 
neurologische complicaties bij preeclampsie. Omdat hoge concentraties sFlt1 de 
BBB lijken te beschermen, zijn er misschien andere pro-inflammatoire circulerende 
factoren betrokken bij het ontstaan van BBB disruptie en cerebraal vasogeen 
oedeem tijdens preeclampsie.
Omdat onze experimenten niet direct lieten zien dat sFlt1 de BBB schaadde maar 
zelfs beschermde, hebben we ons focus verlegd van angiogene/anti-angiogene 
imbalans naar de effecten van hyperlipidemie op het maternale brein tijdens 
preeclampsie. Tijdens de normale zwangerschap is er sprake van een fysiologische 
hyperlipidemie die in preeclampsie verder doorstijgt en schade kan aanrichten aan 
het cerebrale en perifere vasculaire stelsel. Dit kan in het cerebrale vaatbed leiden 
tot dysregulatie van de cerebrale bloedstroom wat kan resulteren in neurologische 
complicaties in vrouwen met preeclampsie. In Hoofdstuk 3 onderzochten 
we de tweede doelstelling van dit manuscript en bekeken of hyperlipidemie 
tijdens de zwangerschap andere effecten heeft op het cerebrale vaatbed in 
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vergelijking tot buiten de zwangerschap. Voor deze experimenten gebruikten we 
zwangere en niet-zwangere ratten en creëerden een “in vivo” hoog-cholesterol 
rattenmodel. Daarnaast onderzochten we ook het effect van peroxynitriet op de 
cerebrale vaatfunctie, omdat peroxynitriet geproduceerd wordt bij hoge lipiden 
concentratie. Peroxynitriet wordt gevormd door superoxide en stikstof monoxide 
en is een bekende beschadiger van de endotheliale functie. We lieten zien dat een 
excessieve hyperlipidemie de spiertonus in zowel de cerebrale vaten van zwangere 
en niet-zwangere ratten verlaagde maar dat dit effect groter was in de cerebrale 
arteriën van zwangere ratten en dat dit toegeschreven was aan peroxynitriet. 
Deze bevindingen werden bevestigd door vorige studies die demonstreerde dat 
peroxynitriet een sterke vasodilator kan zijn in het cerebrale vaatbed. Daarnaast 
zagen we dat een excessieve hyperlipidemie een grotere inflammatoire respons 
veroorzaakte in cerebrale arteriën van zwangere ratten in vergelijking tot de 
arteriën van niet-zwangere ratten door middel van een 12 maal grotere expressie 
van iNOS. 
Een van de vele circulerende factoren die zijn verhoogd tijdens preeclampsie 
en is geassocieerd met hyperlipidemie is geoxideerd LDL (oxLDL). Het is bekend 
dat oxLDL in staat is endotheelschade te veroorzaken in vele ziektebeelden 
zoals hypertensie, diabetes en cerebrale vasculaire ziekten. Echter, of oxLDL ook 
betrokken is bij de pathogenese van  preeclampsie is onbekend. In Hoofdstuk 
4 hebben we onderzocht of oxLDL en LOX-1 (de oxLDL-receptor) activatie een 
mogelijk onderliggend mechanisme kan zijn in het ontstaan van BBB disruptie in 
preeclampsie. Daarnaast hebben we gekeken of er verschillen zijn in het ontstaan 
van BBB disruptie bij vroege preeclampsie (gediagnosticeerd < 34 weken) of late 
preeclampsie (gediagnosticeerd > 34 weken). We hebben nieuwe aanwijzingen 
gevonden dat er mogelijk sprake is van een verschillende etiologie tussen vroege 
en late preeclampsie en we onthullen een potentieel nieuw mechanisme in het 
ontstaan van BBB disruptie bij vrouwen gediagnosticeerd met vroege preeclampsie. 
Circulerende factoren aanwezig in het bloedplasma van vrouwen met vroege 
preeclampsie veroorzaakten een stijging van de BBB permeabiliteit in tegenstelling 
tot vrouwen met een late preeclampsie. Wanneer LOX-1 werd geblokkeerd 
werd de stijging in BBB permeabiliteit ongedaan gemaakt. Dit fenomeen  van 
LOX-1 afhankelijke stijging van de BBB permeabiliteit werd bevestigd “in vivo” in 
zwangere ratten met pathologische LDL concentraties. Circulerend oxLDL, een 
van de belangrijkste bindingsfactoren van de LOX-1 receptor, was 260% hoger in 
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plasma van vrouwen met een vroege preeclampsie in vergelijking met plasma van 
vrouwen met late preeclampsie. We bevestigde de potentie van oxLDL om de BBB 
permeabiliteit te verhogen door middel van experimenten met geïsoleerd oxLDL(in 
vergelijkbare levels van plasma van vrouwen met vroege preeclampsie) welke een 
vergelijkbare significante stijging van de BBB permeabiliteit lieten zien. Daarnaast 
toonde we aan dat de selectieve peroxynitriet decompositie catalyst FeTMPyP 
de oxLDL-geïnduceerde BBB permeabiliteit afremt. Hiermee bevestigen we de 
betrokkenheid van de formatie van peroxynitriet in oxLDL-afhankelijke BBB disruptie. 
Onze resultaten laten voor de eerste maal zien dat verhoogd circulerend oxLDL 
in het bloedplasma van vrouwen met vroege preeclampsie de BBB permeabiliteit 
verhoogt via LOX-1 activatie en vervolgens formatie van peroxynitriet. 
Na deze bevindingen wilden we het mechanisme van oxLDL-geïnduceerde 
BBB permeabiliteit verder onderzoeken en tevens bekijken welke effecten 
oxLDL heeft op de cerebrale vaatreactiviteit. In Hoofdstuk 5 onderzochten we 
de effecten en onderliggende mechanismen van geïsoleerd oxLDL op de BBB 
permeabiliteit en vaatreactiviteit van cerebrale arteriën. In Hoofdstuk 4 vonden 
we dat oxLDL een stijging veroorzaakte in de formatie van peroxynitriet, maar 
het onderliggende mechanisme was nog onduidelijk. Omdat magnesiumsulfaat 
de primaire behandeling is in het voorkomen van neurologische complicaties 
tijdens ernstige preeclampsie, bekeken we in Hoofdstuk 5 ook the potentiële 
beschermende effecten van magnesiumsulfaat (MgSO4) op oxLDL-geïnduceerde 
verandering van de BBB permeabiliteit en cerebrale vaatreactiviteit. We lieten zien 
dat oxLDL een daling van de spiertonus in cerebrale arteriën veroorzaakte dat kon 
worden voorkomen door apocynin (een antagonist voor NADPH oxidase). Niet-
geoxideerd LDL toonde deze effecten niet. Dit suggereert een rol voor NADPH 
oxidase activiteit en superoxide. Behandeling met MgSO
4 
beschermde de BBB en 
voorkwam oxLDL-geïnduceerde BBB disruptie. MgSO4 had geen invloed op de 
oxLDL-geïnduceerde veranderingen in de cerebrale vaattonus. Deze resultaten 
suggereren dat oxLDL BBB disruptie en cerebrovasculaire vaattonus dysregulatie 
veroorzaakt door middel van activatie van NADPH oxidase. We speculeren dat 
oxLDL de NADPH oxidase activiteit verhoogt met als gevolg een toegenomen 
productie van superoxide dat bindt met stikstof monoxide en peroxynitriet vormt, 
resulterend in endotheelschade en vasculaire dysfunctie. Daarnaast bewijst 
MgSO4 dat het de BBB beschermt, maar niet veel invloed heeft op de cerebrale 
vaatreactiviteit. 
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In Hoofdstuk 6 hebben we een groot cohort van vrouwen vergeleken die 
preeclampsie (n=698) of eclampsie (n=88) hebben doorgemaakt. We vergeleken 
de bloeddrukken en circulerende factoren die onderdeel zijn van het metabool 
syndroom van deze vrouwen buiten de zwangerschap.  Dit grote cohort liet zien 
dat vrouwen die een eclampsie hadden doorgemaakt buiten de zwangerschap 
een lagere bloeddruk hadden dan vrouwen die alleen een preeclampsie hadden 
doorgemaakt. Tevens lieten deze data zien dat er sprake was van een negatieve 
correlatie tussen de bloeddruk en het ontstaan van eclampsie. Verder vonden we 
dat 60% van alles eclamptische insulten voor de bevalling ontstonden en 40% 
na de bevalling. Deze observaties zijn van klinisch belang gezien het algemeen 
bekend is dat een groot deel van de vrouwen die een eclamptisch insult doormaken 
voorafgaand geen hypertensie volgens strikte criteria hebben (<140/90 mm Hg). 
We speculeren dat vrouwen met een lagere uitgangsbloeddruk meer kans hebben 
om een eclamptisch insult te ontwikkelen. Het feit dat 40% van de eclampsie 
postpartum ontstaat stipt het belang aan om ook in het kraambed goede 
controles van de bloeddruk te verrichten en goede te letten op de prodromale 
symptomen van eclampsie. Als laatste keken we naar de metabole factoren om 
te bepalen of vrouwen met een voorgaande zwangerschap gecompliceerd met 
eclampsie misschien al aan een vorm van een onderliggend metabool syndroom 
zouden kunnen lijden. Uit onze data komen echter geen verschillen tussen de 2 
subgroepen voor. 
Hoofdstuk 7 geeft een algemene discussie van de meest belangrijke bevindingen 
in dit manuscript. De discussie wordt afgesloten met de volgende conclusies:
1. De zwangerschap stelt het brein voor een unieke uitdaging. Terwijl andere 
maternale organen veranderingen ondergaan om de bloedstroom te 
vergroten, past het brein zich zodanig aan dat de bloedstroom gelijkt blijft 
om de BBB te beschermen. 
2. De BBB adapteert in de normale zwangerschap om een toename van 
de BBB permeabiliteit, BBB disruptie, cerebraal vasogeen oedeem en 
neurologische complicaties te voorkomen. Ondanks dat veel circulerende 
permeabiliteitsfactoren zoals VEGF zijn verhoogd tijdens de zwangerschap, 
verandert de BBB permeabiliteit niet. Buiten de zwangerschap veroorzaakt 
VEGF interessant genoeg wel een significante toename van de BBB 
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permeabiliteit. Het lijkt dat sFLT1 belangrijk is in het reguleren van de VEGF-
geïnduceerde BBB permeabiliteit tijdens de zwangerschap. 
3. BBB disruptie in de zwangerschap kan leiden tot levensbedreigende 
neurologische complicaties zoals stuipen, cerebraal oedeem, cerebrale 
bloedingen en coma. Vooral vroege preeclampsie lijkt een risico factor te 
zijn voor het ontwikkelen van neurologische complicaties. Fysiologische 
hyperlipidemie in de normale zwangerchap kan bij een toename van 
oxidatieve stress omgezet worden in oxLDL wat ook significant verhoogd 
is tijdens vroege preeclampsie. oxLDL verlaagt de spiertonus van cerebrale 
arterien dat mogelijk meewerkt aan cerebrovasculaire dysfunctie en 
verstoring van de cerebrale autoregulatie. Daarnaast verhoogt oxLDL 
significant de BBB permeabiliteit middels productie van superoxide en 
daaropvolgende formatie van peroxynitriet. Dit laat zien dat oxLDL niet 
alleen een onderliggend mechanisme is in het ontstaan van neurologische 
complicaties, maar mogelijk ook een belangrijke therapeutische target is in 
de behandeling van ernstige vroege preeclampsie.  
4. Magnesium sulfaat (MgSO4) beschermt de oxLDL- geïnduceerde BBB 
permeabiliteit rechtstreeks zonder de oxLDL-gerelateerde verlaging van 
de vaattonus te beïnvloeden. Dit suggereert dat MgSO
4
 voornamelijk 
direct de BBB beschermt zonder veel invloed te hebben op de myogene 
veranderingen in de cerebrale vaten. 
5. Vrouwen die een eclampsie hebben doorgemaakt, hebben buiten de 
zwangerschap een significant lagere bloeddruk in vergelijking met vrouwen 
die een preeclampsia hebben doorgemaakt. Er bestaat een negatieve 
correlatie tussen de bloeddruk en het voorkomen van eclampsie. Omdat 
eclampsie niet vaak wordt voorafgegaan door hypertensie en de prevalentie 
van eclampsie toeneemt in het kraambed, is routine bloeddrukcontrole in 
het kraambed geïndiceerd. 
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Introductie
Het brein is een uniek orgaan in het menselijk lichaam dat een strikte regulatie 
vereist om continu van de juiste hoeveelheid zuurstof en voedingstoffen te 
worden voorzien. Om deze strikte regulatie ook onder omstandigheden zoals 
zwangerschap en de daarbij horende veranderingen in circulerende factoren 
en bloedsomloop te waarborgen, moeten de hersenen zich wel kunnen 
aanpassen. Bij vrouwen met zwangerschapvergiftiging (preeclampsie) raakt het 
autoregelulatiesysteem in het brein verstoord en raakt de bloed-hersenbarrière 
(BBB) beschadigd zodat er schadelijke stoffen de hersenen kunnen binnentreden. 
Het huidige proefschrift geeft relevante nieuwe informatie over het functioneren 
van het brein bij de vrouw tijdens de zwangerschap, welke aanpassingen het 
brein doet en wat er fout kan gaan in de regelsystemen van de hersenen met 
name door circulerend LDL cholesterol en vrije zuurstof radicalen. Daarnaast laat 
dit proefschrift zien dat vrouwen die preeclampsie hebben doorgemaakt met 
levensbedreigende complicaties in het brein (eclampsie) verschillen laten zien 
in hartslag en bloeddruk buiten de zwangerschap in vergelijking met vrouwen 
die een preeclampsie hebben doorgemaakt zonder deze complicaties. Dit maakt 
duidelijk dat er verschillende risicofactoren zijn voor het ontwikkelen  van eclampsie 
bij vrouwen met preeclampsie en dat dit een individueel zorgplan vereist tijdens 
de zwangerschap en het kraambed. Maar wat betekenen deze resultaten die tot 
nu toe zijn behaald nu eigenlijk concreet voor onze maatschappij en onze huidige 
gezondheidzorg? In dit hoofdstuk zullen de resultaten van het proefschrift voor 
zover als mogelijk worden vertaald en worden geïmplementeerd in de huidige 
Nederlandse samenleving en gezondheidszorg.  
Relevantie
Preeclampsie en eclampsie zijn levensbedreigende ziektebeelden die tijdens 
de zwangerschap en het kraambed kunnen ontstaan. Het lastige van deze 
ziektebeelden is dat ze een multifactoriële en nog niet volledig bekende oorzaak 
hebben waardoor gerichte behandeling of preventie nog altijd incompleet 
is. De ziektebeelden lijken vrij acuut te kunnen ontstaan en symptoomloos 
te verlopen totdat er al ernstige complicaties aanwezig zijn. Tot op  heden zijn 
deze ziektebeelden ook de hoofdoorzaak van de maternale sterfte (sterfte van 
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vrouwen tijdens de zwangerschap of gedurende het kraambed) in Nederland 
en alle overige ontwikkelde landen in de wereld. Al geruime tijd geleden heeft 
men vast gesteld dat wereldwijd maar vooral in ontwikkelingsgebieden nog 
altijd te weinig aandacht besteed aan de gezondheid van vrouw en kind hoewel 
hun gezondheid aan de basis van het leven staat. Dit heeft zich vertaalt in 
terugdringing van de moedersterfte als concreet doel binnen de Verenigde Naties 
Millenium Doelstellingen. Ieder land, of zelfs regio, zal hiervoor eigen en passende 
oplossingen bedenken. Ondanks de toenemende aandacht van de gezondheid 
van vrouw, moeder en kind in ons land, blijft preeclampsie vooralsnog een groot 
maatschappelijk probleem die nog altijd veel onderzoek en aandacht behoeft. 
Dit proefschrift geeft nieuwe inzichten over het ontstaan van hersenoedeem 
dat vervolgens eclampsie kan veroorzaken. Er worden nieuwe  circulerende 
factoren aangewezen die betrokken zijn in het verstoren van de BBB wat leidt 
tot een toename van hersenoedeem. Dit zijn met name vrije zuurstofradicalen 
die ontstaan door een verhoogd geoxideerd LDL cholesterol. Dit proefschrift 
toont dus aan dat de mate van dyslipidemie erg belangrijk is in het ontstaan 
van eclampsie. Dit legt tevens een belangrijke link tussen de pathogenese van 
preeclampsie en andere cardiovasculaire ziekten zoals atherosclerose, hypertensie 
en diabetes. Omdat deze resultaten gebaseerd zijn op dierstudies is het wel van 
belang dat deze resultaten worden vertaald naar humane studies. Desalniettemin 
zijn dierstudies de basis naar de ontwikkeling van nieuwe behandelmethodes en 
ontwikkeling van preventieprogramma’s. Daarnaast demonstreert dit proefschrift 
ook nog resultaten van een humane studie die suggereert dat zowel de hoogte en 
ook de stijging van de bloeddruk gedurende de zwangerschap van belang is in de 
ontwikkeling van eclampsie. Dit is met name relevant gezien het feit dat de definities 
van preeclampsie hypertensie (of te wel een te hoge bloeddruk) beschrijven maar 
niet ingaan op de verandering van de bloeddrukstijging.  De bloeddruk waarbij wij 
spreken van hypertensie is 140/90 mm Hg waarboven men antihypertensieve en 
preventieve behandeling start. Echter ons onderzoek toont aan dat jonge vrouwen 
die een preeclampsie gecompliceerd door een eclampsie hebben gehad buiten 
de zwangerschap een bloeddruk hebben die aanzienlijk lager is dan deze waarde 
en dat hoe dichter de niet zwangere bloeddruk bij de 140/90 mm Hg ligt hoe 
geringer de kans is dat preeclampsie wordt gecompliceerd door eclampsia. Deze 
gegevens suggereren dat ofwel de grens van eclampsie preventieve behandeling 
of lager moet worden gesteld of dat de stijging in bloeddruk, relatief of absoluut, 
dient te worden meegewogen in de diagnose hypertensie. 
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Doelgroep
De uitkomsten van dit huidige proefschrift zijn voor het overgrote deel het 
resultaat van dierstudies om meer inzicht te krijgen in de veranderingen van de 
BBB tijdens de zwangerschap en om de mechanismen die disruptie van de BBB 
veroorzaken te onderzoeken. De resultaten geven nieuwe belangrijke inzichten in 
de pathogenese van BBB disruptie en het ontwikkelen van eclampsie tijdens de 
zwangerschap en relateert de ontwikkeling van preeclampsie aan het voorkomen 
van toegenomen oxidatieve stress en dyslipidemie. De resultaten dienen wel nog 
verder te worden onderzocht in onze Nederlandse zwangerenpopulatie. Dus 
de huidige resultaten van de dierstudies zijn nog met name van belang voor de 
onderzoeksteams van de afdelingen obstetrie en gynaecologie en neurologie. 
Anderzijds zijn de overige resultaten gebaseerd op een groot cohort van 
zwangere vrouwen die zijn gediagnosticeerd met een preeclampsie of eclampsie 
wel van direct klinisch belang voor verscheidene groepen in de samenleving. 
De resultaten laten zien dat niet zozeer de hoogte van de bloeddruk maar ook 
de stijging van de bloeddruk gedurende de zwangerschap belangrijk is in het 
ontwikkelen van preeclampsie en eclampsie. Daarnaast laten onze resultaten van 
het Nederlandse cohort ook zien dat eclampsie ongeveer in 40% van de gevallen 
in het kraambed ontstond. Deze bevindingen zijn belangrijk voor ziekenhuizen 
en geboortecentra om in hun zorgprotocol op te nemen. Daarnaast zijn deze 
bevindingen ook belangrijk voor 1e lijn verloskundigen en huisartsen. Gezien er 
een significant percentage van de vrouwen die eclampsie ontwikkelen al bevallen 
zijn, dient de zorg in het kraambed, ook voor ogenschijnlijk gezonde vrouwen 
zeker niet te verslappen. Artsen, verloskundigen en huisartsen dienen alert te zijn 
op de bloeddruk van vrouwen aan het begin van de zwangerschap in vergelijking 
met de bloeddruk na hun bevalling. Ook al is bloeddruk in het kraambed volgens 
de internationale hypertensie richtlijnen normaal, voor bepaalde vrouwen kan de 
bloeddruk al verhoogd zijn en lijken ze meer risico te lopen op het ontwikkelen 
van eclampsie in het kraambed. Gezien eclampsie in het kraambed zelfs nog 
weken later kan manifesteren, dienen met name huisartsen (als gynaecologen en 
verloskundigen hun zorgpad hebben afgesloten) goed inzicht te hebben in het 
verloop van de bloeddruk van hun patiënte, zeker indien zij met klachten komen 
die zouden kunnen passen bij preeclampsie en eventueel complicaties in het 
brein. . Tenslotte is deze informatie vanzelfsprekend met name belangrijk voor de 
patiënte zelf. Zij kan met deze informatie zelf haar bloeddruk in de gaten houden 
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(bij risicopatiënten eventueel met geleende gevalideerde apparatuur) en hulp 
inschakelen indien gewenst.  
Activiteiten en producten
De resultaten uit de dierstudies van het huidige proefschrift tonen dat het brein 
zich aanpast tijdens de zwangerschap aan allerlei circulerende factoren die 
vrijkomen. Daarnaast tonen ze een nieuw mechanisme dat disruptie van de BBB 
kan optreden bij verhoogde levels van geoxideerd LDL cholesterol. De resultaten 
worden vertaald in verder onderzoek in cohortstudies van vrouwen die zijn 
gediagnosticeerd met preeclampsie of eclampsie. De resultaten zijn een volledig 
vernieuwend concept in de ontrafeling van de pathogenese van preeclampsie 
en eclampsie maar dienen verder worden uitgewerkt door onderzoeksteams 
van de obstetrie en gynaecologie en tevens eventueel de neurologie om hier 
uiteindelijk therapeutische of preventieve targets te ontwikkelen. De resultaten 
uit het cohort kunnen direct worden vertaald in protocollen van ziekenhuizen, 1e 
lijn verloskundigen en huisartsen. Daarnaast kunnen deze resultaten ook worden 
vertaald in voorlichtingsfolders over hypertensieve aandoeningen tijdens de 
zwangerschap en waar vrouwen op dienen te letten. Uiteindelijk om zorg op maat 
te creëren zou het mooi zijn om vrouwen thuis hun bloeddruk te kunnen laten 
monitoren die via email met een ziekenhuis of verloskundige praktijk in verbinding 
staan. Hier is dan wel gevalideerde apparatuur voor nodig en instructies aan alle 
zwangeren om dit te kunnen realiseren. Daarnaast zullen de bevindingen van dit 
proefschrift worden vertaald en vormgegeven in de follow-up studies van het 
cohort vrouwen die een preeclampsie of eclampsie hebben doorgemaakt. 
Innovatie
De resultaten van dit proefschrift maken een belangrijke stap in het ontrafelen 
van de pathogenese van preeclampsie en eclampsie. Er wordt ontzettend 
veel onderzoek verricht naar de pathogenese van preeclampsie. Echter blijft 
eclampsie hierin vaak nog onderbelicht, terwijl eclampie juist de een van de 
levensbedreigende complicaties vormt. Wat onderzoek naar de complicaties 
in de hersenen nog lastiger maakt, is dat het vaatbed in de hersenen compleet 
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anders is gereguleerd dan het perifere vaatbed in de rest van het lichaam. 
Vandaar is dit proefschrift van waarde om meer begrip te krijgen over de 
fysiologische en pathologische mechanisme die ervoor zorgen dat de BBB zich 
aanpast of beschadigd raakt. Daarnaast wordt de tot nu toe onderschatte waarde 
van dyslipidemie en oxidatie tijdens de zwangerschap belicht en naar voren 
geschoven als sleutelfactor in het ontstaan van complicaties in de hersenen. Dit is 
ook belangrijk voor andere cerebrovasculaire aandoeningen en kan preeclampsie 
hier weer aan gerelateerd worden. Daarnaast lijkt naast chemische factoren het 
voorkomen van eclampsie tijdens preeclampsie ook door de hoogte van de niet-
zwangere bloeddruk te worden beïnvloed, waarmee mogelijk de definities van 
preeclampsie en eclampsie en de daarmee samenhangende start van eventuele 
eclampsie preventieve maatregelen herzien moeten worden. Mogelijk speelt ook 
de stijging van de bloeddruk een rol en behoeft wellicht herijking. Samengevat 
bevat dit proefschrift dus een hoop nieuwe ontwikkelingen die uiteindelijk leiden 
naar een betere herkenning en behandeling van complicaties in de hersenen bij 
zwangere vrouwen en vrouwen in het kraambed. 
Planning en Realisatie
De resultaten uit het cohort zullen direct kunnen worden geïmplementeerd 
in de protocollen van ziekenhuizen en verloskundigenpraktijken zonder extra 
kosten. Daarnaast lijkt awareness bij hulpverleners op zijn plaats bij vrouwen 
in het kraambed in combinatie met hun gemeten bloeddruk, ook als die nog 
geen 140/90 mm Hg heeft bereikt. Richtlijnen van verloskundigen, huisartsen en 
gynaecologen zouden hierin een waarschuwing kunnen opnemen. De verdere 
resultaten uit de dierstudies wordt beschouwd als pionierswerk. Voordat deze 
resultaten vertaald worden in onze zwangerenpopulatie zullen er zeker enkele 
jaren overheen gegaan zijn. Er blijft natuurlijk altijd financiering nodig om deze 
resultaten verder uit te werken in humane studies. Wij zijn er in ieder geval van 
overtuigd dat dit proefschrift ons wederom een stapje dichterbij de pathogenese 
van preeclampsie en eclampsie heeft gebracht, maar zoals vele studies weer 
meer vragen heeft gegenereerd dan antwoorden. Het legt nieuwe correlaties 
tussen cardiovasculaire ziekten waarin dyslipidemie ook een belangrijke rol 
speelt. Juist omdat een normale zwangerschap de basis vormt voor gezonde 
moeders en hun nakomelingen, verdient inzicht en daarmee onderzoek naar 
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de gezonde fysiologische aanpassingen aan de zwangerschap en de verschillen 
die waarneembaar zijn met de pathologische zwangerschap leidend tot 
bovengeschetste levensbedreigende beelden preeclampsie en eclampsie de 
hoogste prioriteit!
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Dankwoord
En ineens beland je bij het dankwoord….mijn proefschrift is af! Tijdens de 
afgelopen jaren waarin ik aan mijn proefschrift heb gewerkt hebben gelukkig veel 
mensen mijn geluk gedeeld tijdens de hoogtepunten en mij ondersteund tijdens 
de dieptepunten. Ik wil iedereen die me heeft bijgestaan van harte bedanken en 
een aantal van deze mensen in het bijzonder. 
Prof. dr. M.J. Cipolla. Dear Marilyn, about who else would I start this section that is all 
about thanking people for their support? If it wasn’t for you, this thesis would not 
have existed today. You were truly an inspiring mentor. Not only have you made 
a scientist of me, you were also a true mentor during my stay in the Vermont in 
all areas possible. Even in the hard days when my health was challenging me, you 
were there for me. You have helped me to become the woman, medical doctor 
and scientist I am today and I want to thank you for that. Finally, I really hope to 
start a new research project with you in the future! 
Prof. dr. M.E.A. Spaanderman. Beste Marc, hoe paden zich toch opeens kunnen 
kruisen. Ze zeggen dat alles met een reden gebeurt. Toen ik onverwacht in 
2013 in het MUMC+ belandde als ANIOS met een Amerikaans onderzoek over 
preeclampsie heb je je meteen voor me ingezet om in Maastricht te kunnen 
promoveren. In deze relatief korte tijd als promotor heb je je ontpopt als een ware 
begeleider, mentor en nog veel meer. Met jouw hulp is dit proefschrift mijn trots 
geworden en ben ik aan de opleiding tot gynaecoloog mogen beginnen. Marc, 
ik ben zo ongelofelijk blij dat ik weer terug ben in Maastricht bij “mijn roots” en ik 
hoop nog veel met je te mogen samenwerken.  
Dr. L.L.H. Peeters. Beste Louis, je staat aan de wieg van dit alles. Zonder jou was ik 
nooit naar Burlington, Vermont vertrokken om onderzoek te verrichten. Zonder 
jou was ik nooit zoveel van de wetenschap gaan houden dan dat ik nu doe. Ook 
al liepen de plannen die we in eerste instantie hebben gemaakt niet zoals we 
hadden gedacht en hebben we verschillende inzichten hierover gehad, ik zal je 
altijd dankbaar blijven me te hebben gestimuleerd te participeren in de wereld 
van het onderzoek. 
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De leden van de beoordelingscommissie: Prof. dr. J.G. Nijhuis, Prof. dr. R.J. van 
Oostenbrugge, Prof. dr. B.W.W. Kramer, Dr. G.G. Zeeman, Dr. M.M. Faas. Bedankt dat jullie 
allen de tijd hebben genomen mijn proefschrift kritisch te bekijken en te beoordelen. 
Een speciaal dankwoord wil ik richten aan Dr. G. G. Zeeman. Gerda, tijdens mijn 
moeilijke periode na mijn terugkeer uit Vermont heb ik veel steun van je gekregen 
en me laten inzien om het beste uit 2 continenten te halen, dank daarvoor!
The colleagues of the Cipolla lab, especially Kelvin Chan, Julie Sweet, Abbie Chapman 
and Emily Houston…Kelvin, you became my first friend when I lived Burlington. We 
could share everything with each other and I could always ask your advise as a 
rookie in the research world. From our first Sunday evening diner learning about 
the meaning of rootbeer, to our many “WII nights” and lab evenings emptying the 
snackdrawer, you became a very good tutor and friend and I hope to see you 
soon again. Emily, o my god, what a great friend have you become, from doing 
projects together in the lab to being inseparable outside the lab. Thank you for 
your patience teaching me mounting a cerebral vessel. Thank you for all the 
good times in Burlington and for being the person I could always count on in my 
professional and personal life. I can’t wait to see you and your lovely family again!
Anne-Eva van der Wijk, ook bij jou wil ik even stil staan uiteraard. Toen je het 
Cipolla team kwam versterken in Burlington woonde ik er alweer 1,5 jaar. Ik wil 
je oprecht bedanken om als Nederlands maatje samen Vermont, Boston en New 
York te verkennen en te spuien over de cultuurverschillen. Daarnaast de wekelijkse 
vrijdagavond kroegsessie gevolgd door een zaterdagochtendje strand waren 
goud waard om het drukke laboratoriumleven even samen te ontzien. Ook beide 
terug in Nederland, heel erg bedankt voor je steun in de voorbereiding van dit 
proefschrift en voor je vriendschap. 
Thanks to all my dear friends from the Burlington area, especially my girls Megan, 
Melissa and Nicole, you are great friends who have made Burlington my second 
home….Further, thank you to all my other friends from the international club, 
the triva “bieber” club, and the college of Medicine. You gave me a second family, 
delicious international diners, entertaining Thursday trivia nights, epic nights out 
in the town and a reminder that in addition to a labnerd I was stil a medical doctor 
too! Because of you all I could make the most out of my research time over there. 
I hope to see you all again.
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Lieve Kim van Delft, geneeskundemaatje, onderzoeksmaatje, opleidingsmaatje en 
bovenal lief vriendinnetje, bedankt voor je steun tijdens mijn onderzoeksperiode 
in Vermont vanuit Londen waar jij zelf aan het promoveren was. Jij wist precies hoe 
het was om ver weg van alles en iedereen een onderzoek op te zetten. Bedankt 
voor de skype sessies om elkaar er doorheen te trekken en uiteraard ons tripje naar 
New York! Nu we beide in opleiding zijn tot Gynaecoloog zullen we zeker nog vaak 
op elkaars steun kunnen vertrouwen! 
Lieve, lieve Mieke Jacobs, jij bent al vanaf mijn kindertijd een onuitwisbare factor 
in mijn leven. Jouw steun en begrip is goud waard! Zelfs Vermont was niet te 
ver om me op te zoeken en me afleiding te bezorgen om samen met Cyrella en 
mij Vermont en Canada te verkennen. Toen je vorig jaar zelf moeder werd van je 
prachtige dochter Eva heb je me helaas ook onbedoeld gewezen op het belang 
van dit onderzoek en zal ik ook voor jou dit zeker voortzetten! Bedankt voor al je 
begrip en steun in de afgelopen jaren en het geduld met me om dit proefschrift af 
te krijgen. Je bent ontzettend belangrijk voor me. 
Kim Heinen, Eva van Gerrevink, Marlies van Bekkum en Wiesje Bressers en alle andere 
lieve vrienden, bedankt om me te steunen toen ik weer terug was in Nederland 
om dit proefschrift ondanks de tegenslagen af te krijgen. Lieve Eva, bedankt voor 
je hulp en steun in de laatste voorbereidingen voor deze dag!
Beste maatschap Gynaecologie uit het Viecuri Venlo, bedankt dat ik bij jullie mijn 
opleiding tot gynaecoloog mocht starten en dat jullie begrip toonde dat dit 
proefschrift naast mijn eerste opleidingsjaar ook nog aandacht verdiende. Zonder 
jullie steun was dit niet gelukt. Een extra bedankje aan mijn onlangs gepromoveerde 
baas Anika Dam die mijn promotiestress altijd begreep en me soms een keertje extra 
liet doorademen. Tevens wil ik alle collega-assistenten uit het VieCuri bedanken 
voor de gezelligheid, teamspirit, luisterende oren en het carpoolen. Met name Ida 
Smailbegovic en Inge de Grauw, met jullie kon ik altijd alles delen. Daarnaast wil ik 
ook de verloskundigen, verpleegkundigen en de rest van het gynaecologie team in 
Venlo bedanken omdat ik me door jullie daar snel thuis voelde. Door jullie kreeg ik 
de energie om dit proefschrift na mijn werk te voltooien!
Alle overige arts-assistenten van het cluster MUMC. Bedankt voor de gezelligheid, 
tips voor de promotie en afleiding tijdens de gezellige borrels en weekends. Ook 
heel veel succes aan degene die volop aan hun promotie bezig zijn.
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Mijn paranimfen Cyrella Beckers en Fleur Kramer. Lieve Cyrella, je bent al ruim 26 jaar 
mijn steun en toeverlaat als vriendin op alle gebieden in het leven. Het klikte al 
toen we nog maar 4 jaar oud waren en zo begrijpen we elkaar nog steeds. Ook 
al hebben we hele verschillende paden in dit leven bewandeld, je bent er altijd 
voor me geweest en ik ben ongelofelijk trots dat je een van mijn paranimfen bent! 
Lieve Fleur, ik heb je leren kennen tijdens ons studentleven in Maastricht. Al snel 
kwamen we erachter dat onze ambities erg met elkaar overeenkomen en dat 
we onze liefde voor een sporadisch tripje naar de McDonals delen. Nu je zelf ook 
met je promotieonderzoek bezig bent hebben we elkaar in de afgelopen jaren 
extra veel steun kunnen geven en zijn me meer dan ooit naar elkaar toegegroeid. 
Bedankt dat je als paranimf naast me staat! 
Lieve broer en zus. Hans, ik heb je bruiloft met je vrouw Marlies moeten missen 
omdat ik in Vermont woonde. Ik weet dat je soms naar begrip moest zoeken 
als je hoorde dat ik nog steeds aan dit proefschrift bezig was, maar bedankt 
voor je steun en geduld om dit voor elkaar te krijgen. Je bent een fijne broer en 
prachtvader voor Sylvio, Roan en Ravi. Lief zusje Maura, bedankt dat je er altijd 
voor me geweest bent tijdens de afgelopen jaren en bedankt voor je bezoek in 
Burlington. Ik weet dat je creditkaart er wat minder blij mee was maar je gaf me 
de broodnodige ontspanning in mijn Amerikaanse leventje. Ook bedankt voor de 
ellenlange skypesessies in moeilijke tijden. Ook terug in Nederland ben je samen 
met je vriend Jesse altijd betrokken. Dank jullie allemaal dat jullie er voor me zijn. 
Daarnaast een bedankje aan al mijn bonus broers en zussen die mij jaar in en uit 
weer met een laptop zagen voorbij lopen of mij weer naar een ander continent 
zagen vertrekken. Bedankt voor jullie support!
Lieve pap en mam, jullie zijn gedurende mijn hele leven een enorme grote 
steunfactor geweest. Jullie hebben me altijd gemotiveerd het beste uit mezelf te 
halen en me gesteund in alle beslissingen die ik heb genomen. Doordat jullie apart 
van elkaar opnieuw geluk hebben gevonden heb ik 2 bonus ouders gekregen 
waardoor ik van 4 ouders onvoorwaardelijke support heb gekregen. Ook tijdens 
mijn verblijf in Vermont zijn jullie een grote steun geweest. Jullie kwamen ieder met 
jullie wederhelften mij opzoeken. Ik mag me gelukkig prijzen met zoveel steun van 
jullie als ouders. Jullie huizen hebben altijd voor me opengestaan! Zonder jullie 
had ik hier vandaag niet gestaan, ik houd van jullie allemaal.
Malou
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Malou Schreurs werd geboren op 23 januari 1985 te Tegelen. Zij behaalde haar 
VWO diploma in 2003 aan het Valuascollege in Venlo. Direct na het behalen van 
dit diploma startte zij met de opleiding Geneeskunde aan de Universiteit van 
Maastricht. Door 2 keuze-coschappen te lopen in het onderzoek bij de Chirurgie 
in Maastricht en in het Maternity hospital in Malawi stond haar belangstelling in de 
Obstetrie en Gynaecologie en de wetenschap vast. In december 2009 behaalde zij 
haar artsexamen. Zij startte in Januari 2010 als ANIOS Obstetrie en Gynaecologie 
in het Flevoziekenhuis te Almere. In oktober 2010 verruilde zij deze baan om 
voor een jaar naar Burlington, Vermont in de Verenigde Staten te verhuizen 
om onderzoek te doen bij Professor Marilyn Cipolla naar de neurologische 
complicaties bij preeclampsie. Een jaar Verenigde Staten werd algauw 2 jaar 
gedreven onderzoek wat als resultaat in dit proefschrift staat beschreven. In 
Oktober 2012 keerde zij terug naar Nederland waar zij in Januari 2013 startte als 
ANIOS obstetrie en Gynaecologie in het MUMC+ te Maastricht. Daar werd haar 
onderzoek geadopteerd door Professor Marc Spaanderman en voortgezet zoals 
in dit proefschrift staat beschreven. In Januari 2014 begon ze aan de opleiding tot 
Gynaecoloog in het Viecuri te Venlo.
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Malou Schreurs was born on the 23rd of January 1985 in Tegelen, the 
Netherlands. After finishing secondary school at the Valuascollege, Venlo, in 
2003, Malou started her study Medicine at the University of Maastricht. When 
Malou decided to expand her medical curriculum by performing research at the 
department of Surgery and gaining experience in Obstetrics at the Maternity 
hospital in Malawi, Africa, she was convinced of her interest for science and 
obstetrics and gynecology. She graduated from the college of Medicine in 
December 2009. After graduating she started working as an intern in obstetrics 
and gynecology at the Flevoziekenhuis in Almere, the Netherlands. In October 
2010 she moved to Burlington, Vermont , USA, to perform research under 
supervision of Professor Marilyn Cipolla about the development of neurologic 
complications during preeclampsia. She decided to stay in Vermont for 2 years 
and published 5 research papers which resulted in this thesis. She returned to 
the Netherlands in October 2012 and started working as a intern in Obstetrics 
and Gynecology in the academic hospital of Maastricht. She continued her 
research under supervion of professor Marc Spaanderman which is described 
in this thesis. Malou started the residency program Obstetrics and Gynecology 
to become a gynecologist at the VieCuri hospital, Venlo, the Netherlands, at 
January 2014. 
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